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Abstract 
 
CD4 T cells play an important role in the initiation and maintenance of 
inflammation in numerous inflammatory diseases. Rheumatoid arthritis (RA) is 
one such autoimmune inflammatory condition where inflammation of the joint 
occurs. CD4 T cells are one of the key cells in RA pathogenesis due to their 
ability to activate or influence other cells in the joint including B cells, 
macrophages and osteoclasts, which collectively lead to joint destruction. The 
recruitment and function of CD4 T cells at inflamed tissues has been studied 
extensively. However, the signals that regulate CD4 T cell accumulation and 
persistence at peripheral inflamed sites are poorly understood.  
In this study, a novel in vivo model of inflammation was designed in the murine 
ear pinnae to study the signals which regulate CD4 T helper 1 (Th1) cell 
persistence at inflamed tissues. Congenically marked, in vitro polarised CD4 Th1 
cells were adoptively transferred directly into inflamed or non-inflamed ear 
pinnae and their persistence and survival were studied using flow cytometry. 
Higher numbers of CD4 Th1 cells were found at the inflamed as compared to the 
non-inflamed site.  
Intravital microscopy was used to further study the behaviour of these cells. Th1 
cells were found to be more mobile in inflamed compared to non-inflamed ear 
pinna. To investigate the molecular mechanism of this, either the ear pinnae or 
the T cells themselves were manipulated.  Introducing cognate antigen at the 
inflamed site did not alter the number of recovered T cells, nor did the T cells 
proliferate at the site.  
Next, the survival of persistent CD4 Th1 cells was examined by investigating 
their expression of active caspases. Lower proportion of Th1 cells recovered 
from inflamed tissues were found to express active caspases compared to those 
from a non-inflamed site. Together these data suggest that local T cell 
activation is not required for persistence but rather, the increase in T cells at 
inflamed sites may be due to a combination of persistence and survival signals. 
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The sphingolipid sphingosine-1-phosphate (S1P) has been implicated in driving 
both egress of T cells out of secondary lymphoid organs and their survival. To 
investigate whether S1P affects Th1 cell persistence and/or survival at inflamed 
tissues, Th1 cells were treated with S1PR agonists or antagonists, prior to 
transfer. Fewer Th1 cells were recovered from the inflammatory site of mice 
injected with antagonist treated cells. Additionally, S1PR agonism was sufficient 
to induce Th1 cell persistence at non-inflamed tissues.  
A trend towards increased expression of active caspases was also found in S1PR 
antagonist treated T cells recovered from inflamed ear pinnae compared to 
untreated controls. Finally, elevated levels of the S1P metabolising enzyme, 
SPHK1, was found in human RA joints compared to OA joints.  
In sum, I propose a novel function for S1P and its receptors in regulating the 
persistence of activated CD4 Th1 cells at inflamed tissue sites. Moreover, 
targeting S1P and its receptors at peripheral inflamed tissues could provide a 
novel target for the development of more effective anti-inflammatory 
therapeutics. 
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Abbreviations 
7TM    Seven transmembrane 
ABC    ATP-binding cassette 
ACAD    Activated cell autonomous death 
ACPA    Anti-citrullinated peptide antibody 
AIA    Antigen induced arthritis 
AICD    Activation induced cell death 
AMP    Anti-microbial peptides 
ANOVA   Analysis of variance 
APAF    Apoptotic-protease-activating factor 
APC    Antigen presenting cell 
ARDS    Acute respiratory distress syndrome 
BAK    BCL-2 antagonist/killer 
BAL    Broncheo-alveolar lavage 
BAX    BCL-2 associated X protein 
Bcl    B cell lymphoma 
BCR    B cell receptor 
BIM    BCL-2 interacting mediator of cell death 
C1P    Ceramide-1-phosphate 
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CAM    Cell adhesion molecule 
CD    Cluster of differentiation 
CFA    Complete freund’s adjuvant 
CIA    Collagen induced arthritis 
CKR    Chemokine receptor 
CLA    Cutaneous leukocyte antigen 
CLP    Common lymphoid progenitor 
CMP    Common myeloid progenitor 
COX    Cyclooxygenase 
cPLA2    Cytosolic phospholipase A2 
CTLA-4   Cytotoxic-T-lymphocyte associated protein-4 
DAB    3,3’ – Diaminobenzidine 
DAMP    Danger associated molecular pattern 
DC    Dendritic cell 
DISC    Death-inducing signaling complex 
DNA    Deoxyribonucleic acid 
DR    Death receptor 
DSS    Dextran sodium sulphate 
DTH    Delayed type hypersensitivity 
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ECM    Extra-cellular matrix 
ELISA    Enzyme-linked immunosorbent assay 
ER    Endoplasmic reticulum 
ESL    E-selectin ligand 
FACS    Fluorescence-activated cell sorting 
FASL    FAS ligand 
FLICA    Fluorescent inhibitor of caspases 
Fox    Forkhead box  
G-CSF    Granulocyte-colony stimulating factor 
GFP    Green fluorescent protein 
GlyCAM   Glycosylation-dependent cell adhesion molecule 
GM-CSF   Granulocyte macrophage-colony stimulating factor 
GPCR    G-protein coupled receptor 
HDL    High-densty lipoprotein 
HEV    High endothelial venule 
HIV    Human immuno-deficiency virus 
HLA    Human leukocyte antigen 
HMGB1   High mobility group box 1 
HSV    Herpes simplex virus 
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IBD    Inflammatory bowel disease 
ICAM    Intercellular adhesion molecule 
ID    Intradermal 
IFN    Interferon 
Ig    Immunoglobulin 
IL    Interleukin 
ILC    Innate lymphoid cell 
IMID    Immune-mediated inflammatory diseases 
KLF    Kruppel-like factor 
LEC    Lymphatic endothelial cell 
LFA-1    Lymphocyte function-associated antigen 1 
LN    Lymph node 
LPS     Lipopolysaccharide 
M-CSF    Macrophage-colony stimulating factor 
MACS    Magnetic-activated cell sorting 
MADCAM   Mucosal vascular addressin cell-adhesion molecule 
MEST    Mouse ear swelling test 
MHC    Major histocompatibility class 
MS    Multiple sclerosis 
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MTX    Methotrexate 
NET    Neutrophil extracellular trap 
NF-kB    Nuclear factor-kB 
NK    Natural killer 
NLR    NOD-like receptor 
NOD    Nucleotide oligomerisation domain 
NOS    Nitric oxide synthase 
OA    Osteoarthritis 
Ova    Ovalbumin 
PAF    Platelet activating factor 
PAMP    Pathogen associated molecular pattern  
PBS    Phosphate buffered saline 
PCD    Programmed cell death 
PCR    Polymerase chain reaction 
PDGF    Platelet-derived growth factor 
PG    Prostaglandin 
PKC    Protein kinase C 
PMA    Phopbol-myristate acetate 
PMN    Polymorphonuclear leukocyte 
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PRR    Pattern recognition receptor 
PSGL    P-selectin glycoprotein ligand 
PTX    Pertussis toxin 
PUMA    p53-upregulated modulator of apoptosis 
PUVA    Psolarin and ultraviolet A 
qRT-PCR   Quantitative-reverse transcription PCR 
RA    Rheumatoid arthritis 
RBC    Red blood cell 
RF    Rheumatoid factor 
RIPK    Receptor-interacting protein kinase 
RLR    RIG-I like receptor 
RNA    Ribonucleic acid 
RORg    RAR-related orphan receptor gamma 
ROS    Reactive oxygen species 
RPMI    Rosswell park memorial institute medium 
RT    Room temperature 
S1P    Sphingosine-1-phosphate 
SD    Standard deviation 
SEM    Standard error of mean 
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siRNA    Small-interfering RNA 
SLE    Systemic lupus erythematosus 
SLO    Secondary lymphoid organ 
SMase    Sphingomyelinase 
SPHK    Sphingosine kinase 
SPNS    Spinster homolog 
STAT    Signal transducer and activator of transcription 
T-PER    Tissue-protein extraction reagent 
T1D    Type-1-diabetes 
TBST    Tris-buffered saline+tween 
TCR    T cell receptor 
Tg    Transgenic 
TGF-b    Transforming growth factor-b 
TLO    Tertiary lymphoid organ 
TLR    Toll-like receptor 
TNF    Tumour necrosis factor 
TRAIL    TNF-related apoptosis inducing ligand 
VEGF    Vascular-endothelial growth factor 
YFP    Yellow fluorescent protein 
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1.1 Overview 
Immune-mediated inflammatory diseases (IMID) are one of the primary causes of 
significant morbidity and mortality in the western world. The term IMID is used 
to describe a group of diseases that share common inflammatory pathways. They 
include diseases such as rheumatoid arthritis (RA), psoriasis and multiple 
sclerosis (MS) amongst others (1).  
IMIDs affect 5-7% of the population (2). They exhibit linked genetic 
susceptibilities which play a crucial role in disease development. Moreover, 
environmental precipitants such as smoking, infection and trauma are also 
shared. Commonly, individual patients present with multiple IMIDs (3).  
The aetiology of most IMIDs is unknown, however, dysregulated cytokine 
networks have been identified as central to disease pathogenesis (4). CD4 T 
lymphocytes, often considered the orchestrator of immune responses play 
essential roles in the regulation of these cytokine networks at inflamed sites (5). 
These T cells accumulate in large numbers at effected tissues. Indeed, T cell 
accumulation is considered a molecular hallmark of multiple IMIDs (6-8). 
Recent studies have investigated CD4 T cell activation, function, migration and 
death at peripheral inflamed tissues in an effort to understand their roles in 
disease pathogenesis (9-11). Processes involved in the trafficking of CD4 T cells 
to and from diseased tissues offers an attractive avenue for the development of 
novel anti-inflammatory therapeutics.  
As part of this, recruitment of T cells to inflamed tissues has been extensively 
studied (12-17). Tissue persistence of these cells, however, remains a critical 
but poorly studied area of research. Considering the destructive influence of 
persistent CD4 T cells at tissues, targeting them remains a prime candidate for 
the development of new therapies.  
This research project was undertaken with the aim to identify novel signals 
regulating pathogenic CD4 T cell persistence at inflamed tissues. This 
introduction will review the fundamental scientific knowledge which underlies 
the immunological basis of CD4 T cell persistence at peripheral inflamed tissues.  
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1.2 Inflammation 
Inflammation is a complex and protective biological response of tissues to 
infection, injury or other harmful stimuli (18). Upon stimulation, tissues 
commence a cascade of events including vascular alteration, inflammatory 
mediator release and immune cell activation/infiltration. Through these 
mechanisms, inflammation aids in the clearance of the initial stimulus and 
restores homeostasis (19). 
1.2.1 History of inflammation research 
Aspects of inflammation were discovered as far back as 5th century BC. The 
Greek philosopher Hippocrates described inflammation as an essential 
component of wound healing. He also introduced the term edema or swelling, 
which is commonly associated with inflammation. Around 30 BC, Celsus, a 
Roman encyclopaedist described four of the five cardinal signs of inflammation. 
The Latin terms calor (heat), dolor (pain), rubor (redness) and tumor (swelling) 
are still in use today to describe inflammation. Virchow, a German pathologist, 
later added the fifth, loss of function (20). 
The 18th and 19th centuries saw the advent of empirical research and with that 
the cellular and molecular details of inflammation began to emerge. Hunter, 
first described angiogenesis in wound healing in the late 18th century. Dutrochet 
described white blood cell adhesion and Cohnheim demonstrated changes in 
blood vessels including vascular leakage. Metchnikoff and Ehrlich, often 
considered the founders of immunology, demonstrated white blood cell 
(leukocyte) accumulation in inflamed tissues. Metchnikoff also described 
phagocytes and phagocytosis (21). 
Technological advancements in the 20th and 21st centuries allowed for rapid 
progress in inflammation research. The application of genetic and molecular 
biology approaches in immunology led to the discovery of inflammatory 
mediators. Cytokines, chemokines, cell adhesion molecules and some of their in 
vivo functions were elucidated using these powerful tools (18). Despite such 
progress, treatments for many inflammatory diseases remain mostly disease 
modifying rather than curative. Moreover, molecular mechanisms underlying 
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multiple inflammatory diseases are as yet unclear. Hence there exists an unmet 
need for fundamental inflammation research. In the following sections, the 
current understanding of inflammation is reviewed.  
1.2.2 Acute inflammation 
Acute inflammation is triggered by infection or tissue damage. Pathogen 
associated molecular patterns (PAMPs) or danger associated molecular patterns 
(DAMPs) released by pathogens or damaged cells respectively are then 
recognised by innate immune cells (22). PAMPs are a set of conserved molecular 
patterns expressed on microbes (23, 24). One of the best known PAMPs is 
bacterial lipopolysaccharide (LPS) found on gram-negative bacteria. DAMPs are 
signals released by cells upon breakdown of homeostasis such as cell death (25-
27). Some of the best-known DAMPs include nucleic acids (DNA/RNA) and high 
mobility group box 1 (HMGB1) proteins (28). These molecules carry out crucial 
functions in intact cells, but act as danger signals upon release from necrotic 
cells (28).  
PAMPs and DAMPs are recognised by pattern recognition receptors (PRRs) on 
tissue resident innate immune cells (29). PRRs include Toll-like receptors (TLRs), 
NOD (nucleotide-binding oligomerisation-domain binding protein)-like receptors 
(NLRs) and RIG-I like receptors (RLRs) (29). LPS and HMGB1 both trigger TLR4 
and TLR2 respectively whereas RLRs recognise various nucleic acids (29-31). The 
recognition of PAMPs/DAMPs by PRRs leads to the production of inflammatory 
mediators such as cytokines, chemokines, adhesion molecules and lipid 
mediators (29).  
Inflammatory mediators elicit local inflammatory exudates. Vascular 
permeability is increased, allowing selective entry of leukocytes, red blood cells 
(RBCs) and plasma proteins into inflamed tissues (32). Selectivity is conferred by 
modulation of gap junction space and adhesion molecule expression on vascular 
endothelial cells (33). Adhesion molecules interact with their receptors on 
leukocytes leading to extravasation (34, 35). Chemokines released at inflamed 
tissues, also aid tissue entry of vascular leukocytes by engaging their chemokine 
receptors (35, 36).  
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Neutrophils, which are polymorphonuclear leukocytes (PMNs), make up the 
majority of early leukocyte populations in inflamed tissues (37). Upon entry, 
neutrophils undergo activation either by direct interaction with the pathogen or 
by the local inflammatory cytokine milieu produced by tissue resident cells. 
Neutrophils engage targets by releasing toxic molecules such as reactive oxygen 
and nitrogen species (ROS), (NOS), proteinases, elastases and cathepsins (38). 
While highly potent, these molecules also cause significant off-target damage, 
often leading to the general pain associated with inflammation (39).  
At the end of a neutrophil response, monocytes and macrophages are recruited 
(40). This is marked by a change of lipid mediator composition at the inflamed 
tissue. Pro-inflammatory prostaglandins are replaced by anti-inflammatory 
lipoxins. This drives the resolution phase of inflammation mediated by 
monocytes and macrophages (41). Monocytes remove apoptotic/necrotic cell 
debris and begin the tissue remodelling process (42). Macrophages carry out 
further tissue repairs and produce amongst others, two potent anti-inflammatory 
mediators transforming growth factor-b (TGF-b) and interleukin -10 (IL-10) (43, 
44). Together these processes reduce inflammation and restore tissue 
homeostasis (45, 46). 
1.2.3 Acute inflammatory diseases 
The most common form of acute inflammation is resolving bacterial/viral 
infection or local tissue damage/wounds. In these cases, the process of acute 
inflammation restores tissue homeostasis (47). However, acute respiratory 
distress syndrome (ARDS) and sepsis are examples of non-resolving acute 
inflammatory diseases. 
1.2.3.1 Acute respiratory distress syndrome 
ARDS is characterised by the sustained accumulation of PMNs within alveolar 
compartments of the lung (48). ARDS occurs in adults usually after traumatic 
injury or bacterial pneumonia (49, 50). In infants, ARDS is most common 
following premature birth (51). Although mechanisms for ARDS development is 
poorly understood, fluids from ARDS lungs demonstrate hallmarks of aberrant 
acute inflammation (52). Bronchoalveolar fluids from ARDS patients contain 
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large numbers of PMNs, fibrin and complement components which are discussed 
in the “mediators of inflammation” section of this introduction. Collectively, 
this causes severely restricted gas exchange in the lungs. The majority of ARDS 
patients die of acute respiratory failure. Some patients resolve disease 
completely, while others suffer from pulmonary fibrosis (53). No effective 
therapy for ARDS exists. Patients are only provided with mechanical ventilation 
and fluids to help them recover (54). 
1.2.3.2 Sepsis 
Sepsis occurs primarily in immunocompromised individuals. It is most commonly 
triggered by bacterial infection of the lungs, although infections of other organs, 
both viral and bacterial can also cause sepsis (55). Like ARDS, mortality rates 
following sepsis are high. In sepsis, patient blood plasma contains large amounts 
of pro-inflammatory mediators such as tumour necrosis factor a (TNFa), 
interleukin-1 (IL-1) and IL-6 (56, 57). Cytokines are discussed in the “cytokines” 
section of this chapter.  
Moreover, vascular endothelium express high levels of adhesion molecules as do 
infiltrating leukocytes (58). The complement and coagulation cascades are 
activated and tissue macrophages show excessively activated phenotypes (59). 
Overall, sepsis is a systemically dysregulated acute immune response. Like ARDS, 
causes of sepsis are unknown and no effective therapy exists.  
1.2.4 Chronic inflammation 
Chronic inflammation ensues once acute inflammation fails to eliminate 
pathogenesis (60). Lymphocytes, plasma cells and macrophages replace the 
primarily monocytic/neutrophilic infiltrates at acutely inflamed tissues (61). If 
these cells fail to control pathogenesis, persistent, long term, inflammation 
develops, potentially leading to the formation of tertiary lymphoid organs (TLOs) 
or granulomas (62). Triggers for chronic inflammation include persistent 
bacterial/viral infections, autoimmunity and foreign bodies (63-65).  
The chronic inflammatory response to each individual trigger can be diverse. 
Whereas an anti-bacterial response in the lung might attract a certain subset of 
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leukocytes and lymphocytes, an autoimmune inflammatory skin lesion could be 
targeted by an entirely different subset of immune cells (66). Finally, foreign 
bodies as well as some pathogens often trigger granulomatous inflammation due 
to unsuccessful phagocytosis by macrophages (67). 
1.2.5 Chronic inflammatory diseases 
1.2.5.1 Psoriasis 
Psoriasis is an autoimmune inflammatory skin disease characterised by epidermal 
keratinocyte hyperplasia (68). This aberrant proliferation of skin cells is 
mediated by accumulation of specific subtypes of inflammatory T helper 17 cells 
(Th17), macrophages and dendritic cells (DCs) (69-71). These cells produce pro-
inflammatory cytokines such as IL-1, IL-6, TNFa, IL-17 and IL-22 which 
perpetuate disease pathogenesis (72).  
Causes of psoriasis remain incompletely understood. However, there is a genetic 
association of psoriasis with T cells and MHC-II expressing cells (73). Treatments 
for psoriasis include immunosuppressants such as methotrexate (74). More 
severe psoriasis is often treated with biologics such as anti-TNFa (infliximab) 
(75). However, as with most chronic inflammatory disease, there are currently 
no drugs that cure the disease. 
1.2.5.2 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory 
disease. It primarily manifests in the small joints of the hands and feet. In RA, 
synovial membranes of the joint are inflamed. Persistent inflammation leads to 
significant bone and cartilage damage which is mediated in part by dysregulated 
osteoclast proliferation (76).  
Like psoriasis, the aetiology of RA is yet to be established. However, certain 
human leukocyte antigen (HLA) genes are negatively implicated (77, 78). These 
genes are critical in regulating antigen presentation to T cells (79). Moreover, 
co-stimulation molecules such as CD28 and CD40 as well as lymphocyte 
activation associated gene PTPN22 are also negatively implicated (80). Hence, 
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activated adaptive immune cells and their products play a key role in RA 
pathophysiology.  
One of the hallmarks of RA is the presence of autoantibodies against the Fc 
portion of IgG known as rheumatoid factor (RF) in patient blood plasma (81, 82). 
Autoantibodies against citrullinated peptides (ACPAs) are another diagnostic 
marker for RA (83). While RF and ACPA implicate B/plasma cells in RA 
pathogenesis, aberrant accumulation of subsets of CD4 T cells such as Th1 and 
Th17 cells are also observed at RA synovia (84). Moreover, therapies targeted 
against T cell co-stimulation are effective in diminishing synovial inflammation 
(85, 86). Evidence suggests that synovial T cells contribute to disease by 
producing pro-inflammatory cytokines IFNg and IL-17 (87-89). 
Pro-inflammatory cytokines in general contribute significantly to RA 
pathophysiology. IL-1, IL-6 and TNFa produced by innate immune cells play 
major roles in disease progression (90). This is highlighted by the fact that the 
most effective therapy for RA targets TNFa (91). Despite its efficacy, not all 
patients respond to TNFa therapies.  
Hence, there exists an unmet need for the development of novel anti-
inflammatory therapeutics. Targeting master regulatory cells of cytokine 
networks, such as the CD4 T cell could provide new avenues for drug 
development. 
Relevance of this section to thesis aims: 
• Accumulation of leukocytes, and in particular T cells, is central to the 
pathogenesis of multiple inflammatory diseases as discussed in this 
section 
• Our knowledge of the signals regulating T cell accumulation in inflamed 
tissues remains incomplete 
• Discovery of novel signals of T cell accumulation at inflamed tissues 
could aid in the development of novel and more effective therapies for 
IMIDs 
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1.3 Mediators of inflammation 
PAMPs and DAMPs are inducers of inflammation. Recognition of PAMPs and DAMPs 
by cells results in complex signalling cascades leading to the production of 
diverse classes of inflammatory mediators (92). These mediators have numerous 
effects including increasing vascular permeability. Furthermore, many regulate 
leukocyte recruitment (93, 94). Inflammatory mediators can be divided into 
seven groups based on their function: Vasoactive amines and peptides, 
complement components, proteolytic enzymes, cytokines, chemokines, cell 
adhesion molecules (CAMs) and lipid mediators (61, 95). A brief overview of 
inflammatory mediators will be provided in this section with emphasis on 
cytokines, chemokines and lipid mediators. 
1.3.1 Vasoactive amines and peptides 
Histamine and serotonin are vasoactive amines. They are the products of 
platelet and mast cell degranulation (96, 97). Vasoactive amines regulate 
vascular permeability (98). This is mediated by context dependent dilation or 
constriction of blood vessels by histamine and serotonin (99). 
In addition, vasoactive peptides also play a critical role in controlling 
vasodilation. This family of small peptides is strongly regulated by the 
coagulation cascade protein Factor XII also known as Hageman factor (100-102). 
Factor XII processes and activates inactive compounds in extracellular fluids such 
as kinin and other fibrin degradation products (103, 104). These activated 
peptides then either act directly on the vasculature or trigger histamine and 
serotonin release by mast cells and platelets (105, 106). Factor XII importantly, 
controls the production of another peptide, Bradikynin (107). Bradikynin on top 
of being a vasodilator is a potent pro-algesic (108).  
1.3.2 Complement components 
Complement proteins C3a, C4a and C5a are produced in response to 
inflammatory stimuli (109, 110). This group of proteins are together known as 
anaphylotoxins (110). They are potent inducers of mast cell degranulation. 
Furthermore, anaphylotoxins promote granulocyte recruitment to inflamed 
tissues (111). 
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1.3.3  Proteolytic enzymes 
Matrix metalloproteinases, elastin and cathepsins form a few of the multitude of 
proteolytic enzymes that mediate inflammation. These proteins function at all 
stages of inflammation. They facilitate leukocyte migration at inflamed tissues 
as well as aid in tissue remodelling and repair at the end of an inflammatory 
response (112, 113). 
1.3.4  Cytokines 
Cytokines are a family of small proteins important in cell-cell communication. 
They are key mediators of both acute and chronic inflammation. At inflamed 
tissues, cytokines are produced by a host of cells including endothelial cells, 
macrophages and neutrophils (114). At chronic sites of inflammation, such as RA 
joints, cytokines produced by osteoclasts and T cells also have critical 
implications for disease pathogenesis (90). Cytokines can be divided into three 
groups based on their function: Growth/survival factors, inflammatory cytokines 
and regulatory cytokines. These have been summarised in Table 1. 
Group Members Target Cell(s) Effect(s) 
 
Growth Factors 
IL-2 B and T cells 
Proliferation 
and activation 
IL-3 Stem cells 
Haematopoietic 
precursor 
proliferation 
and 
differentiation 
IL-4 
B, T cells and 
macrophages 
B, T cell 
proliferation 
and enhances 
MHC II 
expression  
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IL-5 Eosinophils, B cells 
Proliferation 
and 
maturation, 
stimulates IgA 
and IgM 
production 
IL-7 B and T cells 
B, T cell 
growth and 
survival factor 
IL-9 T cells 
Differentiation 
and 
proliferation 
IL-13 
B cells and 
monocytes 
IgE class 
switching and 
MHC class II 
expression 
IL-15 NK and T cells 
NK cell 
development 
and 
maturation, 
memory T cell 
maintenance 
IL-21 NK and T cells 
NK cell 
proliferation 
and T cell 
differentiation 
G-CSF 
Bone marrow stem 
cells 
Granulocyte 
production 
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GM-CSF Stem cells 
Granulocyte, 
monocyte, 
eosinophil 
differentiation 
M-CSF Stem cells 
Monocyte 
activation and 
differentiation 
 
Inflammatory 
Cytokines 
IL-1a Various cell types 
Pyrogenic, 
proliferation 
and 
differentiation 
of cells 
IL-1b Various cell types 
Cell 
proliferation, 
differentiation 
and apoptosis 
IL-6 
B cells and plasma 
cells 
Differentiation, 
IgG production 
IL-11 B cells 
Differentiation, 
induction of 
acute phase 
proteins 
IL-17 
Keratinocytes, 
fibroblasts and 
macrophages 
Pro-
inflammatory 
cytokine 
production and 
cell 
proliferation 
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IL-18 NK and T cells 
T and NK cell 
differentiation 
and 
proliferation 
IL-25 
Eosinophils and T 
cells 
Eosinophil 
proliferation 
and regulation 
of T helper 17 
cell cytokine 
production 
IL-23 T cells 
Pro-
inflammatory T 
cell 
differentiation 
IL-31 Various cell types 
Cell 
proliferation 
and 
homeostasis, 
recruitment of 
leukocytes to 
inflamed sites 
IL-33 
Mast cells, ILCs and 
T cells 
Stimulates pro-
inflammatory 
type 2 cytokine 
secretion 
IL-36 DCs and T cells 
DC, T cell 
activation and 
pro-
inflammatory 
cytokine 
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production 
TNFa Macrophages 
Phagocytosis, 
endotoxic 
shock 
Type I IFNs Various cell types Anti-viral 
IFNg Various cell types 
Macrophage 
activation, 
phagocytosis, 
increased MHC 
I and II 
expression 
 
Regulatory 
Cytokines 
IL-10 B cells, macrophages 
Inhibits 
cytokine 
production and 
cellular 
activation, 
anti-
inflammatory 
IL-12 NK and T cells 
T and NK cell 
activation and 
regulation 
IL-19 Various cell types 
Anti-
inflammatory 
IL-20 Various cell types 
Anti-
inflammatory 
IL-22 Epithelial cells, 
hepatocytes and 
Host defence 
at mucosal 
surfaces and 
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keratinocytes tissue repair 
IL-24 Various cell types 
Wound healing, 
cell survival 
and 
proliferation 
IL-26 Various cell types 
Anti-
inflammatory, 
bactericidal 
IL-27 T cells 
Promotes 
regulatory cell 
type 
differentiation 
and IL-10 
production 
IL-28 
Keratinocytes and 
melanocytes 
Anti-viral 
IL-29 
Keratinocytes and 
melanocytes 
Anti-viral 
IL-35 Various cell types 
Anti-
inflammatory 
TGF-b Various cell types 
Inhibit cell 
proliferation, 
promote wound 
healing 
Table 1 Cytokines, their Targets and Effects 
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Cytokines can have distinct and often antagonistic effects on cells. This is in part 
due to the diverse nature of cytokine receptors and their overlapping 
intracellular signalling pathways (114). The most targeted pro-inflammatory 
cytokines in inflammatory diseases include tumour necrosis factor a (TNFa), 
interleukin-1 (IL-1) family and interleukin-6 (IL-6) (114). Interestingly, these 
cytokines signal through structurally conserved type I cytokine receptors unlike 
most other cytokine receptors, which are structurally divergent (114, 115).  
1.3.4.1 TNFa 
TNFa is one of the most important cytokines in inflammation and immune 
regulation. Primary producers of TNFa are macrophages, although various other 
cell types also produce it at different stages of an inflammatory response (115). 
TNFa activates the production of other cytokines and acute phase proteins by 
various cells (115). It also promotes expression and activation of adhesion 
molecules which allow cell trafficking into inflamed tissues (116, 117). TNFa has 
roles in promoting cell survival, proliferation and apoptosis at inflamed tissues 
(115). Moreover, TNFa has roles in maintaining endothelial function and lipid 
metabolism (118, 119). Inhibiting TNFa using monoclonal antibodies has proven 
efficacious in multiple inflammatory diseases such as RA and psoriasis (1). This 
further signifies the central role of TNFa in mediating inflammation. 
1.3.4.2 IL-1 family 
The IL-1 family of cytokines includes 11 members (120). The most potent pro-
inflammatory cytokines of this family are IL-1a and IL-1b (121). Production of 
these cytokines occurs downstream of PRRs triggered by PAMPs/DAMPs (122, 
123). IL-1 is produced by numerous cells including, but not limited to, 
macrophages, monocytes and DCs (124). IL-1 is an endogenous pyrogen and is 
potently anti-viral (123, 125). Like TNFa, IL-1 promotes production of other 
cytokines and acute phase proteins (126). Likewise, IL-1 receptor antagonists 
such as anakinra and canakinumab are used therapeutically in multiple 
inflammatory disorders including RA and Muckle-Wells syndrome respectively 
(127-130).  
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1.3.4.3 IL-6   
IL-6 is another potent inflammatory cytokine. Unlike TNF and IL-1, IL-6 is 
produced by a wider variety of cells including endothelial cells, bone marrow 
cells and fibroblasts as well as monocytes and macrophages (131). IL-6 is 
important in regulating haematopoiesis (132). IL-6 also controls adaptive 
immune responses by skewing T cell activation towards T helper 17 and 
inhibiting T regulatory cell phenotypes (133, 134). Similar to IL-1 and TNF, IL-6 
plays an important role in the acute phase response (135, 136). Finally, 
monoclonal antibodies targeting IL-6 are also in use to treat RA and juvenile 
idiopathic arthritis (137, 138). Efficacy in other inflammatory diseases is 
currently being evaluated (139). 
1.3.4.4 Cytokines in inflammatory diseases 
Aberrant cytokine signalling contributes to disease pathogenesis in many 
inflammatory disorders (140). IL-1, IL-6 and TNFa levels are elevated in RA, type 
1 diabetes (T1D), psoriasis and systemic lupus erythematosus (SLE) (141-145). In 
RA, TNFa plays a key role in triggering local inflammation and chemokine 
expression (146, 147). Downstream of TNFa, lipid mediators and adhesion 
molecule expression is dysregulated. This leads to tissue oedema and immune 
cell infiltration (148). Although, understood to a lesser extent, IL-1 and IL-6 play 
similar roles in inflammatory disorders. The efficacy of targeting these 
inflammatory cytokines as therapeutics provides strong evidence for their role in 
inflammatory disease pathogenesis (1).   
1.3.5 Chemokines 
Chemokines, also known as chemotactic cytokines, are primary regulators of 
cellular migration. Pro-inflammatory chemokines produced at inflamed tissues 
attract leukocytes (149). An elegant example of this is the chemokine induced 
expression of b2 integrin-lymphocyte function-associated antigen (LFA-1) in 
leukocytes. This promotes the arrest, rolling, diapedesis and extravasation of 
leukocytes from the vasculature into inflamed tissues (150). Although, 
chemokines are named and described for their chemotactic functions, they also 
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carry out a myriad of other functions. Chemokines have been noted for their role 
in haematopoiesis, angiogenesis and cell survival (151). 
1.3.5.1 Chemokine characterisation 
Chemokines are characterised by the presence of three or four conserved 
cysteine residues. They are subdivided into four groups based on their N-
terminal cysteine group positioning. The four groups are called C-C, C-X-C, C, 
and C-X3-C chemokines (152). The majority of chemokines belong to the C-X-C 
and C-C groups of chemokines (153). Chemokines can also be functionally 
divided into inflammatory or homeostatic, although a few perform dual roles 
(150). Table 2 contains a list of the chemokines, their receptors and their main 
function. 
1.3.5.2 Chemokine receptors 
Chemokines signal by binding to a family of seven transmembrane helix family of 
receptors (7TM) known as G-protein coupled receptors (GPCRs) (154, 155). 
Expression of chemokine receptors (CKRs) is temporally and spatially variable on 
a wide variety of cell types (155). Tissue specific leukocyte entry and exit is in 
part controlled by this variability in chemokine and CKR expression. Moreover, 
chemokines play a critical role in adhesion molecule expression which also 
regulate selective tissue entry/exit of leukocytes (36).  
To complicate matters further, CKRs bind their ligands with promiscuity (156). 
Promiscuity amongst CKRs is thought to be an evolutionary adaptation to allow 
redundancy in the system (157). In contrast, knocking out certain CKRs in 
animals leads to embryonic lethality. This demonstrates the fundamental 
importance of some chemokines in the developmental process (158). To date, 20 
signalling CKRs have been described (159). Interestingly, four atypical 
chemokine receptors (ACKRs) have also been described. These receptors are 
incapable of binding to GPCRs and are therefore considered chemokine 
scavengers (160). ACKRs are important in dampening immune responses by 
removing chemokines from the surrounding environment (114). 
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1.3.5.3 Chemokines in inflammatory diseases 
Like cytokines, elevated chemokine and CKR levels contribute to pathogenesis of 
many inflammatory disorders. CXCL8, the prototypical inflammatory chemokine, 
is elevated in RA synovial fluid as well as in the colons of ulcerative colitis 
patients (161, 162). T cell recruitment into inflamed RA synovia is also 
associated with elevated levels of CCL2,3 and 5 (10). In psoriasis, the CKR CXCR3 
is responsible for the infiltration of pathogenic T cells into psoriatic lesions and 
contributing to disease pathogenesis (163). Despite strong evidence of the role 
of chemokines in perpetuating inflammatory disorders, no chemokine mediated 
anti-inflammatory therapeutics currently exist. In part, this is due to the 
difficulty in targeting individual chemokines/CKRs due to their promiscuity 
(164). Multiple chemokine/CKR targeted therapeutics are, however, currently in 
clinical trials (164).               
Group Chemokine Receptor Main Function 
CC CCL1 CCR8,11 Th2 cell and Treg 
trafficking 
CCL2 CCR2 Inflammatory 
monocyte 
trafficking 
CCL3 CCR1,5 Macrophage and 
NK cell migration 
T cell–DC 
interactions 
CCL4 CCR5 
CCL5 CCR1,3,4,5 
CCL6 CCR1,2,3 Myeloid cell 
differentiation, 
CNS homeostasis 
CCL7 CCR1,2,3 Monocyte 
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mobilization 
CCL8 CCR1,2,5,8,11 Th2 response, skin 
homing 
CCL9 CCR1 DC migration, 
Osteoclast 
activation CCL10 CCR1 
CCL11 CCR3 Eosinophil and 
basophil migration 
CCL12 CCR2 Inflammatory 
monocyte 
trafficking 
CCL13 CCR1,2,3,11 Th2 response 
CCL14 CCR1 Monocyte 
activation, 
Monocyte and 
Neutrophil 
chemotaxis 
CCL15 CCR1,3 
CCL16 CCR1 
CCL17 CCR4 Th2 responses, 
Th2 cell 
migration, Treg 
lung and skin 
homing 
CCL18 CCR6,8 Th2 response, 
marker of 
alternatively 
activated 
macrophages, skin 
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homing 
CCL19 CCR7,11 T cell and DC 
homing to LN 
CCL20 CCR6 Th17 responses, B 
cell and DC 
homing to gut-
associated 
lymphoid tissue 
CCL21 CCR7,11 T cell and DC 
homing to LN 
CCL22 CCR4 Th2 response, Th2 
cell migration, 
Treg migration 
CCL23 CCR1 Unknown 
CCL24 CCR3 Eosinophil and 
basophil migration 
CCL25 CCR9,11 T cell homing to 
gut, thymocyte 
migration 
CCL26 CCR3 Eosinophil and 
basophil migration 
CCL27 CCR2,3,1 T cell homing to 
skin 
CCL28 CCR3,10 T cell and IgA 
plasma cell 
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homing to mucosa 
CXC CXCL1 CXCR2 Neutrophil 
trafficking 
CXCL2 CXCR2 
CXCL3 CXCR2 
CXCL4 CXCR3 Procoagulant 
 
CXCL5 CXCR1,2 Neutrophil 
trafficking 
CXCL6 CXCR1,2 
CXCL7 CXCR2 
CXCL8 CXCR1,2 
CXCL9 CXCR3 Th1 response, 
Th1, CD8, NK cell 
trafficking 
 
CXCL10 CXCR3 
CXCL11 CXCR3 
CXCL12 CXCR4,7 Bone marrow 
homing 
CXCL13 CXCR3,5 B cell and Tfh 
positioning LN 
CXCL14 CXCR4 Macrophage skin 
homing (human) 
CXCL15 Unknown Unknown 
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CXCL16 CXCR6 NKT and ILC 
migration and 
survival 
CXCL17 CXCR8 Monocyte/DC 
chemoattractant 
C XCL1 XCR1 Cross-presentation 
by CD8+ DCs 
XCL2 XCR1 
CX3C CX3CL1 CX3CR1 NK, monocyte, 
and T cell 
migration 
Table 2 Chemokines, Receptors and Functions 
 
1.3.6 Cell adhesion molecules (CAMs) 
Cell adhesion molecules are cell surface proteins that allow cells to “adhere” to 
other cells or extracellular matrix (ECM). CAMs further enable entry and exit of 
leukocytes to/from circulation into tissues. There are four families of CAMs. 
They include the Immunoglobulin (Ig) superfamily CAMs, cadherins, integrins and 
selectins (165). 
Inflammatory insult leads to the upregulation of CAMs such as intercellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-
selectin and P-selectin on vascular endothelial cells (166, 167). Likewise, 
activated leukocytes express ligands such as the integrins aLb2 (LFA-1) and a4b1 
(VLA-4) which bind to ICAM-1 and VCAM-1 respectively (168). Leukocytes also 
express E-selectin ligand-1 (ESL-1) and P-selectin glycoprotein ligand-1 (PSGL-1) 
which interact with E and P-selectins respectively (169). 
Expression of CAMs are temporally and spatially co-ordinated during 
inflammation to enable leukocyte rolling, adhesion and diapedesis into tissues. 
Moreover, specific CAMs such as the integrins aEb7 (CD103), a1b1 (VLA-1) and 
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a2b1 (VLA-2) enable leukocyte retention at inflamed tissues (170). Clinically 
efficacious anti-inflammatory drugs such as Natalizumab currently target 
integrins a4b1 and a4b7 in multiple sclerosis and Chron’s disease. Moreover, 
drugs targeting the integrin aEb7 are also undergoing trials in MS and IBD, 
further highlighting the importance of CAMs in regulating inflammation (171).  
1.3.7 Lipid mediators 
Historically, two classes of lipid mediators have been described: eicosanoids and 
platelet activating factors (PAFs) (172). Both mediators are generated by the 
degradation of cell membrane phospholipids. The enzyme phospholipase A2 
breaks down phosphatidylcholine on cell membranes into two components: 
arachidonic acid and lysophosphatidic acid. These form the precursors of the 
two classes of lipid mediators respectively (172). 
1.3.7.1 Eicosanoids 
Eicosanoids are generated when arachidonic acid is metabolised either by 
cyclooxygenase enzymes to form thromboxanes and prostaglandins. 
Alternatively, arachidonic acid can also be metabolised by lipoxygenase enzymes 
to generate leukotrienes and lipoxins. Interestingly, the two subgroups of 
eicosanoids have opposing effects. Prostaglandins and thromboxanes are 
pyrogenic, hyperalgesic and cause vasodilation. Hence, they are potently pro-
inflammatory. In contrast, leukotrienes and lipoxins promote tissue repair and 
resolution of inflammation. Therefore, they are anti-inflammatory (173). 
1.3.7.2 Platelet activating factors 
PAFs on the other hand are generated from the other component of 
phosphatidylcholine metabolism: lysophosphatidic acid. Lysophosphatidic acid is 
acetylated to generate PAFs. PAF was originally described as a single 
phosphoglycerylether molecule. More recently however, PAFs are seen as a 
family of ether like molecules that carry out similar functions. PAFs bind to and 
signal through PAF receptors (PAFRs) which are GPCRs, like CKRs. It is 
unsurprising, therefore, that PAFs contribute to vascular permeability 
regulation, leukocyte recruitment and platelet activation, functions that 
chemokines are also accredited with (173). 
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1.3.8 Sphingolipids: A new family of lipid mediators 
While Eicosanoids and PAFs are classical lipid mediators, sphingolipids have 
recently been identified as a new class of inflammatory lipid mediators. 
Sphingolipids are a class of lipids that are characterised by their eighteen-carbon 
amino-alcohol backbones (174). This backbone is shared amongst all members of 
the family and modification to this structure gives rise to the diverse family of 
sphingolipids.  Sphingolipids are generated by the metabolism of sphingomyelin 
which is another component of the cell membrane (175). 
1.3.8.1 Sphingolipid metabolism: the sphingomyelin cycle 
The breakdown of sphingomyelin is regulated by enzymes known as 
sphingomyelinase (SMase), this pathway is summarised in Figure 1.3.1 (176). 
There are three different isoforms of SMase: Acid SMase, neutral SMase and 
secretory SMase. Acid SMase are found in acidic intracellular lysosomes. Neutral 
SMase are cell membrane bound and are ubiquitously expressed in mammalian 
cells. Secretory SMase is found in the Golgi secretory pathway (174, 177).  
SMase isoforms are activated by a variety of stimuli including growth factors, 
inflammatory cytokines and cell stress (178-180). Activated SMase breakdown 
sphingomyelin to ceramide (177, 181). Ceramide is then either phosphorylated 
to make ceramide 1-phosphate (C1P) or broken down by ceramidase to make 
sphingosine (182, 183). Sphingosine itself can then be phosphorylated by either 
of two sphingosine kinases (SPHK1 or SPHK2) to make sphingosine 1-phosphate 
(S1P) (184, 185). S1P is then dephosphorylated by sphingosine phosphatase or 
degraded completely by S1P lyase (186, 187). Finally, sphingomyelin is re-
synthesised from sphingosine to ceramide by ceramide synthase and then 
ceramide to sphingomyelin by sphingomyelin synthase (188, 189). 
Sphingolipid formation and degradation are intimately connected as 
demonstrated in Figure 1.3.1. It is therefore unsurprising that their functions can 
also be reciprocal. For example, increased ceramide results in a concomitant 
decrease in S1P and is associated with increased cellular apoptosis. In contrast 
increased S1P and a concomitant decrease in ceramide is associated with 
increased survival  (190). Hence, ceramide is considered a pro-apoptotic 
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molecule whereas S1P is considered anti-apoptotic (191). Despite this intimate 
connection, sphingolipids are produced at varied locations in different cell 
types. They can also be functionally distinct. In this section, the three best 
studied sphingolipids ceramide, C1P and S1P will be explored with a detailed 
assessment of S1P. 
 
Figure 1.3.1 The sphingomyelin cycle 
Diagram adapted from (192) 
1.3.8.2 Ceramide 
Ceramide typically forms 16-24 carbon long fatty acid chains that are strongly 
hydrophobic physiologically (193). It is usually synthesised at mitochondrial 
membranes due to the activity of the SMase breaking down sphingomyelin at 
such locations (194). Ceramide regulates a wide variety of signalling pathways 
via interaction with protein kinases and phosphatases (193). Studies have shown 
that ceramide forms lipid raft like structures at the cell membrane to promote 
signalling complex formation (195). Moreover, some proteins have ceramide 
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binding domains such as protein kinase C (PKC) (196). Ceramide is thought to 
regulate PKC mediated signalling by directly binding to PKC (196). 
1.3.8.3 Ceramide in inflammation  
Ceramide production is often regulated by TNF in inflammatory tissues (197). 
TNF mediated ceramide can activate the pleiotropic transcription factor nuclear 
factor-kB (NF-kB) (198, 199). NF-kB are a family of transcription factors that 
control the expression of many inflammatory cytokines, chemokines and lipid 
mediators (199, 200). These include the classical pro-inflammatory cytokines IL-
1b, IL-6 and IL-8 (199). NF-kB also induces the expression of inflammatory lipid 
mediator cyclooxygenase 2 (COX-2) enzyme which subsequently triggers the 
expression of prostaglandin E2 (PGE-2) (201). Ceramide can also upregulate the 
transcription factor CCAAT/enhancer binding proteins (c/EBP) (202). Like NF-kB, 
c/EBP can also induce the production of inflammatory cytokines such as TNF and 
IL-1b (203).    
1.3.8.4 Ceramide 1-phosphate 
C1P is primarily found in the cytoplasm or localised in the perinuclear space 
(204). The intracellular localisation allows C1P to play important roles in 
regulating intracellular signalling pathways. C1P has been shown to regulate the 
eicosanoid metabolism pathway (204). 
1.3.8.5 C1P in inflammation 
C1P is the least studied member of the sphingolipid family. Indeed, since the 
discovery of the ceramide kinase enzyme, many functions ascribed to ceramide 
have been re-assigned as functions of C1P (205). C1P was found to directly 
interact with Ca2+ dependent phospholipid binding domain on cytosolic 
phospholipase A2 (cPLA2) (206). This resulted in the production of PGE-2 and its 
downstream effects (207). Moreover, C1P was found to cause mast cell 
degranulation in a Ca2+ dependent manner (208). Inhibiting ceramide kinase was 
found to reverse this effect (209).  
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1.3.8.6 Sphingosine 1-phosphate  
S1P is the most widely studied member of the sphingolipid family. S1P is 
produced by one of two enzymes SPHK1 or SPHK2 (210). Both enzymes are either 
found in the cytosol or bound to the nuclear membrane (211). S1P can have both 
autocrine and paracrine effects on cells (205). Intracellular S1P can regulate 
calcium response pathways via modulation of phospholipase C/inositol 1,4,5 tri-
phosphate pathways (212). S1P also affects cell proliferation and survival by 
regulating B cell lymphoma-2 (Bcl-2) family members (213, 214).  
Paracrine effects are possible due to the extracellular export of S1P by ATP-
binding cassette (ABC) or spinster homolog 2 (Spns2) transporters (215, 216). 
Blood plasma constitutively carries high levels of S1P (217). This S1P is produced 
by vascular endothelial cells, RBCs or platelets which are the most potent 
producers of S1P (217). S1P concentrations are typically very low in interstitial 
fluids. Therefore, S1P forms a strictly regulated gradient in mammalian systems 
(217). This gradient is critical for the regulation of leukocyte migration and will 
be explored in further detail in the “T cell trafficking” section of this thesis 
(218). 
Paracrine functions of S1P is mediated via five S1P receptors (S1PR1-S1PR5) 
(219-221). These are all 7TM GPCRs. The S1P GPCRs can couple to multiple 
different heterotrimeric G proteins and thus they can signal through multiple 
signalling pathways (212). Once S1PRs are ligand bound and signalling has 
occurred, S1PRs are internalised. Internalised S1PRs either undergo lysosomal 
degradation or are recycled back to the cell surface (212, 222, 223). Like 
chemokines, temporal and spatial expression of S1PRs are critical in determining 
the responses the ligand elicits on the target cell (205, 224). In homeostatic 
conditions, S1PR1-S1PR3 are widely expressed in various tissues and cell types 
(225). S1PR4 expression is restricted primarily to lymphoid and haematopoietic 
cells while S1PR5 is mainly found in the brain and the skin (226-229). 
S1P is constitutively expressed in almost all mammalian cell types as part of the 
plasma membrane turnover (230). However, under inflammatory conditions, 
multiple stimuli upregulate S1P production. TNF-a, TGF-b and growth factors 
including platelet derived growth factor (PDGF) and vascular endothelial growth 
 
 
 51 
factor (VEGF) have so far been identified to positively regulate S1P production 
(231). All of these factors increase S1P production by regulating SPHK1 
expression levels (231).  
In contrast, very little is known about external factors that downregulate S1P 
levels at the end of inflammatory events. It is known that phosphatases and 
ceramidases play an important role in regulating levels of S1P (174). However, 
external regulation of phosphatase and ceramidase enzymes in the sphingolipid 
metabolism pathway (Figure 1.3.1) has not been yet been demonstrated (232).  
Known negative regulators of S1P include DNA damage detection, high-density 
lipoproteins (HDLs) and ceramide (231, 233-235). DNA damage downregulates 
SPHK1 expression, thus directly abrogating S1P production (235). In contrast, 
HDL regulates plasma S1P concentrations by controlling the extracellular 
transport and bioavailability of S1P to other cells (236). Ceramide is a well-
known negative regulator of S1P (177, 190). Increased levels of intracellular 
ceramide, itself regulated by exogenous stimuli such as FAS ligand and oxidative 
stress, leads to increased S1P degradation and ceramide production (237).  
Regulators of S1P and its functions are succinctly summarised in  
Figure 1.3.2. 
 
Figure 1.3.2 Regulation of S1P 
S1P levels are regulated by a variety of factors. Inflammatory cytokines and growth factors such as 
TNF-a, TGF-b, VEGF and PDGF promote the production of S1P. In contrast, DNA damage, high-
density lipoproteins (HDLs) and ceramide negatively regulate S1P levels. 
Growth 
Factors TGF-β
TNF- ⍺
CeramideDNA Damage
S1P
S1P
HDL
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1.3.8.7 S1P receptor modulators 
Functional aspects of S1P signalling were elucidated in large parts by studying 
the effect of S1PR modulators. These include S1PR pan agonists and S1PR pan 
antagonists as well as selective agonists and antagonists for individual S1P 
receptors. Here three S1PR modulators will be described very briefly. 
The best known S1PR modulator is FTY720. It is derived from a fungal protein 
and is a functional antagonist of S1PR1,3,4 and 5 (238). FTY720 binding with 
S1PRs causes receptor internalisation and their subsequent degradation (222). 
Essentially this makes the cell insensitive to S1P signals mediated via any of the 
aforementioned receptors. FTY720 has also been clinically approved for use in 
MS which is an autoimmune neuro-inflammatory disease (238). S1PR1 antagonism 
is believed to cause the arrest of auto-reactive T cells at SLOs (239). This results 
in a reduction of pathogenic T cell migration to the central nervous system, 
leading to disease abrogation (238).   
W146 is an S1PR1 selective antagonist. It is a synthetically derived small 
molecule inhibitor. W146 binds to and blocks S1PR1 mediated signalling (240). 
Finally, SEW2871 is an S1PR1 selective agonist. It is also a synthetically derived 
small molecule inhibitor. SEW2871 binding to S1PR1 causes receptor 
internalisation and signalling followed by receptor recycling to the cell surface 
(223, 241). Unlike FTY720, neither of these drugs have been approved in the 
clinic. They have primarily been used as research tools to elucidate functions of 
S1P and S1PRs (240, 241). 
S1PR modulators were primarily used in lymphocyte migration studies. T cell 
trafficking section of this thesis describes some of these studies.          
1.3.8.8 S1P in inflammation  
S1P is rapidly emerging as a critical mediator of inflammation. The primary role 
of S1P in inflammation control is to regulate the trafficking of immune cells to 
and from inflamed tissues (242). S1P controls the dwell time and egress of 
activated lymphocytes from SLOs (243). Modulating S1PR signalling via FTY720 
was found to induce tissue retention of CD4 T cells in mice (244). The same 
study reported that increased S1P levels at inflamed tissues reduce T cell egress 
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from such sites (244). Impaired T cell egress from inflamed peripheral tissues has 
been associated with exacerbation of inflammation (245). Thus, S1P controls the 
adaptive immune response to an inflammatory insult.  
Likewise, S1P regulates migration and endocytosis of DCs as well as the 
recruitment and chemotaxis of macrophages to inflamed tissues (246, 247). S1P 
further effects monocyte activation and monocyte mediated TNFa production 
(248). S1P, therefore also plays a key role in innate immune responses to 
inflammatory insults.     
S1P also regulates mast cell mediated inflammatory responses. Ligand binding to 
mast cell IgE receptors leads to S1P production in a SPHK2 mediated manner 
(249, 250). Animals with abrogated SPHK2 expression have reduced mast cell 
degranulation, cytokine and eicosanoid production (251, 252). S1P produced by 
mast cells is also transported out of the cell to elicit autocrine and paracrine 
effects (253). Mast cells express both S1PR1 and S1PR2. S1P binding to mast cell 
S1PR1 leads to mast cell migration. In contrast, S1P binding to mast cell S1PR2 
leads to mast cell degranulation (224).  
1.3.8.9 S1P in airway inflammation 
Mast cells are key contributors to airway inflammation (254). Therefore, it is 
unsurprising that S1P levels were found to be elevated in the bronchoalveolar 
lavage of asthmatics, which is an airway inflammatory disease (255). In mouse 
models of airway inflammation, FTY720 administration was found to reduce Th1 
and Th2 cell infiltration in the airway and the animals had abrogated disease 
pathogenesis (256, 257). Inhibition of SPHK1 was also shown to reduce airway 
inflammation as well as S1P concentration in bronchoalveolar lavage (258).   
S1P is involved in regulating TNF mediated responses in L929 fibroblasts and 
A549 lung epithelial cells. In these cell lines, SPHK1 was found to regulate TNF 
mediated COX-2 and PGE2 production (259). Similarly, in LPS stimulated 
macrophages, SPHK1 was found to regulate COX-2 production (260). S1P was also 
found to directly stimulate arachidonic acid production in A549 lung epithelial 
cells (261). 
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1.3.8.10 S1P in autoimmune inflammatory diseases 
Inflammatory bowel diseases (IBD) incorporate ulcerative colitis and Crohn’s 
diseases. These are both inflammatory diseases of the intestinal mucosa (262). 
Disease pathogenesis is usually mediated by dysregulated production of 
inflammatory cytokines and dysregulated T cell infiltration (262, 263). In animal 
models of colitis, FTY720 administration was found to significantly dampen 
intestinal inflammation. This was associated with an FTY720 mediated decrease 
in inflammatory cytokine production and a concomitant increase in regulatory 
cytokine production (264). In another study with SPHK1-/- animals, intestinal 
inflammation was found to be significantly reduced compared to wild type 
animals treated with an inflammatory chemical (DSS) (265). Finally, animals with 
colitis treated with oral SPHK1 inhibitors showed substantially reduced intestinal 
inflammation and inflammatory cytokine production (266).   
A role for S1P has also been suggested in RA pathophysiology. S1P levels were 
elevated in RA joints compared to osteoarthritic (OA) joints (267). Moreover, 
SPHK1 and SPHK2 expression was found to be increased in RA synovial tissues 
(268, 269). Most interestingly, in a mouse model of joint inflammation, inhibiting 
SPHK1 was found to reduce disease severity, articular inflammation and joint 
damage (270, 271). 
On top of this, S1P plays a key role in lymphocyte trafficking (272). Many 
inflammatory diseases have dysregulated lymphocyte trafficking patterns (273-
276). Therefore, one of the primary mechanism of S1P action in inflammatory 
diseases is by regulating lymphocyte trafficking (277). This will be explored in 
greater detail in the “T cell trafficking” section.  
Relevance of this section to thesis aims: 
• T cell activation, trafficking and function is regulated by inflammatory 
mediators 
• S1P and chemokines in particular, are critical for T cell trafficking 
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• Are there novel chemokine pathways that influence T cell persistence at 
inflamed tissues? 
• Does S1P also control egress or persistence of T cells at peripheral 
inflamed tissues? 
• S1P targeted drugs (FTY720) are already approved for use in MS. Could 
targeting S1P prove an effective therapeutic in other inflammatory 
diseases? 
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1.4 Innate and adaptive immunity in inflammation control 
The inflammatory response is initiated once host cells are activated by infection 
or injury. A specialised family of innate immune cells known as antigen 
presenting cells (APCs) such as DCs pick up fragments of pathogen or damaged 
tissue and migrate to downstream draining lymph nodes. Present in the lymph 
nodes are naïve cells of the adaptive immune system (T lymphocytes). 
Professional APCs process and present these epitopes known as antigens on MHC 
II to these T cells (278, 279).  
T and B cells (another adaptive lymphocyte), express unique receptors which are 
specific for a single antigen. Once, an APC carrying that antigen, encounters a T 
cell, the lymphocyte undergoes activation and clonal proliferation (279). In 
contrast, B cells primarily sense soluble antigen directly using their B cell 
receptor (BCR) (280). B cells can also however, be activated by APCs carrying 
antigen (281). 
Activated or effector T cells exit the lymph node and home to inflamed tissues 
to carry out effector functions (276, 282). Effector B cells in contrast, produce 
class switched and affinity matured antibodies which are carried in blood plasma 
to inflamed tissue sites (283). The majority of effector T/B cells undergo 
apoptotic cell death at the end of a response (284). A few of these cells 
however, become memory T/B cells and persist long term in the host (285). 
These long-lasting memory cells remain primed for rapid response in the case of 
a secondary infection by the same pathogen (285). 
While the functions of these cells are strictly regulated, in many inflammatory 
diseases functional regulation is altered or lost leading to pathogenesis (279). In 
this section, the contribution of some of these innate and adaptive immune cells 
at inflamed tissues will be explored. 
1.4.1 Neutrophils 
Neutrophils form the immune system’s primary line of defence. They constitute 
the largest proportion of leukocytes in the mammalian immune system (286). In 
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homeostatic conditions, neutrophils circulate in a resting state which ensures 
that toxic neutrophilic granules are locked away (287). Pathogenic insult or 
injury, leads to rapid neutrophil priming, recruitment and activation (288).  
Neutrophil priming occurs either by encountering PAMPs/DAMPs directly or via 
cytokine mediated manner. This leads to rapid upregulation of cell surface 
adhesion molecules which allows neutrophils to extravasate into tissues (288). 
Once in tissue, neutrophils migrate towards the pathogenic insult by sensing 
chemokine gradients such as CXCL8 (289).  
At an infected site, neutrophils can release antimicrobial peptides (AMPs), 
phagocytose or form neutrophil extracellular traps (NETs) to kill the pathogen 
(290-292). AMPs are small proteins that kill pathogens by forming pores in their 
membranes (293). Phagocytosed pathogens are killed by ROS found inside 
neutrophil intracellular phagosomes (294). NETs consist of a meshwork of 
chromatin fibres that are dotted with immobilised microbicidal molecules 
derived from neutrophil granules. NETs function by trapping and immobilising 
pathogens followed by their degradation by the microbicidal granules (295). 
Neutrophils are also adept at producing pro-inflammatory cytokines including 
TNFa, IL-1b, IL-6 and lipid mediators (296, 297). This stimulates other cells such 
as endothelial cells and macrophages to carry out their effector function (298, 
299). 
1.4.1.1 Role of neutrophils in inflammatory disease 
Neutrophils play a critical and positive role in acute infectious inflammation. 
Indeed, in human diseases of reduced blood neutrophils (severe congenital 
neutropenia), a lack of neutrophil recruitment to infected tissues leads to severe 
immunodeficiency (300). Likewise, in animal models of acute infection, systemic 
neutrophil depletion increased disease severity (301). However, the role of 
neutrophils in chronic inflammatory diseases remains controversial. 
1.4.1.2 Neutrophils in psoriasis 
One of the hallmarks of psoriasis is neutrophil accumulation in inflamed dermis 
and epidermis of the skin (302). This leads to the formation of psoriatic lesions 
(302).  Here, neutrophils get stuck in a positive feedback loop. Activated 
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neutrophils produce inflammatory cytokines, chemokines and other mediators 
which activate local macrophages and keratinocytes (303, 304). These cells 
produce more neutrophil chemoattractants and activators or undergo hyper 
proliferation (303, 305).  
The importance of neutrophils in maintaining psoriasis has been highlighted in 
animal studies where neutrophil depletion was found to alleviate symptoms in 
flaky skin mice (306). Moreover, pan selectin inhibitors, which reduced 
neutrophil recruitment to inflamed skin were found to be efficacious in murine 
models of psoriatic skin inflammation as well as in human psoriasis (307, 308). 
Finally, current anti-psoriatic therapies exert their effects, at least in part, 
through neutrophils (309). 
1.4.1.3 Neutrophils in RA 
The most abundant immune cell found in RA synovial fluid are neutrophils (310). 
Moreover, neutrophils are found in large numbers in the pannus/cartilage 
interface where most joint destruction occurs (311). Here, aggregated 
immunoglobulins activate neutrophil degranulation which leads to the 
production of ROS (311). Increased ROS production mediated oxidative stress and 
inflammatory cytokine production is directly implicated in RA pathogenesis 
(312).  
Mouse models of joint inflammation implicate neutrophils in disease further. 
K/BxN mice develop symmetrical joint swelling, pannus formation, synovial 
hyperplasia and cartilage destruction. Serum transfer from K/BxN mice to other 
mice leads to similar joint inflammation. Neutrophil depleted mice however, 
develop no diseases pathogenesis upon serum transfer. In this model, the 
inflammatory lipid mediator leukotriene B4 (LTB4) has been identified as the key 
arthritogenic molecule (313). 
In Antigen induced arthritis (AIA) and collagen induced arthritis (CIA), blocking 
neutrophil recruitment via CXCR1/2 or complement C5a receptor blockade 
abrogated joint pathology respectively (314). Lastly, as in psoriasis, first line RA 
therapy methotrexate (MTX) reduces neutrophil chemotaxis and ROS production. 
MTX also increases neutrophil apoptosis (315).   
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1.4.2 Macrophages 
The term macrophage translates as “big eaters” in Greek. Metchnikoff was the 
first person to describe the macrophage based on its primary function: eating or 
phagocytosis (316). Since discovery, macrophages were found to be much more 
heterogeneous with functions as diverse as metabolism control, wound healing, 
infection control and bone remodelling (317). Macrophages are found in almost 
all tissues of an adult mammal (318). Mouse macrophages are usually identified 
by their cell surface expression of CD64 and/or F4-80 along with CD11b in mice 
and CD11b and CD68 in humans (317, 319, 320). 
Despite significant research, macrophage development remains a topic of 
debate. The most accepted system of macrophage ontogeny defines 
macrophages as the most mature form of mononuclear phagocytes (monocytes) 
(321). Monocytes originate in the bone marrow and circulate in the vascular 
system. Some migrate into tissues and mature into tissue resident macrophages. 
Others are recruited rapidly upon tissue damage and mature into activated “M1” 
or alternatively activated “M2” macrophages based on the type of insult and 
local cytokine environment (321, 322).  
Inflammatory M1 macrophages are best known for their role in 
pathogen/apoptotic cell uptake and killing through nitric oxides. These 
macrophages also activate adaptive immune responses by presenting antigen to 
naïve T and B cells after migration to SLOs. In contrast, M2 macrophages are 
accredited with anti-parasitic and regulatory functions (323). A third group of 
macrophages have recently been identified as wound healing macrophages. They 
promote tissue repair (324). 
M1 Macrophages are the primary producers of pro-inflammatory cytokines TNFa, 
IL-1b and IL-6 amongst a myriad of other pro-inflammatory cytokines. Through 
these mechanisms macrophages control acute inflammatory insults. In contrast, 
M2 macrophages are potent producers of the anti-inflammatory cytokines TGFb 
and IL-10 which dampen immune responses (325). Dysregulation of macrophage 
activation and their mediators play key roles in development and persistence of 
many inflammatory diseases (326). 
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1.4.2.1 Macrophages in psoriasis 
The role of monocytes and macrophages in psoriatic inflammation is not well 
characterised. However, enrichment of inflammatory M1 macrophages have been 
identified in human psoriatic lesions (327). These macrophages were also found 
in other human inflammatory skin diseases such as atopic dermatitis (328). In 
two different mouse models of psoriasis-like disease, depletion of macrophages 
expressing F4-80 and CD11b were found to resolve skin inflammation (70, 329). 
In another model, polarisation of inflammatory macrophages to an M2 phenotype 
was found to abrogate allergic skin inflammation. In the absence of M2 
macrophages however, inflammation persisted (330). Interestingly, despite 
psoriasis being a disease of non-resolving skin inflammation, to date, no studies 
have investigated a role for wound healing macrophages in regulating psoriasis. 
These studies suggest that a skewed macrophage phenotype at inflamed skin 
contributes to disease pathogenesis.      
1.4.2.2 Macrophages in RA 
Macrophages play a very important role in RA pathogenesis. They are the 
primary producers of joint destructive pro-inflammatory cytokines (331). These 
cytokines activate chondrocytes and osteoclasts leading to cartilage damage and 
bone erosion (332). Macrophage numbers in the synovial lining can be used as a 
predictive biomarker for disease severity (333). Indeed, the hallmark of early RA 
is macrophage accumulation at synovial lining (334).  
Disease flares in RA strongly correlate with increased M1 macrophage 
enrichment in the joint. In contrast, quiescent phases of disease display an 
increase in M2 macrophages in the synovium (335). At an inflamed joint, 
macrophages have been shown to induce angiogenesis and hypoxia (336, 337). 
Macrophage growth factors granulocyte colony stimulating factor (G-CSF), 
macrophage colony stimulating factor (M-CSF) and granulocyte/macrophage 
colony stimulating factor (GM-CSF) are also found abundantly in inflamed joint 
tissues (335).  
Critically, most clinically effective biologics were shown to reduce macrophage 
trafficking to joints (338). Finally, in multiple models of inflammatory joint 
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diseases in mice as well as human trials, systemic depletion of macrophages 
using agents such as liposomal clodronate abrogated joint inflammation (339). 
These studies suggest that macrophages play a key role in mediating local joint 
pathology in RA.      
1.4.3 Dendritic cells 
Dendritic cells (DCs) are professional antigen presenting cells of the innate 
immune system. Their primary role is to shape adaptive immune responses by 
the activation of T and B cells (340, 341). DCs were first described by Steinman 
and Cohn as cells possessing dendritic morphology (342, 343). Like macrophages, 
DCs are found in almost all mammalian tissues. DCs are identified by their cell 
surface expression of CD11c and MHC II molecules (340).  
Subsets of DCs are often defined by combinations of additional cell surface 
receptor expression including CD11b, CD103, CD207 and CD8a. CD103 DCs are 
often described as migratory tissue DCs. They are the primary cell type that 
activate T and B cells in the SLOs. In contrast, CD8a DCs are known for their 
ability to cross present antigen to CD8 T cells. CD207 expressing DCs are also 
known as Langerhans cells. One of their specialised functions include the 
induction of regulatory T cell differentiation. Functional differences between 
subsets remain controversial however, primarily due to the plastic nature of 
DCs. Dendritic cell ontogeny and function is exhaustively reviewed by Merad et 
al. and should be read for more in depth information (340). 
DCs develop in the bone marrow from either the common myeloid progenitor 
(CMP) or the common lymphoid progenitor (CLP) (344). These differentiated but 
immature, DCs constantly sense their surroundings and either rest at tissue sites 
or circulate in the vasculature (340). Once DCs encounter pathogenic stimuli, 
usually through their PRRs, they undergo maturation which includes both 
phenotypic and morphological changes. Mature DCs process and present antigen 
on peptide:MHC complexes (341). They also express co-stimulatory molecules 
CD80/CD86 and CKR CCR7 (345, 346). They further produce pro-inflammatory 
cytokines which direct T cell polarisation (347, 348). These combined changes 
allow DCs to migrate to SLOs and present antigen to T and B cells.       
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DCs play a critical role in inflammation control by selectively driving T cell 
responses. DC activating stimuli as well as location allow DCs to imprint tissue 
homing signature on T cells (349). Furthermore, DC mediated co-stimulation and 
cytokines are the primary regulators of Th1/Th2/Th17/Treg differentiation 
(350). It is therefore unsurprising that DCs have a central role in inflammatory 
disease pathogenesis. 
1.4.3.1 Dendritic cells in psoriasis 
DC mediated activation of adaptive immune responses occur at very early stages 
of psoriasis (351). Since this breach of tolerance phase occurs prior to clinical 
manifestations, it is difficult to study and thus poorly understood in all human 
inflammatory diseases. Nonetheless, roles for skin resident dermal DCs and 
recruited plasmacytoid DCs (pDCs) have been described in maintaining psoriatic 
inflammation (351, 352). Psoriatic lesions display the presence of both Th1 and 
Th17 cells at different phases of disease (353, 354). This is believed to be 
mediated by the local cytokine environment in which DCs are activated prior to 
T cell activation (71). Moreover, the local inflammatory environment favours the 
skewing of Th17 responses with abundant presence of IL-23, IL-12 and TNF (72).   
DCs in psoriatic lesions also contribute to inflammation by their cytokine 
production. pDCs are primary producers of type I IFNs in psoriasis which acts on 
dermal DCs to stimulate their production of IL-12 (355). Moreover, DCs produce 
TNF and IL-1b to add to the local inflammatory microenvironment (356). Local 
DC-T cell interactions in ectopic lymphoid tissue like aggregates further support 
T cell activation and persistence in psoriatic plaques (357). This is particularly 
important since studies in mice have suggested that local populations of tissue 
resident DCs and memory T cells alone can initiate disease (358).  
Lastly, multiple effective therapeutics in psoriasis are found to disrupt DC-T cell 
interactions. Psolarin and ultraviolet A (PUVA) treatment reduces chronic plaque 
psoriasis by depleting lesional DCs and epidermal T cells (359). Efalizumab is a 
monoclonal antibody targeting LFA-1 on DCs. Efalizumab disrupts interaction of 
DCs with intercellular adhesion molecule-1 (ICAM-1) expressing T cells. This 
results in disease abrogation via decreased numbers of CD11c+ DCs in lesions 
 
 
 63 
(360). Finally, alefacept, a fusion protein that depletes CD2 expressing DCs and 
T cells, is also effective in psoriasis (361).      
1.4.3.2 Dendritic cells in RA  
DCs play a very similar role in RA as in psoriasis. DCs are important in breach of 
tolerance and disease initiation as demonstrated in multiple animal studies (362-
364). Inflamed synovial microenvironment allows activated DCs to constantly 
prime polarised and inflammatory Th1/Th17 cells which maintain pathogenesis 
(365, 366). DCs themselves contribute to joint destruction by producing pro-
inflammatory cytokines in synovial tissue (367). Finally, as in psoriasis, DCs play 
a key role in the formation of ectopic lymphoid aggregates near the synovium 
which maintains chronic disease (368). 
RA therapies reduce disease severity rather than cure disease. Anti-TNF and 
abatacept are two examples that act by inhibiting DC and T cell functions (369, 
370). One avenue of research being explored in RA include engineering DCs to 
tolerise activated T cells or drive regulatory instead of inflammatory T cell 
polarisation pathways. If successful, this avenue has the potential to yield a cure 
for multiple inflammatory diseases (371, 372).      
1.4.4 B cells 
B cells are adaptive immune cells of the lymphoid lineage whose primary 
function is the production of antibodies. B cells develop and mature in the bone 
marrow. Here, they undergo selection and training processes which allow them 
to discriminate self-antigen from foreign antigen. B cells express cell surface 
receptors called the B cell receptor (BCR). They use this receptor to detect 
antigen both during maturation and during a pathogenic insult (373). 
Once mature, B cells travel to SLOs where they remain until they encounter 
their cognate antigen. Antigen recognition through the BCR activates B cells to 
undergo clonal proliferation and produce antibodies. B cells are also professional 
APCs and potent cytokine producers. Certain types of antigens known as T-cell 
dependent antigens, require help from T cells to activate B cells. In these cases, 
T and B cells specific for the same antigen meet in designated areas of SLOs. In 
this area, known as the germinal centre, specialised CD4 T cells known as 
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follicular T helper cells (Tfh) provide co-stimulation and cytokine mediated 
signals to B cells (373). 
These signals allow B cells to undergo proliferation, affinity maturation and 
somatic hypermutation to produce affinity matured and class switched 
antibodies. Some B cells become long lived plasma cells which constantly 
produce low levels of antibodies. Memory B cells are also produced. These cells 
enter circulation and constantly survey the periphery to provide a rapid response 
to secondary insult from the same pathogen (373). 
B cells and their products are involved in the initiation and maintenance of 
multiple inflammatory diseases. The function of B cells in psoriasis and RA are 
briefly explored in the next sections:    
1.4.4.1 B cells in psoriasis 
The role of B cells in psoriatic inflammation remains controversial. In human 
studies, CD19+ B cell levels were found to be elevated in human psoriatic lesions 
(374). Moreover, increased levels of the cytokine IL-21 was found in psoriatic 
lesions. IL-21 is produced by Tfh cells to activate B cells in the germinal centre. 
This suggests a role for B cells in the formation of ectopic lymphoid tissues (375, 
376). Interestingly, B cells were found to produce IL-10 in psoriatic lesions, 
suggesting they may play an anti-inflammatory role (377). 
This was supported when depletion of CD20+ B cells by Rituximab therapy in RA 
or SLE patients was found to cause psoriatic inflammation in genetically non-
susceptible people (378). Animal studies further support this finding. CD19 
deficient animals were found to have increased skin inflammation in an 
imiquimod-driven model of psoriatic inflammation (377). This was directly 
associated with the depletion of IL-10 producing B10 B cells. Adoptive transfer of 
these cells ameliorated disease (377). However, no antibody mediated pathways 
have been investigated in the pathogenesis of psoriasis. Hence, while B cells may 
play a role in psoriasis, they do not seem to be a major contributor to disease 
pathogenesis.  
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1.4.4.2 B cells in RA 
B cells play a more prominent role in RA disease pathogenesis. In animal models 
of RA, B cell deficiency was found to abrogate disease (379, 380). B cells are 
thought to contribute to RA pathogenesis primarily by the production of 
autoantibodies. Autoantibodies against citrullinated peptides (ACPA), type II 
collagen (CII) and Fc portion of IgG known as rheumatoid factor (RF) are all 
major indicators of RA (381). Moreover, antibodies to CII has a direct effect on 
joint pathology by modifying collagen fibril synthesis (382, 383). Antibodies 
recognising CII also form immune complexes in the joint activating multiple pro-
inflammatory pathways including complement activation and cytokine 
production by innate cells (384). 
Evidence indicates that B cells may play a role in antigen presentation to T cells 
in the synovium. ACPA specific B cells have recently been found to be enriched 
in RA joints (385). Likewise, large presence of citrullinated peptides in RA joints 
has also been reported (386). This leads to the possibility that B cells might be 
interacting with ACPA specific T cells in the synovial environment, contributing 
to pathology (368). Rituximab therapy was also found to be efficacious in RA 
suggesting a prominent role for B cells in disease pathogenesis (387).   
1.4.5 T cells  
T cells are adaptive immune cells of the lymphoid lineage. T cells develop in the 
bone marrow and later migrate and mature in the thymus. Here they diverge 
into two separate lineages, CD4 and CD8. T cells express unique receptors on 
their cell surface named the T cell receptor (TCR). The TCR comprises of an a 
and a b chain. T cells also express CD3 and either CD4 or CD8 co-receptors (388).  
During thymic development, random gene rearrangement events allows each T 
cell to express a unique TCR. The TCR recognises a single peptide antigen in the 
context of self MHC molecules. This system allows for T cells to recognise up to 
1018 unique antigen specificities. T cells also undergo selection processes in the 
thymus which eliminate highly self-reactive cells. Despite this, some self-
reactive T cells remain and in many cases, are partly responsible for the onset of 
autoimmunity (388). 
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Once educated, naïve T cells circulate through the blood and lymphatics and 
SLOs (389). This process only stops once the T cell encounters its cognate 
antigen. Upon recognition of antigen, and co-stimulation signals from the APC, T 
cells undergo clonal proliferation and maturation (390). These effector T cells 
then migrate to inflamed or infected tissues where they carry out their effector 
functions (12, 391-393).  
Finally, upon pathogen clearance, the majority of effector T cells undergo 
apoptosis (284). A small minority of cells however, undergo transcriptional 
changes and become long lived memory cells (5).  
In this section, the various cell types will be briefly explored with a focus on CD4 
T cells and their role in mediating inflammatory diseases. 
1.4.5.1 CD8 T cells 
CD8 T cells are known as cytotoxic T cells. They regulate immune responses by 
killing damaged, infected or cancerous cells. Naïve CD8 T cells recognise antigen 
in the context of MHC I presentation by APCs. This recognition leads to clonal 
proliferation of CD8 T cells. These cells then migrate to tissue sites where they 
recognise their cognate antigen again on MHC I molecules which are expressed 
on all nucleated cells. Recognition triggers CD8 T cells to kill by forming pores 
using perforin and releasing toxic granzyme molecules inside the target cell 
(388).    
1.4.5.2 CD4 T cells 
CD4 T cells are often known as master regulators of the immune system. They 
primarily regulate immune responses via cytokine production (394). Upon 
antigen recognition via MHCII presentation by APCs, naïve CD4 T cells 
differentiate into one of five major subsets (395-399). The differentiation of T 
cells into subsets is regulated by cytokines in the immediate environment, 
usually produced by the APC (400). Table 3 below summarises the T cell subsets, 
cytokines needed for their differentiation, key transcription factors, CKR 
expression and effector cytokines. Proliferated CD4 T cells migrate to infected 
or inflamed tissues where they produce their effector cytokines. Subsets of 
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effector T cells also preferentially express sets of CKRs which allow them to 
home to specific tissue sites (14, 393, 401). 
  
T cell 
subset 
Key cytokines 
required for 
differentiation 
Transcription 
factor required 
for differentiation 
Cytokine 
profile 
Chemokine 
receptor 
expression 
Th1 IL-18 
IL-12 
T-bet 
STAT4 
IFNγ 
TNFa 
 CCR5, CXCR3 
Th2 IL-4 
IL-2 
GATA3 
STAT6 
IL-4 
IL-5 
IL-13 
 CCR4, CCR3 
Th17 TGF-β 
IL-6 
IL-21 
RORγT 
STAT3 
IL-17 
IL-22 
 CCR6 
Tfh IL-6 
IL-21 
Bcl6 
STAT3 
IL-21  CXCR5 
Treg TGF-β Foxp3 TGF-β 
IL-10 
 CCR4,5,6,8 
Table 3 CD4 T cell subsets 
 
1.4.5.3 Memory T cells 
Memory T cells (CD4 or CD8) either remain at tissue sites or circulate through 
the vasculature, tissues and SLOs (5). This allows memory cells to come into 
rapid contact with recurring pathogens (402). However, unlike naïve T cells 
which require multiple signals for activation and proliferation, memory T cells 
have a much lower threshold of activation (403). Upon activation, memory T 
cells carry out their effector functions both more quickly and with a greater 
magnitude (404). In the case of CD8 memory T cells, this usually leads to faster 
and more effective cytotoxicity (405). CD4 memory T cells rapidly produce large 
quantities of their effector cytokines (404).   
Like CD4 T cells, subclasses of memory T cells also exist (5). Memory T cells are 
subdivided based on their migration patterns. Tissue resting memory cells are 
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aptly termed tissue resident memory cells (Trm cells) while, circulating memory 
cells in SLOs or tissues are known as central memory T cells (Tcm cells) or 
effector memory T cells respectively (Tem cells). These cells are defined by 
their cell surface receptor expression (5). Table 4 summarises the memory cell 
subsets, their transcriptional profile and cell surface marker expression. 
  
Memory cell subset 
Cell surface marker 
expression 
Tissue location 
Tissue resident 
memory T-cells 
(Trm) 
CD103+, CD69+ Non-circulating, resident in 
peripheral tissues 
Effector memory T-
cells (Tem) 
CD62L lo, CCR7 lo Circulating and found in both 
SLOs and in peripheral tissues 
Central memory T-
cells (Tcm) 
CD62L hi, CCR7+ Found primarily at SLOs, 
mobilised upon infection 
Table 4 Memory T cell subsets 
 
1.4.5.4 Role of CD4 T cells in infection and inflammatory disease 
CD4 T cells carry out critical functions in the control of infection and 
inflammation. Tfh cells provide help to B cells to produce class switched 
antibodies which directly aid in infection control (399). Th1 cell production of 
IFNg primes macrophages for increased phagocytosis, increased pathogen killing 
and increased antigen presentation (325). IFNg also has anti-viral effects by 
reducing viral replication and activating NK cells which are potent killers of 
virally infected cells (406).  
Th2 cells on the other hand help in parasitic infection control. Th2 cytokines, IL-
4, IL-5 and IL-13 activate basophils, eosinophils and mast cells. They carry out 
multiple functions such as degranulation which are anti-parasitic. Finally, Tregs 
are potent producers of the anti-inflammatory cytokines IL-10 and TGFb. These 
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cytokines dampen immune responses by reducing inflammatory mediator 
production as well as activating pro-resolving pathways (407).  
While CD4 T cells are crucial in controlling infection and inflammation, 
dysregulation of CD4 T cell function causes some of the most debilitating and 
difficult to treat inflammatory conditions. Various functions of CD4 T cell subsets 
have been implicated in chronic inflammatory diseases. 
1.4.5.5 CD4 T cells in Psoriasis 
Psoriasis is an autoimmune inflammatory disease of the skin. Psoriatic lesions 
demonstrate significant hyperplasia of keratinocytes (68). For this reason, 
psoriasis was initially considered a disease of skin cell dysfunction. However, 
genetic analysis of psoriatic patients soon implicated adaptive immune cells and 
specifically CD4 T cells (73).  
Subsequently, subsets of CD4 T cells were found to accumulate in psoriatic skin 
lesions (7, 408). Moreover, Th1 and Th17 cell cytokines IFNg and IL-17 levels 
were found to be elevated in both psoriatic lesions as well as in peripheral blood 
of psoriasis patients (353, 354). Interestingly, IFNg was shown to increase Th17 
cell migration into murine inflamed skin lesions (409). Th17 cell cytokines IL-23 
and IL-21 were found to directly cause keratinocyte hyperplasia (410). This 
provided key evidence that psoriasis was mediated by a combination of Th1 and 
Th17 cells. 
Further evidence in the role of CD4 T cells in psoriasis pathogenesis comes from 
studying the efficacy of psoriasis therapeutics. T cell co-stimulation blocker 
anti-CTLA4 Ig is efficacious in psoriasis (411). Recently developed monoclonal 
antibody against the adhesion molecule LFA-1 was also highly successful. This 
antibody interferes with T cell-DC interactions but also stops effector T cell 
migration into psoriatic lesions (1, 360).   
1.4.5.6 CD4 T cells in RA      
RA is an autoimmune disease characterised by articular destruction. However, 
joint destruction occurs months or even years downstream of the breakdown of 
immunological tolerance. It is this critical event, that leads to the development 
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of auto-reactive CD4 T cells which ultimately orchestrate RA pathogenesis (363) 
. Large numbers of CD4 T cells accumulate at RA synovial tissues throughout 
disease (84).  
Moreover, in multiple mouse inflammatory joint disease models, CD4 T cells are 
essential for disease initiation, progression and pathogenesis (412, 413). 
Likewise, CD4 T cell depletion using multiple mechanisms abrogated joint 
pathology in mice (414, 415). In humans, CD4 T cell co-stimulation blockade was 
also found to be efficacious (370). Therefore, evidence strongly implicates CD4 T 
cells in RA pathology. 
Unlike infectious diseases where homogeneous CD4 T cell subsets often regulate 
disease; multiple T cell subsets are implicated in RA pathophysiology at different 
disease stages (416). Analysis of early RA joints demonstrates an abundance of 
Th2 and Th17 cytokines. Established disease joints however demonstrate 
aggregates of IFNg producing Th1 cells (417). These T cell cytokines enable 
constant activation of tissue resident macrophages, stromal cells, osteoblasts 
and chondrocytes leading ultimately to joint destruction (90). 
While accumulation of T cells at inflamed tissues is not unusual, RA joints 
exhibit large numbers of non-joint specific T cells such as influenza specific T 
cells (418). Moreover, a joint homing chemokine profile has not been identified. 
Some studies have implicated type I IFNs in aiding T cell persistence via 
decreased apoptosis at RA joints (419, 420). Others have identified the 
chemokines CXCL12/CXCR4 as important in T cell retention (84, 421). 
Psoriasis and RA are two examples of inflammatory diseases where trafficking of 
T cells remains a critical but poorly studied area. Considering the destructive 
influence of effector T cells in these tissues, targeting T cell trafficking 
pathways remains an attractive area for anti-inflammatory therapeutics. This 
project aims to use reductionist models to elucidate mechanisms of T cell 
persistence at inflamed tissues. In the next section, an overview of current 
understanding of T cell trafficking will be explored. 
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Relevance of this section to thesis aims: 
• CD4 T cells play critical regulatory role in inflammatory disease 
pathogenesis 
• Do innate immune cells at inflamed sites directly or indirectly influence 
the persistence of activated CD4 T cells? 
• Do APCs influence the persistence of CD4 T cells at inflamed sites? 
• Does the activation status of the T cell influence its persistence at 
inflamed sites? 
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1.5 T cell trafficking 
In a naïve host, only a few thousand T cells are specific for a given antigen 
(422). Naïve T cells therefore, constantly circulate through SLOs using blood and 
lymphatic vasculature to encounter its cognate antigen (389). Upon antigen 
encounter, effector T cells proliferate and migrate out of SLOs and enter 
inflamed tissues (390). Here, they carry out their effector function and either 
egress back into circulation or undergo apoptosis. In the long term, some cells 
also develop into memory cells (403).  
The processes of naïve circulation, activation, effector cell LN egress, tissue 
entry, apoptosis and tissue egress are strictly controlled. In this section, these 
aspects of T cell trafficking will be explored in the context of inflammation. 
1.5.1 Naïve T cell circulation 
Naïve lymphocyte recirculation between blood and SLOs was first demonstrated 
as far back as the 1960s (423). Circulating naïve T cells express CD62L, a lymph 
node homing molecule (424). CD62L interacts with glycosylation-dependent cell 
adhesion molecule-1 (GlyCAM-1) expressed by cells of the high endothelial 
venules of SLOs (424). This interaction enables T cells to enter LNs through high 
endothelial venules (HEVs). Naïve T cells express high levels of the CKR CCR7, 
which is often considered a LN homing CKR (424). Upon LN entry, CCL19/21 
levels guide T cell motility, migration and positioning (425, 426). These naïve T 
cells spend 6-12 hours surveying a LN for antigen. If no antigen is detected, 
naïve T cells migrate through cortical or medullary sinuses of the LN and exit 
through efferent lymphatic vessels (427, 428).  
T cell exit from LNs is regulated by S1PR1 and its ligand S1P (239, 243). 
Lymphatic endothelial cells (LECs) produce S1P in efferent lymphatic vessels 
(429). T cells expressing S1PR1 migrate towards increased S1P gradients in LECs 
which guides them out of the LN (430). In most cases, these T cells travel to the 
downstream draining lymph node and carry out the same process, eventually 
exiting back into the bloodstream. 
 
 
 73 
1.5.2 T cell activation and effector cell LN egress 
Along with CCR7, naïve T cells also express high levels of S1PR1 (431). Upon LN 
entry and survey, if a T cell detects their cognate antigen, some immediate 
changes take effect to alter its migration pattern. T cells upregulate CD69, a 
cell surface C-type lectin protein (432). CD69 is a negative regulator of S1PR1 
(433). Therefore, activated T cells rapidly downmodulate their S1PR1 expression 
(434). This ensures increased T cell dwell time in LNs to allow them to undergo 
clonal proliferation. These T cells also express increased levels of CCR7 to 
further aid LN retention (243). Sustained CCR7 signals however, desensitise the 
CKR (435).  
At this stage, the now effector T cells are ready for LN exit. They rapidly 
upregulate S1PR1 on their cell surface and downregulate CCR7 (243). This 
releases T cells from a retention phenotype to an egress phenotype. These T 
cells start randomly moving in the LN until they encounter a lymphatic sinus 
where they can sense S1P (436, 437). This promotes egress of effector T cells 
from LNs. Studies using the S1PR1 functional antagonist FTY720, demonstrated 
that T cells “log jam” at lymphatic sinuses and fail to exit LNs in the absence of 
S1P signals (272, 438, 439). S1P concentration is low in LNs, gradually increases 
in lymphatic vessels and is greatest in blood vessels (430, 440). Effector T cells 
use this gradient to circulate between SLOs and vasculature (430).  
1.5.3  Effector T cell tissue entry 
Effector T cells display tissue tropism (441). Tropism refers to the tendency of a 
T cell to preferentially migrate to a particular tissue site for example, the skin 
over others such as the gut. This tissue tropism is determined by selective 
expression of tissue homing receptors upon T cell activation (13, 15, 349). Which 
tissue-homing receptors are expressed on T cells are determined by the 
environment of the lymph node where they were activated. Moreover, the 
location of the migratory DCs which activates the T cell also plays a role in 
determining T cell tissue tropism (441). 
Tissue homing receptors primarily include cell adhesion molecules and CKRs 
(441). In humans, two such adhesion molecules, integrin a4b7 and cutaneous 
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leukocyte antigen (CLA), have been found to direct effector T cells to the gut 
and the skin respectively (13, 15, 16, 442). Inflamed vascular endothelium 
adjacent to these tissue sites express elevated levels of mucosal vascular 
addressin cell-adhesion molecule 1 (MADCAM-1) and E-selectin or P-selectin 
which are ligands for a4b7 and CLA respectively (13, 15, 16, 442).  
Chemokines and CKRs are likewise necessary for T cell tissue tropism to the gut 
and skin. a4b7 expressing T cells also selectively express the CKR CCR9 (443). 
CCL25, the ligand for CCR9 is expressed almost exclusively in the small intestinal 
lamina propria (17). Similarly, CKRs CCR4 and CCR10 are considered skin homing 
(444, 445). Most CLA expressing CD4 T cells also express CCR4 (445). Moreover, 
CCR4 ligand CCL27 is exclusively expressed by skin resident keratinocytes (14, 
444). Similar to adhesion molecules, chemokines are upregulated at inflamed 
tissues, allowing tissue specific effector T cell entry into the affected tissue. 
Therefore, adhesion molecules and CKRs synergistically regulate effector T cell 
tissue entry at inflamed sites. 
It is however, important to note, that many tissue specific effector T cells can 
be found at other tissue locations such as the lung or the brain (446). The tissue 
“post-code” system is therefore not absolute. Additionally, inflamed tissues are 
generally a permeable environment for circulating leukocytes (149). As such, 
many non-specific effector and even naïve T cells can be found at profoundly 
inflamed tissues (447, 448). 
1.5.4 Tissue egress  
Effector and memory CD4 and CD8 T cells produce cytokines and kill infected 
cells at inflamed tissues respectively (449). At the end of an effector response, T 
cells leave inflamed tissues via afferent lymphatics into tissue draining LNs (450, 
451). Failed exit of effector T cells has been associated with persistent tissue 
inflammation (245). A couple of studies have identified CCR7/CCL21 as well as 
S1PR1/S1P as regulators of T cell tissue exit (244, 452).  
Brown et al. demonstrated that fewer CCR7-/- T cells exited tissues compared to 
wild type cells in acute but not chronic inflammation (453). Additionally, CCR7-/- 
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T cells persisted at acutely inflamed lungs, epithelial tissues and skin (452, 454, 
455).  
Overexpression of S1PR1 on CD8 T cells was found to increase their tissue exit 
from multiple tissues including lungs, kidney, skin and salivary gland (456). 
Furthermore, CD69 deficient CD8 T cells failed to persist at HSV infected skin 
tissue. When these same cells were treated with an S1PR1 agonist however, 
their skin retention was restored (433). In contrast, two studies on CD4 T cells 
demonstrated that at acutely inflamed tissues, S1PR1 signals were responsible 
for reduced T cell egress from tissue sites (244). At chronically inflamed tissues 
however, S1PR1 and S1P was found to once again promote T cell tissue egress 
(453).              
1.5.5 T cell death 
Following tissue egress or indeed while still in tissue, most effector T cells 
undergo programmed cell death (PCD) (284). PCD can be triggered via one of 
three mechanisms: Autophagy, necroptosis or apoptosis. 
1.5.5.1 Autophagy 
Macroautophagy (referred to as autophagy) is a catabolic cellular process that is 
important in protein and intracellular organelle turnover as well as cytoplasmic 
renewal (457). Autophagy occurs in autophagosomes which are double 
membraned vesicles with cytoplasmic material inside. Autophagy is regulated by 
a host of autophagy related genes (ATG) (457).  
In T cells, autophagy has been reported to promote both apoptosis and survival 
(458). Two recent studies have demonstrated that effector CD4 T cells undergo 
cell death via autophagy in the absence of FADD, caspase-8 or Irgm-1 proteins 
(459, 460). In contrast, decreased number of thymocytes and peripheral T cells 
were found in ATG5-/- mice. Furthermore, increased numbers of ATG5-/- T cells 
underwent apoptosis on TCR stimulation than WT T cells (461). Inhibition of 
autophagy in effector Th2 cells was also found to increase T cell death (462).  
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1.5.5.2 Necroptosis 
Necroptosis is a programmed form of necrosis (463). It shares characteristics 
with both necrosis (unprogrammed cell death) and apoptosis. Necroptotic cells 
undergo nuclear condensation and organelle swelling like necrotic cells. 
However, the programmable nature of this death makes it similar to apoptosis. 
Molecular characterisation of necroptosis identified the use of two proteins 
receptor-interacting protein kinase 1 and 3 (RIPK1, RIPK3) as the hallmark of 
necroptotic cell death (464).  
Evidence for necroptosis in T cells is minimal. One study by Ch’en et al. 
demonstrated that caspase-8 deficient effector T cells undergo cell death using 
RIPK1 and RIPK3 mediated pathways. Moreover, they displayed typical 
necroptotic morphology (465). More recently, another study by Kesarwani et al. 
found that tumour specific CD8 T cells undergo TCR stimulation mediated 
necroptosis. Pre-treating T cells with necroptosis inhibitors increased CD8 T cell 
tumour persistence (466).       
1.5.5.3 Apoptosis 
Apoptotic cell death is the best studied and most common form of effector T cell 
death. Apoptotic cell death can occur using multiple mechanisms which can be 
largely divided between extrinsic apoptotic pathways and intrinsic apoptotic 
pathways (284). T cells undergo activated cell autonomous death (ACAD) which 
occurs in the absence of survival signals by the intrinsic apoptotic pathway 
(467). Activation induced cell death (AICD) may also be triggered in effector 
cells with TCR restimultation in the absence of secondary signals (468). This is 
mediated by the extrinsic apoptotic pathway. 
A set of proteins, often termed “the executioners of death” are caspases. 
Caspases are produced by cells as inactive zymogens that must be activated for 
effector function (469). There are two classes of caspases: initiator caspases 
(caspases 1,2,4,5,8,9,10, 11 and 12) and effector caspases (caspases 3,6,7 and 
14) (470, 471). Initiator caspases undergo activation by external stimuli and form 
large multi-protein complexes where effector caspases are activated. Effector 
caspases disrupt various cellular processes such as actin polymerization and 
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nuclear lamin formation. This causes the characteristic chromatin condensation 
and nuclear shrinkage (470, 471). Figure 1.5.1 provides a simple overview of 
both the intrinsic death pathway. 
1.5.5.3.1 Extrinsic apoptotic pathway 
Extrinsic pathway signals emanate from extracellular signals. These include TNF, 
CD95L or FAS ligand (FASL) and TNF-related apoptosis inducing ligand (TRAIL). 
They interact with their respective death receptors which include TNFR1, CD95 
or FAS, TRAILR1 and TRAILR2 (468, 472, 473). Death receptor triggering results 
in the formation of death-inducing signalling complex (DISC). In the case of 
FASL-FAS pathway, complex molecular interactions in the DISC results in the 
activation of initiator caspases 8 and 10 (474, 475). These caspases then activate 
effector caspases 3,6 and 7 which initiate apoptosis (284, 476). 
Alternatively, caspase 8 can also activate the pro-apoptotic functions of the 
mitochondria by cleaving the BCL-2 (B cell melanoma-2) family protein BID (BH3 
interacting domain-death agonist) to tBID (truncated BID). tBID causes the 
aggregation of pro-apoptotic proteins BAX (BCL-2 associated X protein) or BAK 
(BCL-2 antagonist/killer) to the mitochondria. This causes the release of 
cytochrome c from the mitochondria. Cytochrome c directs the formation of 
another death complex known as the apoptosome. In this complex, molecular 
interactions result in the activation of caspase 9. Caspase 9 then activates 
effector caspases 3,6 and 7 which initiates apoptosis (284, 476, 477).  
AICD is an example of extrinsic cell death in T cells. AICD is triggered in T cells 
by the ligation of FASL, TNFR1 and TRAILR. Most activated T cells express these 
receptors after undergoing several rounds of clonal proliferation (284). 
Interestingly however, T regulatory cells are resistant to FASL mediated 
apoptosis (478).   
1.5.5.3.2 Intrinsic apoptotic pathway 
The intrinsic pathway of apoptosis is triggered by a myriad of stimuli including 
TCR stimulation, DNA damage and cytokine deprivation. These stimuli instigate 
the permeabilisation of the mitochondrial membrane which results in the release 
of cytochrome c (479). Cytochrome c, in conjunction with APAF1, (apoptotic-
 
 
 78 
protease-activating factor 1) found in the cytoplasm, form the apoptosome. 
Apoptosome formation results in activation of caspase 9 and the downstream 
activation of caspases 3,6 and 7 as stated previously (471). 
ACAD is an example of intrinsic cell death in T cells. Activated T cells deprived 
of cytokines, produce BCL-2 family members BIM (BCL-2 interacting mediator of 
cell death) and PUMA (p53-upregulated modulator of apoptosis). These are both 
pro-apoptotic molecules that bind to, and inhibit anti-apoptotic molecules BCL-2 
and BCL-XL. BCL-2 and BCL-XL themselves inhibit accumulation of pro-apoptotic 
BAX or BAK to the mitochondria, thus maintaining mitochondrial membrane 
integrity. Once BCL-2 and BCL-XL are inhibited however, BAX or BAK actively 
accumulate at the mitochondria and induce the release of cytochrome c and its 
downstream effects (284, 476). 
 
Figure 1.5.1 The intrinsic apoptotic pathway 
Diagram adapted from Life and death in peripheral T cells (284) 
1.5.6 T cell retention 
To enable effector T cells to carry out their functions, they must persist at 
tissue sites following their recruitment and prior to their egress or death. This 
phenomenon is referred to as their retention. Retention of T cells remains, 
arguably, the least understood area of the T cell trafficking pathway. Current 
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models suggest that retention of T cells at tissue sites is mediated by a 
combination of three factors. T cells respond to positive cues which keep them 
at inflamed tissues (9, 170, 421, 480, 481). In addition, T cells downregulate 
egress receptors slowing down their exit (244, 245, 432, 433, 453). Finally, T 
cells alter their metabolic programming to enable prolonged survival (482, 483). 
One of the earliest identified retention signals for T cells was the TCR-Peptide 
MHC interaction. APCs at sites of infection/inflammation interact with effector T 
cells with cognate antigen/TCR, forcing their arrest and accumulation at 
peripheral tissues (392).  
Another positive retention cue is the cytokine TGF-b. TGF-b stimulates the 
expression of the integrin aEb7, also known as CD103, on CD8 and CD4 T cells 
(484). This enables CD8 and CD4 Trm cells to bind to E-cadherin expressed by 
epithelial cells, leading to their retention in peripheral tissues including skin, 
small intestine and brain (485-488). Likewise, CD25+ FoxP3+ regulatory CD4 T 
cells also express CD103 for their retention at peripheral tissues (481).  
Multiple chemokine-chemokine receptor pairings have also been found to 
provide tissue retention signals to T cells.  CX3CL1 was found to be necessary for 
the retention of effector CD4 T cells in the skin in a model of atopic dermatitis 
(480). In human rheumatoid synovium, CXCL12 and CXCR4 interactions have 
been described as crucial for the retention and accumulation of T cells (421). 
Chemokines have also been found to increase the survival of T cells at peripheral 
inflamed tissues. Indeed, CXCL12 was found to increase the survival of tumour 
infiltrating T cells as well as increase their chemotaxis (489, 490). Likewise, IL-
15 is necessary for the survival and retention of CD8 Trm cells at peripheral 
tissues (491). Expression of the aryl hydrocarbon receptor (AHR) has also been 
implicated in aiding survival mediated persistence of T cells at tissue sites (492). 
Recently, TRM cells have also been found to alter their metabolic programming 
and depend on fatty acid uptake and metabolism for their survival and 
persistence in tissues (483). 
Egress of T cells out of tissues is regulated by the receptors CCR7 and S1PR1 as 
discussed previously (239, 451, 452). The expression of both S1PR1 and CCR7 is 
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under the regulation of the transcription factor KLF2 (450, 456, 485). Moreover, 
CD69 is another molecule which regulates the expression of S1PR1 (433, 434). 
Both CD8 TRM cells and CD4 TRM cells have been found to express high levels of 
CD69 and low levels of KLF2 (456, 493). Indeed, while long term tissue resident 
cells may need increased chemotactic cues as well as decreased egress cues, a 
reduction in egress cues alone could be enough to increase the dwell time of 
early effector T cell populations. This would enable pathogen elimination 
without causing long term inflammation induced tissue damage. The dynamic 
regulation of S1PR1 and CCR7 expression makes them the perfect molecules to 
facilitate early retention of T cells in tissues. 
 
Figure 1.5.2 Regulation of T cell retention at peripheral tissues 
T cell retention is regulated by positive retention cues which include TCR-pMHC, CD103 and 
chemokines. T cells also receive specialised survival signals such as IL-15, AhR ligands and fatty 
acids which enables their prolonged survival in tissues. Finally, T cells downregulate egress 
receptors CCR7 and S1PR1. S1PR1 and CCR7 expression is regulated by KLF2. CD69 is also a 
negative regulator of S1PR1 expression. 
Relevance of this section to thesis aims:  
• T cell persistence at inflamed tissues could be regulated at multiple 
checkpoints of the T cell trafficking pathway 
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• Is activated T cell persistence due to decreased egress or increased 
retention signals at inflamed tissues? 
• Could increased activated T cell persistence be linked with their improved 
survival at inflamed tissues?  
• Could the behavioural patterns of activated T cells at inflamed sites 
influence their persistence? i.e. their interaction with other immune cells 
or the availability of localised soluble mediators. 
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1.6 Aims of the project 
Effector CD4 T cells accumulate at inflamed tissues in large numbers. As 
demonstrated in psoriasis and RA, accumulated CD4 T cells contribute to disease 
pathology. Moreover, removal of these cells from such sites abrogates disease. 
Increased T cell accumulation can be controlled at multiple points of the T cell 
trafficking pathway. Most studies have targeted T cell activation, inhibiting LN 
egress as well as inhibiting tissue entry of effector CD4 T cells. 
In contrast, little is known about effector T cells after entry at inflamed 
peripheral tissues. Signals that allow CD4 T cells to persist at inflamed tissues 
are poorly understood. Likewise, few studies have investigated regulation of 
effector T cell egress from inflamed tissue sites.       
This study aims to identify novel mechanisms of CD4 T cell persistence at 
inflamed tissues. Understanding these mechanisms will permit improved 
targeting of CD4 T cell mediated therapies at inflamed tissues. To achieve these 
goals, the aims in the project were set out as follows: 
1. Establish a model inflamed tissue where effector CD4 T cells persist. 
2. Identify which signals promote CD4 T cell persistence at inflamed tissue. 
3. Identify the effect these signals have on CD4 T cell behaviour. 
4. Identify whether similar control mechanisms exist in established human 
inflammatory disease.
 
 
2 Materials and Methods 
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2.1 Animals 
All animals were housed at the University of Glasgow central research facility in 
accordance with UK home office guidelines. Animals were caged appropriately 
and allowed food and water ad libitum. All procedures undertaken were 
approved under Prof. Paul Garside’s home office project license (60/4368). 
During this project, five different strains of animals were used:  
2.1.1 C57BL/6 
Male C57BL/6 mice were purchased from Harlan laboratories UK (currently 
ENVIGO) at 6 weeks of age. Mice were rested for 7 days upon arrival prior to 
commencement of any procedures. All C57BL/6 mice were used within the ages 
of 6-10 weeks as recipients in adoptive transfer experiments. 
2.1.2 CD45.1 OT-II 
CD45.1 OT-II T cell receptor (TCR) transgenic (Tg) mice (494) were bred in 
house. Most T cells in OT-II mice express a TCR which exclusively recognises 
ovalbumin (OVA) peptide 323-339. OT-II mice in my lab also express CD45.1 on 
all leukocytes. CD45 is a pan-leukocyte tyrosine phosphatase. There are two 
alleles of CD45, CD45.1 and CD45.2 They are both functionally identical. This 
enables the identification of cells transferred from a donor to a host with 
different congenic backgrounds (i.e. transfer cells from an OT-II CD45.1 host to a 
C57BL/6 CD45.2 donor) by flow cytometry. T cells from male OT-II mice were 
used between 6-10 weeks of age as donors for polarisation and adoptive transfer 
experiments. 
2.1.3 hCD2DsRed x CD45.1 OT-II (OT-II DsRed) 
hCD2DsRed mice were originally gifted by D Kioussis and A Patel, National 
Institute of Medical Research, London and bred in house at the University of 
Glasgow (495). hCD2DsRed mice have a DsRed fluorescent reporter tag attached 
to the CD2 promoter. This allows T cells to fluoresce red when excited with 
554nm wavelength of light. Some NK cells and lymphoid tissue inducer (LTi) cells 
also express DsRed in these animals. hCD2DsRed mice were crossed with CD45.1 
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OT-II mice to make OT-II DsRed mice. This ensured that most DsRed T cells also 
expressed a TCR specific for ovalbumin peptide 323-339 as described above.    
2.1.4 LysMGFP 
LysMGFP mice (496) were originally gifted by Sussan Noursargh, William Harvey 
Research Institute, London, and bred in house at the University of Glasgow. 
LysMGFP mice have a green fluorescent protein (GFP) tag attached to mouse 
lysozyme M protein. Monocytes, neutrophils and some macrophages in these 
mice express GFP. LysMGFP mice were used as recipients for some intravital 
microscopy experiments.    
2.1.5 CD11cYFP   
CD11cYFP mice (497) were bred in house and used as recipients for intravital 
microscopy experiments. These mice have a yellow fluorescent protein (YFP) tag 
attached to the CD11c protein. This enables most dendritic cells and some 
macrophages and monocytes to fluoresce yellow when excited with 500nm 
wavelength of light. CD11cYFP mice were used as recipients for some intravital 
microscopy experiments.   
2.2 Induction of inflammation 
2.2.1 LPS model 
Animals were first anaesthetised by isoflurane inhalation prior to LPS injection. 
Inflammation was then induced by intradermal injection of 10µg of bacterial 
lipopolysaccharide (LPS) from Escherichia coli (E.coli) strain 0111:B4 (Sigma-
Aldrich) in a final volume of 10µl in sterile phosphate buffered saline 
(PBS)(Gibco). Intradermal injection was carried out in the ear pinnae of mice to 
allow the development of an inflamed tissue site in the mouse skin.   
2.2.2 Chronic inflammatory model – using inert polybeads 
The beads model is akin to a delayed type (DTH) inflammation in mouse ear 
pinnae. To achieve this, mice were injected subcutaneously with OVA emulsified 
in complete Freund’s adjuvant (CFA). 100µg of a OVA/CFA was injected 
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subcutaneously into the scruff of mice in a final volume of 100µl in PBS. 
Following a rest period of 7-9 days, 25µg of OVA conjugated to polystyrene 
beads was injected intradermally into the ear pinnae of anaesthetised mice in a 
final volume of 10µl in PBS. 
2.2.3 Preparation of Beads 
Polybeads (Polysciences Inc.) were made up using the standard manufacturers 
guidelines. Briefly, 500µl of beads (2.6% w/v) (12.5mg) were washed twice in 
polylink wash buffer then resuspended in 0.17ml polylink coupling buffer. 20µl of 
a 200mg/ml EDAC solution was then added to the coupling buffer and beads mix. 
Subsequently, 2mg of OVA made up in 1ml of PBS was added to the same tube 
incubated overnight at room temperature (RT) in a shaker. The next day, the 
beads were washed twice, making sure to collect and store the supernatant for 
free protein measurement. The beads were finally resuspended in 0.4ml of 
storage buffer and stored at 4º C until required. The supernatant was measured 
for free protein using a nanodrop and the total protein bound to the beads was 
calculated accordingly.   
2.3 T cell polarisation 
2.3.1 Tissue harvesting 
OT-II and C57BL/6 mice were euthanised by cervical dislocation or CO2 
administration. Lymph nodes (OT-II) and spleen (OT-II and C57BL/6) were 
collected in PBS and stored on ice at all times. Tissues from OT-II mice and 
C57BL/6 mice were used for T cell isolation and antigen presenting cell (APC) 
fraction preparation respectively.   
2.3.2 Tissue processing 
Collected tissue was prepared into a single cell suspension by disrupting them 
through a 40µm sieve (Greiner Bio-One) using the rubbery side of the plunger of 
a 3ml syringe (BD Biosciences) in 1ml of PBS. The cells were washed through 
using sterile PBS and collected in a 50ml falcon tube (Corning). Cells were then 
centrifuged at 400x G for 5 minutes at 4°C to form a pellet. The supernatant was 
poured off and the pellet resuspended in either 1ml/10 LNs MACS buffer (1% FCS, 
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2mM EDTA in HBSS) or 0.5ml/spleen red blood cell (RBC) lysis buffer 
(eBioscience).  
Splenocytes were incubated at 4°C for 2 mins before washing thoroughly with 
PBS. The splenocytes were then resuspended in 5ml of complete RPMI (cRPMI) 
(10% FCS, 5% Pen/Strep, 5% L-glutamine) and stored at 4ºC for later use. 
2.3.3 CD4 T cell isolation 
CD4 T cells were isolated by negative selection from single cell suspension of the 
LNs and spleens from OT-II mice. To do this, a CD4 isolation kit was used from 
STEMCELL technologies (Vancouver, Canada) according to their guidelines. 
Briefly, cells were transferred from 50ml falcon to a 5ml polystyrene tube 
(Corning). 50µl of rat serum (STEMCELL technologies) was added to the tube per 
ml of cell suspension. Subsequently, 50µl of the isolation antibody cocktail was 
added to the tube per ml of cell suspension and incubated for 10 minutes at RT.  
Next, 75µl of RapidSphere beads were added per ml of cell suspension and mixed 
thoroughly before incubating at RT for 2.5 mins. These magnetic beads bind to 
all cells with antibody bound to them. The tube was then topped up to 2.5, 5 or 
10ml based on the number of LNs harvested with MACS buffer. The tube was 
then inserted into a Big Easy magnet and incubated at RT for 2.5 minutes 
allowing beads bound cells to separate from untouched CD4 T cells. Finally, the 
magnet was inverted rapidly with the tube inside to allow the unbound CD4 T 
cells to flow out into a 50ml falcon tube. 
2.3.4 APC fraction preparation 
The beads bound cells from the CD4 T cell isolation were washed and mixed in 
with the splenocytes prepared earlier in cRPMI and centrifuged and resuspended 
in 10mls of cRPMI (APC fraction). 500µl of Mitomycin C (Sigma-Aldrich) prepared 
at 1mg/ml with sterile PBS was then added to the APC fraction and all cells 
incubated for 1hr at 37°C with intermittent mixing. Mitomycin C interferes with 
DNA, RNA and protein synthesis and therefore restricts APC proliferation or 
cytokine production. Mitomycin C treated APCs were then washed 3 times in 
cRPMI before using them for T cell polarisation.    
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2.3.5 CD4 T cell polarisation 
Isolated T cells were cultured with mitomycin C treated APCs at a ratio of 
0.5x106 T cells:2.5x106 APC ratio in cRPMI. These cells were cultured in Th1 
polarising conditions. For Th1 polarisation, cultured cells were supplemented 
with 1µg/ml Ova Peptide323-339 (Sigma-Aldrich), 2-4µg/ml anti-IL4 (BioXcell) and 
10ng/ml IL-12 (R&D systems). Cells were cultured in a T25 flask in 50ml volume 
for 3 days at 37°C and 5% CO2.  
2.4 T cell treatments 
For some experiments, CD4 T cells were treated with certain compounds before 
their adoptive transfer. Polarised CD4 T cells were treated with Pertussis Toxin 
(100ng/ml) (Sigma-Aldrich), FTY720 (Sigma-Aldrich) (0.5µg/ml), SEW2871 (R&D 
Systems) (5µg/ml), W146 (R&D Systems) (5µg/ml) or vehicle for 60 mins 
(Pertussis Toxin) or 90 mins in cRPMI at 37°C and 5% CO2. Once treated, T cells 
were washed thoroughly in PBS three times. The cells were then resuspended in 
PBS in preparation for adoptive transfer. 
2.5 T cell fluorescent labelling 
For proliferation experiments, T cells were fluorescently labelled before 
adoptive transfer. After polarisation, T cells were incubated with cell tracker 
blue (Thermo-Fischer scientific) at 5µM for 15 mins at 37° C in PBS. The cells 
were shaken at 5 min intervals. Following staining, the dye was quenched by 
mixing with 1/5 volume of FCS and incubating for 5 mins. The cells were then 
washed in cRPMI twice to remove any excess dye and resuspended in PBS for 
adoptive transfer.  
2.6 T cell adoptive transfer 
T cells were adoptively transferred intradermally into inflamed or non-inflamed 
ear pinnae. This transfer was carried out for subsequent enumeration of cells by 
flow cytometry or imaging by intravital microscopy. 
For flow cytometry enumeration, polarised cell culture was washed and 
resuspended in MACS buffer in a 5ml polystyrene tube in a total volume of 5-
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10ml. The tube was then placed in the Big Easy magnet for 2.5 mins to remove 
all beads. The beads free cell suspension was poured into a 50ml falcon and 
resuspended in a known volume of sterile PBS and counted. 2-3x106 cells were 
then adoptively transferred into mouse ears. 
For intravital microscopy, similar steps were carried out, however, a much lower 
number of cells, 2-300x103 were transferred in very small volume (2-4µl) at 
shallow depths in the ear pinnae. This facilitated the visualisation of cells with 
an intravital microscope.  
2.7 Tissue digestion for flow cytometry 
Mouse ears and superficial cervical draining lymph nodes were harvested into 
empty 6 well plates or submerged in PBS respectively. The ears were then cut 
into small pieces and digested using 2mg/ml Collagenase IV (Sigma-Aldrich), 
2mg/ml hyaluronidase (Sigma-Aldrich) and 100 Units/ml DNase I (Invitrogen) 
prepared in PBS (Gibco) and incubated at 37ºC for 40 min at 180 RPM in a 
rotating incubator in a total volume of 2 ml. Following incubation, a single cell 
suspension of the ears was prepared with a gentleMACS dissociator (Miltenyi 
Biotec) using a gentleMACS C tube (Miltenyi Biotec). The cells were then counted 
using a haemocytometer and dead cells were excluded via trypan blue staining. 
Samples were stained for flow cytometry as described in section 2.8.  
Draining lymph nodes and spleens were disrupted into a single cell suspension in 
a petri dish between two pieces of 40µm nitex. The cells were then counted and 
stained for flow cytometry using antibodies as described in section 2.8. 
2.8 Flow cytometry 
Multiple types of flow cytometry staining were undertaken as part of this 
project. These included extracellular, intracellular and FLICA staining: 
2.8.1 Extracellular staining 
Single cell suspensions of cells were added to a 96 well round bottomed plate. 
The cells were incubated with a fixable viability dye (eBioscience) diluted in PBS 
for 20 mins at 4ºC. The cells were subsequently incubated with FC block (24G2 
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grown in house and mouse serum) for 20 mins at RT. Flow cytometry antibodies 
were then added at the appropriate concentration (section 2.8.6) and the cells 
were incubated for a further 20 mins at RT. Finally, cells were washed in FACS 
buffer and transferred through 40µm nitex into polystyrene FACS tubes. The 
samples were acquired on a Macsquant analyser (Miltenyi Biotec). 
2.8.2 Intracellular staining 
Intracellular staining was carried out following staining with extracellular 
antibodies using the BD bioscience intracellular staining kit. Samples were fixed 
and permeabilised using the fixation/permeabilisation buffer, incubated at RT 
for 30 mins, then washed using a perm/wash buffer.  Intracellular antibodies 
were diluted in perm/wash buffer and then added to the samples. Samples were 
incubated at RT for 45 mins. The cells were then washed, transferred through 
nitex and acquired as stated previously. 
2.8.3 FLICA staining 
Cell death was assayed using a fluorescent inhibitor of caspase assay kit (FLICA) 
(Life technologies). After extracellular staining, samples were resuspended in 
100µl cRPMI, then incubated with FLICA reagent diluted in PBS. Cells were 
cultured for 60 mins at 37°C with 5% CO2. The cells were then washed, 
transferred through nitex and acquired as stated previously.    
2.8.4 Data analysis 
Flow cytometry data was analysed using Flowjo (Treestar) version 10.0 and 
graphs were plotted on Graphpad PRISM for statistical analysis. 
2.8.5 Gating strategy 
Representative flow cytometry gating strategies are outlined below for mouse 
ear tissue and lymph nodes. All subsequent analyses were carried out on the 
gated transferred OT-II CD4 T cells. 
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2.8.5.1 Ear pinnae 
 
Figure 2.8.1 Gating strategy for the analysis of transferred CD4 T cells in ear pinnae 
Cells were first selected based on their forward and side scatter. Doublets were excluded by using 
FSC-A and FSC-H. Dead cells were then excluded and immune cells were identified based on their 
expression of CD45. Finally, transferred OT-II T cells were identified by selecting for the cells 
expressing both CD45.1, Va2 and CD4. Total cell numbers were determined by back calculating 
from these plots. 
2.8.5.2 Selection of transferred OT-II T cells 
 
Figure 2.8.2 Gating strategy for the selection of transferred OT-II T cells 
Transferred cells were identified by their expression of CD45.1, CD4 and/or Va2. Gates for 
transferred cells were set on samples from animal tissue where no OT-II T cells were transferred. 
This enabled the clear identification of transferred OT-II T cells. 
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2.8.5.3 Lymph nodes 
 
Figure 2.8.3 Gating strategy for the analysis of transferred CD4 T cells in lymph nodes 
Cells were first selected based on their forward and side scatter. Doublets were excluded by using 
FSC-A and FSC-H. Dead cells were then excluded and immune cells were identified based on their 
expression of CD45. Finally, transferred OT-II T cells were identified by selecting for the cells 
expressing both CD45.1, Va2 and CD4. Total cell numbers were determined by back calculating 
from these plots. 
 
2.8.6 Antibody list 
Cells analysed using flow cytometry studies were co-stained with the following 
antibodies in various combinations and conjugated to various fluorophores: 
Antibody Clone Dilution Company 
CD45.1 A20 1/200 eBioscience 
CD4 RM4-5 1/400 eBioscience 
Va2 B20.1 1/200 BD bioscience 
MHC II M5/114.15.2 1/800 eBioscience 
CD64 X54-5/7.1 1/200 Biolegend 
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CD8a 53-6.7 1/200 eBioscience 
CD103 M290 1/200 BD horizon 
Ly6G 1A8 1/200 BD bioscience 
CD69 H1.2F3 1/200 BD bioscience 
S1PR1 713412 5µl/sample RnD systems 
IFNg XMG1.2 1/200 Biolegend 
CD44 IM7 1/200 eBioscience 
CCR4 2G12 2µl/sample Biolegend 
CCR5 HM-CCR5 1/200 Biolegend 
CX3CR1 SA011F11 1/400 Biolegend 
Table 5 List of antibodies used for flow cytometry 
Table details information about the antibody target proteins, clones, dilutions used at and the 
companies from which they were purchased. 
2.9 Chemokine array 
The chemokine array was carried out using a chemokine profiler kit (RnD 
systems). Mouse ear tissue was digested according to section 2.7 and then 
counted. Cells were lysed in recommended lysis buffer with complete ultra mini 
protease inhibitors (Roche). Once added, cells were lysed for 30 mins in a 
shaking incubator at 4ºC. After lysis, cells were centrifuged and the supernatants 
were extracted for further processing. 
Blots from the kit were activated and blocked and cell lysate samples were 
prepared with buffers from the kit as described in the manual. A detection 
antibody cocktail was added to the samples and incubated for 1 hour at RT. 
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The activation/blocking buffer was aspirated from the blots and 
antibody+sample mix were added to 2 separate blots on the plate provided in 
the kit. The blots were then incubated overnight on a rocking shaker at 4ºC. 
Next, membranes were washed 3 times in the wash buffer provided for 10 mins 
each on a rocking platform at RT. Streptavidin-HRP was prepared according to 
the manual and added to the blots and incubated for 30mins at RT in a rocker. 
The membranes were then washed 3x as before and then carefully blot dried. 
They were then placed on plastic sheets and 1 ml of chemi reagent mix was 
added per blot as described in the manual. Another piece of plastic was placed 
on top and air bubbles ironed out. The blots were then incubated with the chemi 
reagent mix for 1 min. The blots were dried by very gently blotting blue roll on 
them. The top was then covered with another plastic sheet and imaged on a C-
Digit blot scanner (LI-COR bioscience) machine. Different exposure times were 
used to get the optimum image. 
The blot images were subsequently analysed using HLImage++ software. This 
software can differentiate the intensity of the dots and normalise it to give 
value for each chemokine assayed. 
2.10 Intravital microscopy 
2.10.1 Animal preparation 
Animals were anaesthetised using 10mg/kg ketaset mix administered intra-
peritoneally and maintained with low volume isoflurane inhalation using a gas 
mask. The ear was immobilised on a stand using veterinary grade glue and the 
core temperature of the animal maintained at 37ºC using a heat mat.  
2.10.2 Imaging 
Microscopy was carried out using a Zeiss LSM 7MP system equipped with 20×/1.0 
NA water-immersion objective lens (Zeiss UK, Cambridge, UK) and a tunable 
Titanium: sapphire solid- state two-photon excitation source (Chameleon Ultra 
II; Coherent Laser Group, Glasgow, UK) and optical parametric oscillator (OPO; 
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Coherent Laser Group). Videos were acquired in 15-30 min intervals at an X-Y 
pixel resolution of 512x512 with 1.5µm increments in Z stack. 
2.10.3 Image analysis 
Videos were analysed in Volocity version 6 after correction for tissue drift using 
second harmonic as the anchor. Individual cells were defined as objects and 
tracked manually in 3D. The generated values were used to calculate the 
velocity, meandering index and displacement of T cells. 
2.11 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISAs were performed on excised mouse ear tissue to determine the 
concentration of cytokines and chemokines. Prior to performing the ELISA, tissue 
was processed and protein concentration was measured via the bicinchoninic 
acid (BCA) assay. 
2.11.1 Tissue processing 
Mouse ears were collected and cut into small pieces in a 1.5ml eppendorf in 200-
500µl of tissue protein extraction reagent (T-PER) (Thermo Fisher scientific) in 
the presence of protease inhibitors complete ultra mini (Roche). Once cut, the 
tissue was homogenised by a motorised mortar and pestle into a fine mix. The 
eppendorfs were then centrifuged at 10,000x G for 5 mins. The supernatants 
were then collected and stored at -80ºC for further analysis. 
2.11.2 BCA assay 
BCA assays were performed to determine protein concentration of ear 
homogenates. This enabled normalisation of ELISAs by loading the same amount 
of protein sample in each well for ELISA measurement. To perform the BCA assay 
an assay kit was used from BIO-RAD laboratories following the manufacturer’s 
guidelines. Briefly, a 1mg/ml BSA was prepared in water as a stock solution. The 
BCA solution was diluted 1 in 5 as instructed in distilled water (BCA mix). A 6 
point, 1:2 serial dilution of the BSA stock solution was made using the BCA mix, 
ranging from 12µg/ml to 2µg/ml in a 96 well plate in duplicate. These samples 
are used to generate a standard curve. 1µl of each homogenate sample was then 
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added to 1ml of the BCA mix. Duplicates of this sample was added to wells in the 
96 well plate. The plate was then read in sunrise ELISA reader (Tecan) to 
determine the optical density of the samples. 
Using the standard curve, the protein concentration of each homogenate sample 
was determined and normalised appropriately for future ELISAs.  
2.11.3 CCL5 ELISA 
The CCL5 ELISA kit was purchased from RnD technologies as a duoset ELISA kit. 
Manufacturer’s guidelines were followed to perform the ELISA. Briefly, diluted 
capture antibody was coated on a 96 well microtiter plate and incubated 
overnight at RT. The plates were then washed 3 times and blot dried thoroughly. 
The plates were then blocked for non-specific binding by incubating with 
reagent diluent for 1 hour at RT. Plates were washed and dried again and 
appropriately diluted samples or standards were added to the appropriate wells. 
The plates were sealed with a plate sealer and incubated at RT for 2 hours.  
The plates were once again washed and dried before adding appropriately 
diluted detection antibody. The plates were then sealed again and incubated at 
RT for 2 hours. The plates were once again washed and dried and appropriately 
diluted streptavidin-HRP was added to each well and incubated in the dark for 
20 mins at RT. Following a further washing and drying step, substrate solution 
was added to each well and the plate incubated in the dark for 20mins at RT. 
Finally, the reaction was stopped by adding a stop solution to each well. 
The colour development was quantified using a sunrise ELISA reader (Tecan) at 
450nm with wavelength correction at 540nm. 
2.11.4 IL-7 and FASL ELISA 
IL-7 and FASL ELISAs were carried out using quantikine ELISA kits from RnD 
technologies. Manufacturer’s guidelines were followed to perform the ELISA. 
Briefly, 50µl of assay diluent was added to each well along with 50µl of 
appropriately diluted sample, standard or control. The plate was sealed and 
incubated for 2 hours at RT on a plate shaker. Wells were washed using the 
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provided wash buffer 5 times and the plate thoroughly blot dried. 100µl of 
provided conjugate was added to each well. The plates were sealed and 
incubated for 2 hours at RT on a plate shaker. The plate was washed and dried 
as before and 100µl of substrate solution was added to each well and incubated 
at RT for 30 mins in the dark. Finally, 100µl of stop solution was added to each 
well. 
Colour development was quantified using a sunrise ELISA reader (Tecan) at 
450nm with wavelength correction at 540nm. 
2.11.5 TNF ELISA 
Mouse TNF OptELA ELISA kit was purchased from BD bioscience. Manufacturer’s 
guidelines were followed to perform the ELISA. Briefly, a 96 well microtiter 
plate was coated with 100µl of capture antibody, sealed and incubated overnight 
at 4ºC. Wells were washed 3 times with recommended wash buffer and blot 
dried thoroughly the next morning. The plates were then blocked with 200µl of 
assay diluent and incubated at RT for 1 hour. After another round of washing and 
drying, 100µl of appropriately diluted standard, sample or control was added 
into appropriate wells. The plate was sealed and incubated at RT for 1 hour. The 
plates were washed and dried again and 100µl of working detector reagent 
(detection antibody + streptavidin-HRP) was added to each well. The plate was 
sealed and incubated in the dark for 1 hour at RT. The plates were washed and 
dried as before and 100µl of substrate solution was added to each well and 
incubated at RT for 30 mins in the dark. 50µl of stop solution was added to each 
well to stop the reaction. 
The colour development was quantified using a sunrise ELISA reader (Tecan) at 
450nm with wavelength correction at 570nm.  
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2.12 Mouse tissue histology and fluorescence 
microscopy 
2.12.1 Tissue harvesting and processing 
Mouse ears were collected and fixed in neutral buffered formalin between two 
pieces of filter paper ensuring the tissue remained flat to keep its structure. The 
tissue was then embedded in paraffin and cut using a cryotome at 10µm thick 
sections and embedded on superfrost plus glass slides. The slides were stored at 
4ºC until further processing.  
2.12.2 Staining for fluorescence microscopy 
Stored tissue was first deparaffinised by submerging in xylene and then hydrated 
through decreasing grades of alcohol and into water. After washing twice in Tris-
buffered saline + 0.05% tween (TBST), peroxidase activity was blocked by 
submerging slides in 0.5% hydrogen peroxide in methanol for 30 mins at RT. The 
antigens were then retrieved by boiling the slides in antigen retrieval buffer 
(abcam) for 8 mins. The sections were washed twice in TBST and blocked with 
2.5% horse serum for 30 mins at RT.  The tissue was further blocked with an 
avidin/biotin kit (Vector Labs) for 30 mins at RT. Rabbit polyclonal anti-SPHK1 
(2.5ug/ml) (abcam) or rabbit IgG (2.5ug/ml) (abcam) was then added to the 
sections and incubated overnight in a dehumidified chamber at 4ºC. The sections 
were subsequently washed and stained with anti-rabbit biotin (1-200) (Vector 
Labs) for 30 mins. The sections were finally stained with Streptavidin-PE (1-200) 
(Vector Labs) and mounted with prolong gold anti-fade mountant with DAPI. 
2.12.3 Imaging and analysis 
Slides were imaged using cell observer SD (Zeiss). Ear sections from individual 
animals were imaged using a tile scan and analysed using Imagej software (NIH). 
Three equally sized areas were randomly selected per section and the number of 
total and SPHK1+ cells manually counted, and percentages determined.  
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2.12.4 Histology staining 
For histology staining, ear section slides were deparaffinised and hydrated as 
before. The sections were then dipped in haematoxylin and washed in running 
water. The sections were then dipped in eosin, dehydrated through graded 
alcohols and xylene and mounted with DPX mounting media. The slides were 
then allowed to dry overnight. 
2.12.5 Imaging of histology sections 
Stained sections were imaged using an Olympus BX 41 microscope attached with 
a DP 25 camera with axiovision software at 10X or 20X. 
2.13 Human tissue immunohistochemistry 
2.13.1 Patient samples 
Synovial tissue specimens were obtained from RA and OA patients at the time of 
arthroscopic biopsy or total joint replacement surgeries at Glasgow Royal 
Infirmary (Glasgow, U.K.).  All RA and OA patients fulfilled the diagnostic 
criteria for RA and OA classification respectively, and written consent form was 
obtained from all subjects. All procedures received Ethics Approval (West of 
Scotland Research Ethical Committee Approval: 11/S0704/7). Collected tissue 
was preserved in 10% formalin, embedded in paraffin and cut using a cryotome 
at 5µm thick sections. 
2.13.2 Immunohistochemical staining 
Collected tissue was deparaffinised by xylene submersion and hydrated through 
decreasing grades of alcohol and into water. The sections were washed twice in 
TBST and the peroxidase activity was blocked by submerging in 0.5% hydrogen 
peroxide in methanol for 30 mins. The antigens were then retrieved by boiling 
the slides in antigen retrieval buffer (abcam) for 8 mins. The sections were then 
blocked with 2.5% horse serum for 30mins at RT. The tissue was then further 
blocked with an avidin/biotin kit (Vector Labs) for 30 mins at RT. 200µl of Rabbit 
polyclonal anti-SPHK1 (2.5ug/ml) (abcam) or Rabbit IgG (2.5ug/ml) (abcam) was 
then added to the sections and incubated overnight in a dehumidified chamber 
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at 4oC. The sections were subsequently washed and stained with anti-rabbit 
biotin (1:200) (Vector Labs) in 2.5% horse and human serum for 30 mins at RT. 
Sections were washed again and avidin/biotin complex (Vector Labs) was added 
and incubated for 30 mins. Finally, the sections were washed and dried before 
3,3’ – diaminobenzidine (DAB) (Vector Labs) was added to the sections. The 
sections were allowed to develop for 2 mins before washing, dehydration and 
mounting in DPX mountant solution. 
2.14 Statistical analysis 
All data shown were analysed using Graphpad Prism version 6. Error bars 
represent standard error of mean (SEM). One-way ANOVA statistical analysis 
tests (more than 2 groups), Mann-Whitney test (2 groups) or Student’s T-test (2 
groups) were carried out for all the data shown with Tukey’s multiple 
comparison tests (ANOVA only) to compare the differences between groups. * 
Denotes p values of <0.05, ** p<0.01 *** p<0.001. **** p<0.0001. Blank or n.s. 
denotes not significant. 
 
 
 
3 Establishment of a model inflamed site to test 
CD4 T cell persistence in mouse ear pinnae 
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3.1 Introduction 
CD4 T cells play a critical role in the initiation, maintenance and resolution of 
inflammation in numerous diseases. Immunological dogma dictates that antigen 
specific CD4 T cells proliferate and migrate to inflamed tissues. These T cells 
then carry out their effector function. Most effector T cells subsequently 
undergo apoptosis, while some turn into memory cells (284). 
Evidence from several inflammatory conditions demonstrate that activated T 
cells may also accumulate at inflamed tissues (7, 9, 84, 421, 498). Accumulation 
of CD4 T cells at inflamed tissues is associated with increased disease 
pathogenesis (245). The migration, persistence, survival, proliferation, retention 
and egress of T cells are therefore key checkpoints in controlling T cell numbers 
at inflamed tissues. A loss of regulation of these signals may lead to aberrant 
and long-term accumulation of T cells at such sites.  
3.1.1 Migration and Accumulation 
There have been numerous studies, using various models to identify and 
understand migration and accumulation signals of T cells at non-lymphoid 
tissues. Some of the earlier studies identified a critical role for selectins in 
effector T cell entry into inflamed tissues (499). Analysis of endothelial cells on 
inflamed skin has revealed abundant expression of P- and E-selectin. 
Furthermore, Th1 cells were found to express their ligands P-selectin 
glycoprotein ligand 1 (PSGL-1). These discoveries together suggested that 
selectin mediated mechanisms were critical for migration of T cells to inflamed 
skin (12).  
Later, a plethora of chemokines were identified that guided migration of specific 
subsets of CD4 T cells (Th1 vs. Th2) to home to particular tissues (393). Analysis 
of Th1 associated diseases such as RA and MS revealed an important role for the 
Th1 chemokine receptors CCR5, CXCR3 and their ligands in effector T cell 
accumulation in affected tissues (401, 500). In contrast, Th2 cells were found to 
preferentially express a different set of chemokine receptors. CCR3, CCR4, CCR8 
and CXCR4 were all identified as Th2 guiding chemokines (393, 501, 502). The 
interaction between CCR3 on Th2 cells and its ligand Eotaxin (CCL11) was 
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further identified as crucial in the migration and accumulation of these cells in 
the allergic airway (503, 504). 
Teleologically, the idea that the migration and accumulation of antigen specific 
T cells to inflamed tissues is initiated and maintained by cognate antigen and 
local tissue signature was attractive to many in the field. Hence their 
importance was investigated in several studies. Using a localised subcutaneous 
IFA injection and antigen specific T cell adoptive transfer model, Reinhardt et 
al. demonstrated that effector CD4 T cells preferentially home to, and 
accumulate in, antigen depot sites (392).  
Other studies identified that T cells primed in skin draining lymph nodes were 
preferentially recalled to the infected skin site. In contrast, T cells that were 
primed in the Peyer’s patches returned to the gut to carry out their effector 
function (505, 506). More recently, there has been a focus on the role of 
integrins in tissue homing of T cells. Conrad et al. elegantly demonstrated that 
the integrin a1b1 was crucial for the accumulation of Th1 cells in a psoriasis 
model of skin inflammation (7). Furthermore, another study found a critical role 
for aV integrins in mediating CD4 T cell motility at inflamed tissues by multi-
photon microscopy (391). Finally, the integrin CD11a was shown to be critical in 
regulating CD8 T cell accumulation in an adipose tissue inflammation model 
(507).  
3.1.2 Survival, Proliferation and Egress 
On top of increased migration and accumulation in inflamed tissues, studies have 
also suggested that inflamed tissues may provide local survival, proliferation and 
reduced egress signals to activated T cells (9, 244, 508). This increases their 
tissue dwell time, effector response time and perhaps their likelihood to develop 
into Tissue resident memory T cells (Trm).  
One study found that T cells in the RA synovium were less susceptible to 
apoptotic cell death and this increased survival was mediated by T cell 
interaction with fibroblasts in an integrin-ligand mediated manner (419). Piling 
et al. also demonstrated that T cells at chronically inflamed tissues receive 
survival cues from stromal cells via interferon b (420).  
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The local proliferation of effector CD4 T cells was demonstrated in a DTH model 
of inflammation. Here effector T cell accumulation was largely associated with 
tissue proliferation and decreased egress from local inflamed tissue which was 
mediated by CCR7 (9). Gomez et al. demonstrated in another study that 
disrupting CCR7 mediated egress of T cells from inflamed tissues led to 
aggravated local tissue inflammation (245). Lastly, the signalling sphingolipid 
S1P was found to cause tissue retention of naïve T cells at inflamed tissue sites 
in an integrin mediated manner (244). 
3.1.3 Aims of this chapter 
These elegant studies clearly demonstrate that accumulation of T cells at 
inflamed tissues is a multi-step process, regulated by several redundant factors. 
The studies also however, highlight the difficulty in separating one factor from 
another. For instance, do the chemokine receptors that signal migration of T 
cells into inflamed tissues also cause their long-term retention? Additionally, 
chemokines such as CCR7, that are responsible for tissue egress may further act 
as retention signals by desensitizing or downregulating their receptors.  
The activation and polarisation state of the T cell likewise, may have a major 
role in their mechanism of retention. Chemokine receptors are differentially 
expressed on distinctive T cell subsets. Thus, one may expect early inflamed 
tissues to recruit and retain Th1 or Th2 cells but later on attract regulatory T 
cells to help resolve the inflammation.  
In this chapter, a novel tissue adoptive transfer model was established to 
differentiate migration, persistence, retention and egress signals of CD4 Th1 
cells at inflamed tissue sites. This model was utilised in subsequent chapters, to 
specifically identify new signals which cause prolonged persistence of CD4 Th1 
cells. 
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3.2 Results 
3.2.1 Cellular profile of inflamed vs. non-inflamed ear pinnae 
An easily manipulatable inflamed tissue was required to study the fundamental 
mechanisms of CD4 T cell persistence. Requirements for such a site included 
non-invasive access to the tissue, allowing simple manipulations of the site such 
as the application of inflammatory stimuli and adoptive transfer of cells. For 
enumeration purposes, the tissue had to be relatively simple to process for both 
flow cytometric analysis and intravital microscopy. 
Furthermore, the model had to be relatively short to negate both the 
recirculation of transferred cells and the effects of endogenous T cell 
recruitment to such sites. Acknowledging this, LPS, an endotoxin from the gram-
negative bacteria E.coli was injected intradermally (ID) in the ear pinnae of 
mice to elicit acute inflammation.  
ID LPS administration in the skin leads to rapid oedematous lesion formation, 
increased vascular permeability followed by haemorrhagic necrosis within the 
space of 24 hours (509). LPS also activates TLR 4 which induces transcription of 
MyD88. This leads to production of inflammatory mediators such as TNFa and IL-
1b (510).  
To establish that LPS administration induced skin inflammation in mouse ear 
pinnae, LPS or saline was injected ID into the ear pinnae of mice. 24 hours later 
the animals were euthanised and their ears were assessed for inflammatory 
changes (Figure 3.2.1A). LPS challenged ear pinnae underwent significantly 
increased swelling compared to PBS challenged ears, suggesting oedema 
formation (Figure 3.2.1B). Visually, LPS inflamed ears developed red 
colouration, signifying an increase in local vascular permeability and perhaps 
haemorrhage of blood vessels and red blood cell infiltration (Figure 3.2.1C).  
Finally, histology was performed on LPS inflamed and saline mouse ears by 
sectioning them and staining them with haematoxylin and eosin. Haematoxylin 
typically stains cell nuclei with a blue colouration. Eosin is a non-specific protein 
stain, and it often stains red blood cells pink or red (511). LPS inflamed ears 
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displayed substantial infiltration of red blood cells and an overall increase in 
cellularity. The increase in ear pinnae thickness was also evident in LPS 
administered ears (Figure 3.2.1C). 
While histology and morphology are important in determining the state of a 
tissue, flow cytometry allows for a more rigorous approach in understanding the 
cellular changes that take place at the inflamed mouse skin. Moreover, it was 
important to determine the cellular composition of the inflamed skin to 
speculate and target potential signals that may influence CD4 T cell persistence.  
Hence, to determine the cellular changes that take place at LPS inflamed skin, 
mice were injected with LPS or saline ID as before. 24 hours later, the animals 
were euthanised and their ears collected and processed for flow cytometry. 
Inflamed ears were found to contain significantly reduced percentage of 
macrophages and CD8a DCs without affecting their total number (Figure 
3.2.2A,B). This decrease in percentage could be due to the influx of other cells 
such as CD103 DCs and neutrophils. Significant increases were found in both the 
percentage and total numbers of these cells at inflamed tissues (Figure 
3.2.2B,C).  
In summary, the data demonstrates that 24 hours post LPS administration, the 
mouse ear has undergone significant changes in its morphology and cellular 
content, suggesting the tissue has undergone a profound inflammatory response. 
The data also suggests that using LPS as an inflammatory stimulus in the mouse 
skin may be suitable to model an inflamed site to study molecular signals 
provided to T cells at inflamed tissues to cause their persistence. 
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Figure 3.2.1 Inflamed tissues undergo substantial cellular and morphological changes 
Ear thickness of age matched C57BL/6 mice at 6 weeks of age were measured prior to challenge 
with LPS (10µg/10µl) or PBS in their right ear pinnae. 24 hours later, the ears were measured 
again. Animals were then, euthanised and their ears harvested, photographed and processed for 
histology. The tissue was then stained with haematoxylin and eosin and mounted in DPX medium 
before imaging using a standard light microscope. Images shown are representative of 1 
experiment with 5 animals per group. Image magnification: 20x. Scale bar in image shows 200µm. 
Error bars in graph represent SEM. Statistical differences between groups were determined by 
carrying out an unpaired Student’s T-test in Graphpad PRISM. * denotes a p value of <0.05, ** 
<0.01. *** <0.001 and **** <0.0001 (A) Schematic of inflamed ear pinnae model. (B) Graph 
demonstrates change in ear thickness 24h after LPS or PBS administration compared with 
thickness measured prior to substance administration (time zero). (C) Representative photograph 
and H&E stained sections of LPS and PBS challenged ear pinnae.   
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Figure 3.2.2 Increased numbers of APCs and neutrophils are found at inflamed tissue sites 
Age matched C57BL/6 mice were challenged with 10µg/10µl of LPS or 10ul of PBS in their right 
ear pinnae. 24 hours later, animals were euthanised and their ears were harvested, processed and 
stained for FACS. Data is representative of 2 independent experiments with 4 animals in each 
group. FACS plots were pre-gated on live CD45+ lymphocytes. Error bars represent standard error 
of mean. Statistical differences were determined by carrying out an unpaired Student’s T test in 
Graphpad prism. * denotes a p value of <0.05, ** <0.01. *** <0.001 and **** <0.0001 
3.2.2 Detectable populations of T cells can be recovered from 
mouse ears and dLNs following adoptive transfer 
Upon establishing the potent inflammatory environment created by the 
administration of LPS in mouse ear pinnae, it was necessary to optimise both the 
dose of LPS as well as the number of T cells to transfer into the tissue. This was 
critical to reduce the use of reagents, animals and severity of the procedure. 
To test the recovery of T cells from ear skin and draining lymph nodes, 0.5, 1 or 
3 million in vitro polarised CD4 Th1 cells were adoptively transferred ID in the 
ear pinnae of mice. 24 hours later, the animals were euthanised and their ears 
and draining lymph nodes were harvested and the proportion of transferred cells 
recovered were enumerated by flow cytometry (Figure 3.2.3).  
Populations of transferred T cells, signified by their co-expression of CD45.1 and 
Va2 were observed in all three groups (Figure 3.2.3A). The best recovery of cells 
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was observed in the 3 million cell group with up to 44.5% of CD4 T cells 
representing transferred cells from the ear pinnae and up to 0.30% in the 
draining lymph node. Likewise, there was a lower, but modest recovery of 
transferred cells in the 1 million group with up to 10.8% of CD4 T cells 
representing transferred cells from the ear pinnae and 0.11% in the dLN. The 
populations recovered from the 0.5 million group however was quite modest 
from both the ear pinnae and dLN (4.41% and 0.078% respectively) (Figure 
3.2.3A).  
Next, it was important to check whether higher doses of LPS improved recovery 
of T cells from the ear tissue or dLN. To test this, mouse ear pinnae were 
challenged with either 10µg or 20µg of LPS. 24 hours later, 3 million CD4 Th1 
cells were adoptively transferred ID into the ear pinnae. 24 hours after that, the 
animals were euthanised and their ear pinnae and dLN were harvested and the 
number of T cells recovered from the tissues enumerated by flow cytometry. 
No significant differences were observed in the recovery of transferred CD4 Th1 
cells from mouse ears treated with either 10µg or 20µg of LPS. Moreover, the 
recovery of transferred cells from the draining lymph node was also not affected 
(Figure 3.2.3B) 
Hence, 10µg of LPS and greater than 1 million T cells per animal was chosen as 
the optimal conditions to test CD4 Th1 cell persistence. These values are used 
henceforth in all experiments in this thesis. 
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Figure 3.2.3 Transferring between 1 and 3.0e6 cells allows recovery of detectable population 
of CD4 Th1 cells from tissues and no difference in T cell recovery is observed between 10 
and 20ug LPS administration 
A: 0, 0.5, 1 or 3.0e6 polarised CD4 Th1 cells were adoptively transferred into the ear pinnae of age 
matched C57BL/6 mice. 24 hours later, animals were euthanised and their ears and dLN were 
harvested, processed and stained for FACS. Cells were stained with a viability dye followed by 
fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were initially 
gated on live CD45+, CD4+ cells and subsequently analysed for their expression of CD45.1 and 
Va2. FACS plots show representative examples from one experiment with 3 animals in each group. 
B: Age matched C57BL/6 mice were challenged with 10 or 20µg of LPS in their ear pinnae. 24 
hours later 3.0e6 CD4 Th1 cells were adoptively transferred into their right ear pinnae. 24 hours 
later, animals were euthanised and their ears and draining lymph nodes were harvested, 
processed and stained for FACS as above. Graphs show combined data from 1 experiment with 4 
(LPS 20µG) or 5 (LPS 10µG) animals in each group. Statistical differences were determined by 
carrying out an unpaired student’s T-test. N.s. denotes not significant. 
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3.2.3 Greater number of CD4 Th1 cells are recovered from 
inflamed tissue sites 
Accumulation of CD4 T cells at inflamed tissues has been documented in 
numerous inflammatory diseases (84, 408, 498, 512-514). However, 
accumulation of T cells comprises of distinct steps including recruitment, 
persistence, retention and egress of cells to/from inflamed sites. While studies 
have been undertaken to address each of these steps, persistence specific 
signals for CD4 T cells at inflamed tissues are poorly studied.  
Hence, an intradermal tissue adoptive transfer model was designed to 
specifically address the question of T cell persistence at inflamed tissues. To do 
this, animals were injected with LPS intradermally in their ear pinnae. Following 
the development of inflammation, activated CD4 Th1 cells were adoptively 
transferred directly into the inflamed tissue. Direct injection of T cells negated 
confounding recruitment signals. 
Th1 cells were used since activated rather than naïve T cells are usually found at 
inflamed tissues (515). Moreover, Th1 rather than Th2 or 17 cells have been 
documented to persist at inflamed RA tissues (417). Therefore, OT-II CD4 T cells 
were polarised to Th1 phenotype by culturing them in the presence of ovalbumin 
peptide (323-339), IL-12 and anti-IL-4 antibody in the presence of mitomycin C 
treated splenocytes to act as antigen presenting cells. 
OT-II mice have a transgenic TCR which specifically recognises ovalbumin at 
peptides 323-339 (494). The majority of the CD4 T cells in OT-II mice carry this 
transgenic TCR. Mitomycin C cross links DNA and causes cell cycle arrest of 
splenocytes (516). While this allows antigen presentation, it stops splenocytes 
from proliferating. IL-12 promotes naïve CD4 T cells to polarise to a Th1 
phenotype. Finally, anti-IL-4 antibody was used to ensure a pure population of 
Th1 cells were present post culture. 
Activated T cells were assessed for their polarisation into a Th1 phenotype prior 
to adoptive transfer. Th1 cells were treated with phorbol-myristate acetate 
(PMA) and Ionomycin in the presence of brefeldin A. PMA is an activator of 
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protein kinase C (PKC) and Ionomycin is a calcium ionophore (517). Brefeldin A is 
a Golgi transport inhibitor (518). Together, these compounds increase the 
production of cytokines (PMA/Ionomycin) and allows their intracellular detection 
(brefeldin A) by flow cytometry (519). 
Expression of CD44 and IFNg by polarised T cells was assessed to ensure that CD4 
T cells were of the Th1 phenotype. CD44 is a cell surface glycoprotein and cell 
adhesion molecule that is often associated with antigen experienced and 
activated CD4 T cells (520). IFNg is a cytokine that is classically associated with 
Th1 cell polarisation (521). T cells in the presence or absence of stimulation 
were universally found to express CD44. However as expected, only 
PMA/Ionomycin treated cells demonstrated a substantial production of IFNg 
(Figure 3.2.4). The data therefore demonstrates, that the polarisation protocol 
has produced a pool of activated and antigen specific CD4 Th1 cells.  
 
Figure 3.2.4 Most polarised Th1 cells express CD44 and produce IFNg 
CD4 T cells were isolated from the lymph nodes and spleens of CD45.1 OT-II mice using a 
STEMCELL technologies CD4 T cell isolation kit. The cells were then cultured with IL-12, anti-IL-4 
and ovalbumin peptide323-339 in the presence of mitomycin C treated splenocytes for 72 hours at 
37°C with 5% CO2. Thereafter, cells were stimulated with or without PMA and Ionomycin with 
brefeldin A for 4 hours. The cells were subsequently stained with fluorescently labelled antibodies 
against CD4, CD44 and intracellular IFNγ for FACS. Cells were initially gated on live CD4+ 
lymphocytes and subsequently analysed for their expression of IFNγ and CD44. Number shows the 
percentage of plotted cells in top right-hand quadrant. The plots shown are representative of 3 
independent experiments.  
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Next, these polarised Th1 cells were adoptively transferred intradermally into an 
LPS inflamed or saline treated ear pinnae. The animals were allowed to rest for 
12 or 24 hours before they were euthanised and their ear tissue and draining 
lymph nodes were harvested, assessed and enumerated at both of these time 
points.  
Significantly greater proportions and numbers of transferred Th1 cells were 
recovered from inflamed ear pinnae when compared to non-inflamed ear pinnae, 
12 hours after their transfer (Figure 3.2.5A). However, no significant differences 
were found in the transferred T cell numbers between the ear draining lymph 
nodes of inflamed or resting ears 12 hours after CD4 Th1 cell transfer (Figure 
3.2.5B). Although a trend towards decreased number of Th1 cells in the draining 
lymph nodes of inflamed ears was observed, this did not reach significance 
(Figure 3.2.5).  
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Figure 3.2.5 Greater Numbers of CD4 Th1 cells are recovered from inflamed tissues 12 
hours after adoptive transfer 
Age matched C57BL/6 mice were challenged with LPS (10µg/10µl) or PBS (10µl) in their right ear 
pinnae. 24 hours later 2.0e6 polarised CD4 Th1 cells were transferred into the same ear pinna. 12 
hours after that animals were euthanised and their right ear pinna (A) and draining lymph nodes (B) 
were harvested, processed and stained for FACS. Cells were stained with a viability dye followed 
by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were 
initially gated on live CD45+, CD4+ cells and subsequently analysed for their expression of CD45.1 
and Va2. Percentages are representative of 2 independent experiments with 11 (PBS) or 7 (LPS) 
animals in each group. Number graphs are combined data from 2 independent experiments with 11 
(PBS) or 7 (LPS) animals per group. Error bars represent standard error of mean. Statistical 
differences were determined by carrying out a Mann-Whitney test in Graphpad prism. * denotes a p 
value of <0.05, ** <0.01. n.s. denotes not significant. 
At 24 hours post transfer, significantly greater proportions and numbers of 
transferred T cells were again recovered from inflamed ears compared to resting 
ears (Figure 3.2.6A). Likewise, mimicking the 12 hour results, no differences 
were observed in the number of transferred T cells recovered from the draining 
lymph nodes of inflamed ear pinnae compared to resting ear pinnae (Figure 
3.2.6B). A similar trend of decreased transferred T cell recovery from inflamed 
ear draining lymph nodes was observed.  
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In all, the data indicates that LPS inflammation generates signals which cause 
persistence of CD4 Th1 cells early after insult in mouse skin tissues. Increased T 
cell persistence however, is not due to reduced egress of cells to ear draining 
lymph nodes. 
 
Figure 3.2.6 Greater Numbers of CD4 Th1 cells are recovered from inflamed tissues 24 
hours after adoptive transfer 
Age matched C57BL/6 mice were challenged with LPS (10µg/10µl) or PBS (10µl) in their right ear 
pinnae. 24 hours later 5.0e6 polarised CD4 Th1 cells were transferred into the same ear pinna. 24 
hours after that animals were euthanised and their right ear pinna (A) and draining lymph nodes (B) 
were harvested, processed and stained for FACS. Cells were stained with a viability dye followed 
by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were 
initially gated on live CD45+, CD4+ cells and subsequently analysed for their expression of CD45.1 
and Va2. FACS plots and percentage plots are representative of 3 independent experiments with 
12 animals in each group. Number graphs are combined data from 3 independent experiments with 
12 animals per group. Error bars represent standard error of mean. Statistical differences were 
determined by carrying out a Mann-Whitney test in Graphpad prism. ** <0.01. n.s. denotes not 
significant.  
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3.2.4 Transferred T cells do not circulate within 24 hours 
Earlier in this chapter it was stated that one of the requirements for a model to 
study T cell persistence was to minimise T cell circulation. This was important 
because systemic circulation of ID transferred T cells would complicate the 
enumeration of persistent T cells. The number of T cells recovered from the 
inflamed tissue, in that case, may represent cells that had left the tissue and 
returned prior to their enumeration. 
To investigate whether circulation of T cells occurred in this model, mice were 
challenged with PBS or LPS in their right ear pinnae. 24 hours later 2 million CD4 
Th1 cells were transferred into the same ear pinnae. 24 hours following the 
transfer, the animals were euthanised and their left ear pinnae (contra-lateral 
to the injected ear) as well as their spleen were harvested and enumerated by 
flow cytometry.  
No transferred cells were recovered from the contralateral ear of either the PBS 
or LPS challenged ear pinnae (Figure 3.2.7A). Likewise, no transferred T cells 
were detectable in the spleen of either PBS or LPS challenged ear pinnae (Figure 
3.2.7B). These data indicate that 24 hours after ID adoptive transfer of T cells in 
the ear pinnae, cells do not undergo systemic circulation. 
 
Figure 3.2.7 Few transferred T cells are recovered from peripheral tissues of mice within 24 
hours of adoptive transfer 
Age matched C57BL/6 mice were challenged with LPS (10µg/10µl) or PBS (10µl) in their right ear 
pinnae. 24 hours later 2.0e6 polarised CD4 Th1 cells were transferred into the same ear pinna. 24 
hours after that animals were euthanised and their right ear pinna (A) and draining lymph nodes (B) 
were harvested, processed and stained for FACS. Cells were stained with a viability dye followed 
by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were 
initially gated on live CD45+, CD4+ cells and subsequently analysed for their expression of CD45.1 
and Va2. FACS plots are representative of 1 experiment with 4 animals in each group. 
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3.2.5 T cells recovered from inflamed tissues are functionally 
distinct from those at resting sites 
Following the finding that activated CD4 T cells persist at LPS inflamed ear 
pinnae, it was necessary to perform some functional and phenotypic analysis of 
the recovered cells. One of the primary functions of activated CD4 T cells at 
inflamed tissues is to produce effector cytokines (449). As discussed previously, 
Th1 cells produce IFNg. Therefore, to assess the function of persisting CD4 T 
cells, their IFNg production was measured.  
Polarised Th1 cells were transferred into LPS or saline treated ear pinnae. 24 
hours later animals were euthanised and their ears and draining lymph nodes 
were harvested. After tissue processing, single cell suspensions were cultured in 
the presence of a cell stimulation cocktail containing PMA/Ionomycin and 
brefeldin A for 4 hours, following which cells were stained for extra and 
intracellular flow cytometry. A very small percentage of transferred Th1 cells 
recovered from inflamed tissues produced IFNg when compared to those 
recovered from non-inflamed tissues (Figure 3.2.8A). In the draining lymph 
nodes however, no differences were observed between the two groups (Figure 
3.2.8B). 
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Figure 3.2.8 Significantly lower proportion of CD4 Th1 cells produce IFNg at inflamed tissue 
site 
Age matched C57BL/6 mice were challenged with LPS or PBS in their right ear pinnae. 24 hours 
later 2.0e6 polarised CD4 Th1 cells were transferred into the same ear pinna. 24 hours after that 
animals were euthanised and their right ear pinna (A) and draining lymph nodes (B) were 
harvested, processed and stained for extra and intracellular FACS. Cells were stained with a 
viability dye followed by fluorescently labelled antibodies against CD45, CD4, CD45.1 and IFNg. 
Lymphocytes were initially gated on live CD45+, CD4+, CD45.1+ cells and subsequently analysed 
for their expression of IFNg. Data shown is from one experiment with 5 animals in each group. 
Error bars represent standard error of mean. Statistical differences were determined by carrying 
out an unpaired Student’s T-test in Graphpad prism. * denotes a p value of <0.05, n.s. denotes not 
significant. 
Additionally, activated T cells express CD69. CD69 is a C-Type lectin receptor 
which has often been associated with early lymphocyte activation (522). CD69 
expression is also associated with Trm cells (523). Thus, expression of CD69 by 
Th1 cells was assessed both before and after transfer.  
Before transfer, typically greater than 95% of the CD4 T cells in culture were 
found to express CD69 (Figure 3.2.9A). However, 24 hours after transfer, only 
around half the cells were expressing CD69 (Figure 3.2.9A). No differences were 
observed in CD69 expression between inflamed and non-inflamed ears (Figure 
3.2.9B).  
In contrast, significantly lower proportion of Th1 cells recovered from lymph 
nodes draining inflamed ears expressed CD69 when compared to cells recovered 
from resting draining lymph nodes (Figure 3.2.9B). Altogether, the data indicates 
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that persisting Th1 cells differ in their cytokine potential at inflamed vs. resting 
tissue sites. Furthermore, differences in CD69 expression may also play a role in 
the persistence or drainage of T cells to/from inflamed tissues. 
 
Figure 3.2.9 CD4 Th1 cells express CD69 in vitro but no difference was observed in T cell 
CD69 expression ex vivo between inflamed and resting tissues 
A: CD4 T cells were isolated from the lymph nodes and spleens of CD45.1 OT-II mice using a 
STEMCELL technologies CD4 T cell isolation kit. The cells were then cultured with IL-12, anti-IL-4 
and ovalbumin peptide323-339 in the presence of mitomycin C treated splenocytes for 72 hours at 
37°C with 5% CO2. The cells were subsequently stained with fluorescently labelled antibodies 
against CD4 and CD69 for FACS. Cells were initially gated on single, lymphocytes and 
subsequently gated for their expression of CD69 and CD4. The plot shown is representative of 3 
independent experiments.  
B,C: Age matched C57BL/6 mice were challenged with LPS or PBS in their right ear pinnae. 24 
hours later 2.0e6 polarised CD4 Th1 cells were transferred into the same ear pinna. 24 hours after 
that animals were euthanised and their right ear pinna (B) and draining lymph nodes (C) were 
harvested, processed and stained for FACS. Cells were stained with a viability dye followed by 
fluorescently labelled antibodies against CD45, CD4, CD45.1 and CD69. Lymphocytes were 
initially gated on live CD45+, CD4+, CD45.1+ cells and subsequently analysed for their expression 
of CD69. Data shown is combined from 4 experiments with 22 animals in each group. Error bars 
represent standard error of mean. Statistical differences were determined by carrying out a Mann-
Whitney test in Graphpad prism. ** denotes a p value of <0.01, n.s. denotes not significant. 
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3.2.6 Naïve CD4 T cells are retained at inflamed tissue sites 
T cells differ significantly in their form and function based on their activation 
and polarisation status. This allows naïve T cells to traffic through secondary 
lymphoid organs and re-circulate in the blood stream (389). It also allows 
effector T cells to traffic to target tissues (12, 14). Therefore, testing whether 
naïve T cells also persist at inflamed skin could provide clues as to the 
mechanism of effector T cell persistence.    
To test this, congenically labelled naïve T cells were transferred into ear pinnae 
treated with LPS or saline 24 hours previously. 24 hours after the transfer of 
cells, animals were euthanised and their ears and draining lymph nodes, which 
drain the ear, were analysed to enumerate the persistence and drainage of 
transferred cells. 
Significantly greater proportion and number of transferred CD4 T cells were 
recovered from inflamed ear pinnae compared to non-inflamed ear pinnae 
(Figure 3.2.10A). Additionally, the draining lymph nodes of inflamed ear pinnae 
contained significantly lower number of transferred T cells than the draining 
lymph node of the resting ear (Figure 3.2.10B).  
Together these data indicate that LPS inflamed skin tissues cause the retention 
rather than persistence of naïve T cells.    
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Figure 3.2.10 Greater Number of naïve CD4 T cells are recovered from inflamed tissues 24 
hours after adoptive transfer 
Age matched C57BL/6 mice were challenged with LPS or PBS in their right ear pinnae. 24 hours 
later 2.0e6 freshly isolated CD4 T cells from OT-II mice were transferred into the same ear pinna. 
24 hours after that animals were euthanised and their right ear pinna (A) and draining lymph nodes 
(B) were harvested, processed and stained for FACS. Cells were stained with a viability dye 
followed by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes 
were initially gated on live CD45+, CD4+ cells and subsequently analysed for their expression of 
CD45.1 and Va2. Data is representative of 1 independent experiment with 5 animals in each 
group. Error bars represent standard error of mean. Statistical differences were determined by 
carrying out a Mann-Whitney test in Graphpad prism. * denotes a p value of <0.05, ** <0.01. 
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3.2.7 Polarisation state of CD4 T cells does not alter their 
persistence at inflamed tissues 
The migration and retention of T cells at peripheral tissues is often dictated by 
their specific expression profile of chemokines and cell adhesion molecules (14, 
36, 393, 502). Th1 cells are known to express chemokines such as CCR5 and 9 
while Th2 cells predominantly express CCR3 and 4, guiding them to peripheral 
tissue sites (393, 502). Moreover, polarisation of T cells also influences their 
death and survival mechanisms (483, 524, 525). Hence, understanding whether 
the polarisation state of the cell contributes to their persistence in the tissue 
could enlighten a path towards understanding the mechanism of Th1 cell 
persistence at inflamed tissues. 
To investigate this, OT-II T cells were activated with ovalbumin peptide in the 
absence of an IL-12 polarising signal to generate non-polarised but activated T 
cells (referred to as Th0 cells henceforth). These cells were then adoptively 
transferred ID into LPS or PBS challenged ear pinnae as before. 24 hours later, 
the animals were euthanised and their tissues were harvested and enumerated 
by flow cytometry.  
Greater numbers of CD4 Th0 cells were recovered from LPS inflamed ear pinnae 
compared to resting tissues (Figure 3.2.11A). However, there were no 
differences observed in the proportion of transferred cells recovered from the 
tissue. Furthermore, no differences were observed in either the proportion or 
the number of transferred cells in the ear draining lymph nodes (Figure 3.2.11B). 
It is important to note that the total number transferred cells recovered from 
peripheral tissues and draining lymph nodes were far lower than the ones 
recovered from experiments where either Th1 or naïve cells were transferred. 
Altogether, the data indicates that polarisation state of the T cell may play a 
role in the persistence of T cells at inflamed tissues.  
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Figure 3.2.11 Greater number, but not proportion of Th0 cells are recovered from inflamed 
peripheral tissues 
Age matched C57BL/6 mice were challenged with LPS (10µg/10µl) or PBS (10µl) in their right ear 
pinnae. 24 hours later 3.0e6 polarised CD4 Th0 cells were transferred into the same ear pinna. 24 
hours after that animals were euthanised and their right ear pinna (A) and draining lymph nodes (B) 
were harvested, processed and stained for FACS. Cells were stained with a viability dye followed 
by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were 
initially gated on live CD45+, CD4+ cells and subsequently analysed for their expression of CD45.1 
and Va2. FACS plots and percentage plots are representative of 2 independent experiments with 9 
animals in each group. Number graphs are combined data from 2 independent experiments with 9 
animals per group. Error bars represent standard error of mean. Statistical differences were 
determined by carrying out a Mann-Whitney test in Graphpad prism. ** <0.01. n.s. denotes not 
significant.  
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3.2.8 Type of inflammation plays a role in T cell persistence 
Chronically inflamed tissues often differ from acute sites of inflammation. 
Chronic inflammation is not only defined by its period of persistence but also by 
the involvement of adaptive immune cells (61). Crucially, most human 
inflammatory diseases are examples of chronically inflamed tissues such as an RA 
joint and a psoriatic skin lesion (1).  
Previous studies have demonstrated differential regulation of cellular 
accumulation based on the inflammatory stimuli (244, 453). Thus, a model of 
persistent T cell mediated skin inflammation was designed to investigate this 
question. In this model, animals were immunised subcutaneously with ovalbumin 
emulsified in CFA. CFA consists of heat killed mycobacterial particles. It is a 
potent activator of immune responses. The emulsified solution forms a 
granulomatous depot at the site of challenge which drives persistent antigen 
presentation and antigen specific T/B cell activation in the draining lymph nodes 
(526).  
7 days post immunisation, animals were challenged with PBS, inert polybeads or 
polybeads conjugated with ovalbumin intra-dermally in the ear pinnae. The 
beads were designed to persist at the site of injection for a prolonged period of 
time. Persistent antigen at peripheral tissues is known to elicit delayed type 
hypersensitivity responses in previously immunised hosts (9). 
Ear inflammation was allowed to persist for 9 days. Inflammation was measured 
by a mouse ear swelling test (MEST) throughout the period of inflammation. 
Mouse ear thickness was found to be significantly increased in animals 
challenged with ovalbumin conjugated beads compared to beads alone or PBS 
challenged animals (Figure 3.2.12A).  
CD4 Th1 cells were then adoptively transferred ID in the previously challenged 
ear pinnae. 24 hours after transfer, animals were euthanised and their ear 
pinnae and draining lymph nodes were harvested and stained for flow cytometric 
analysis. No significant differences were observed in the proportion or number of 
transferred cells recovered from either the resting compared to the inflamed ear 
pinnae (Figure 3.2.12B).  
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Interestingly however, significantly greater proportion and number of 
transferred T cells were recovered from the draining lymph node of mice 
challenged in the ear pinnae with ovalbumin conjugated beads compared with 
either beads alone or PBS (Figure 3.2.12C).   
Finally, differences in the number of endogenous CD4 T cells were enumerated 
to determine whether T cell mediated inflammation had taken place. 
Significantly greater numbers of endogenous CD4 T cells were recovered from 
the ear pinnae of animals challenged with ovalbumin conjugated beads 
compared to either beads alone or PBS. No significant differences were observed 
in the number of endogenous CD4 T cells between the groups in the draining 
lymph nodes (Figure 3.2.12D). 
These data demonstrate that T cell persistence at inflamed tissues is dependent 
on the type of inflammation. While acute bacterial inflammation promotes 
persistence of Th1 cells, chronic hypersensitive inflammation does not. 
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Figure 3.2.12 CD4 Th1 cells do not persist at chronically inflamed tissues 
Age matched C57BL/6 mice were challenged with Ovalbumin emulsified in CFA (100µg/100µl) 
subcutaneously. 7 days later, PBS, beads alone or ovalbumin conjugated beads were injected 
intradermally in their right ear pinna. Ear swelling was measured using digital callipers over the 
next 9 days (A). 2.0e6 CD4 Th1 cells were then adoptively transferred into the same ear pinnae. 24 
hours later, animals were euthanised and their ear pinnae or draining lymph nodes were harvested, 
analysed by flow cytometry and the number of transferred (B,C) or endogenous (D) CD4 T cells 
enumerated. Cells were stained with a viability dye followed by fluorescently labelled antibodies 
against CD45, CD4, CD45.1 and Va2. Lymphocytes were initially gated on live CD45+, CD4+ cells 
and subsequently analysed for their expression of CD45.1 and Va2. Representative FACS plots 
are shown from 1 of 2 independent experiments. Graphs show combined data from 2 independent 
experiments with 10 animals per group. Error bars represent standard deviation. Statistical 
differences were determined by carrying out a One-way ANOVA and Tukey’s multiple comparisons 
test in Graphpad PRISM. * denotes a p value of <0.05. 
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3.2.9 Cellular profile of chronically inflamed tissues 
The interesting finding that Th1 cells did not persist in antigen mediated delayed 
type hypersensitivity inflamed tissue led to the hypothesis that LPS inflamed and 
DTH inflamed tissues were different from each other. Thus, the myeloid cell 
profile of the chronically inflamed tissue was also characterised. 
Mice were challenged subcutaneously with Ova emulsified in CFA. 7 days later, 
PBS or ovalbumin conjugated beads were injected intradermally to induce 
inflammation. 9 days later, OT-II Th1 cells were transferred into these same 
ears. 
Mice injected with Ova-beads had significantly greater numbers of macrophages, 
CD103 DCs, CD11b DCs, CD8a DCs and neutrophils compared to PBS challenged 
mice. No differences were observed in the proportions of macrophages or CD8a 
DCs but reduced proportions of CD103 and CD11b DCs were found at ova-beads 
challenged ears compared to PBS challenged ears. The proportion of neutrophils 
were also substantially increased in Ova-beads challenged ears. These data 
indicate that antigen-mediated chronic DTH inflammation causes significant 
infiltration of multiple myeloid cell populations (Figure 3.2.13). 
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Figure 3.2.13 Chronically inflamed tissues have increased proportions and numbers of 
APCs and neutrophils compared to non-inflamed tissues 
Age matched C57BL/6 mice were challenged with Ovalbumin emulsified in CFA (100µg/100µl) 
subcutaneously. 7 days later, PBS or ovalbumin conjugated beads (Ova-beads) were injected 
intradermally in their right ear pinna. 9 days later, animals were euthanised and their ears were 
harvested, processed and stained for FACS. Data is representative of 2 independent experiments 
with 4 animals in each group. FACS plots were pre-gated on live CD45+ lymphocytes. Error bars 
represent standard error of mean. Statistical differences were determined by carrying out an 
unpaired Student’s T test in Graphpad prism. * denotes a p value of <0.05, ** <0.01. *** <0.001 and 
**** <0.0001. n.s. denotes not significant. 
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3.3 Discussion 
Immune cell trafficking to and from inflamed tissues is a critical process for the 
mammalian immune system. It enables CD4 T cells to be at the right place at the 
right time. Naïve T cells circulate through SLOs until they encounter their 
cognate antigen (389). In contrast, effector T cells migrate from SLOs to 
inflamed peripheral tissues, upon activation (276). Once at inflamed tissues, CD4 
T cells can help clear pathogen and resolve inflammation. However, in chronic 
inflammatory diseases, CD4 T cells can accumulate at affected tissues (7, 84, 
421). This can prolong and exacerbate inflammation, leading to tissue damage. 
In this chapter, an inflamed tissue model was developed to study effector CD4 T 
cell persistence. Understanding T cell persistence may allow us to develop 
therapies which reduce inflammation in chronic diseases or increase persistence 
in vaccine settings.   
3.3.1 LPS elicits substantial tissue inflammation 
To set up a short-term tissue inflammation model, LPS was administered 
intradermally in the ear pinnae of mice. LPS was chosen as an inflammatory 
stimuli due to its ability to induce rapid acute inflammation (527). Rapid 
inflammation was necessary to enable the study of early stages of inflammatory 
responses. 
LPS injection in the ear pinnae caused significant ear swelling 24 hours after 
administration. In addition, histology showed that inflamed ear pinnae had 
significant RBC extravasation into the tissue. Both of these findings are 
supported by previous studies and confirmed that LPS caused early and 
significant inflammation in mouse skin. 
LPS administration also caused substantial cellular changes. Significantly greater 
numbers of neutrophils and CD103+ DCs were found in inflamed ear pinnae. 
Neutrophil influx into early inflamed tissues is well documented (527). Early 
neutrophil influx is guided by the chemokine CXCL8 (528, 529). LPS mediated 
upregulation of CXCL8 production has been reported in multiple studies (530, 
531). Likewise, the recruitment of CD103+ DCs into inflamed or damaged tissues 
at early time points is well documented in the literature (532). 
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In sum, injection of LPS in the mouse ear pinnae caused a significant 
development of inflammation, 24 hours post administration. This model tissue 
site may form a suitable site to study the persistence of CD4 T cell persistence. 
3.3.2 Tissue inflammation promotes T cell persistence 
To develop a model of T cell persistence at the newly designed inflamed tissue, 
polarised CD4 Th1 cells were adoptively transferred intradermally into the pre-
treated ear pinnae. Direct transfer of cells into the inflamed tissue was a key 
point in the design of the model and played a significant role in the choice of 
tissue site. Direct transfer enabled me to exclude compounding recruitment 
signals. Hence, any effects observed would be as a direct result of signals which 
the cells received following their artificial recruitment into the tissue. The ear 
pinnae was a suitable site for such adoptive transfers (244). Likewise, Th1 cells 
were chosen due to their reported accumulation at, and role in, early stages of 
tissue inflammatory diseases such as RA and psoriasis (7, 66, 69, 413). 
A greater proportion and number of transferred cells were recovered from 
inflamed ear pinnae compared to resting ear pinnae, 12 and 24 hours after T cell 
transfer. In contrast, no differences were observed in the numbers of 
transferred cells at lymph nodes draining the inflamed or resting ear pinnae. 
While these results established that greater numbers of T cells remained at 
inflamed tissues, they also confirmed that this was not due to decreased T cell 
egress to draining lymph nodes. This is a key point as previous studies have 
demonstrated a role for CCR7 in controlling T cell accumulation at inflamed 
tissues by regulating their tissue egress (451, 452). Hence, my model indicates 
that mechanisms other than CCR7 mediated retention also play a role in the 
regulation of peripheral T cell accumulation. 
3.3.3 T cells at inflamed tissues are functionally distinct 
Transferred T cells recovered from resting or inflamed tissues were analysed for 
their production of IFNg. A significantly greater proportion of T cells recovered 
from resting tissues were found to produce IFNg, compared to T cells from 
inflamed tissues. This finding was surprising since effector T cells normally carry 
out their function at inflamed tissues (441). IFNg plays a critical role in 
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activating macrophages to induce pathogen killing (533, 534). In contrast, IFNg 
can increase pathogenesis in chronic inflammatory diseases by aberrant and 
prolonged activation of innate immune cells which in turn causes tissue damage 
(535).  
One explanation for this could be, that Th1 cells were artificially placed in a 
tissue site where they did not receive the correct signals. Therefore, their 
production of IFNg was not a directed response. Studies have previously shown 
that CD4 T cells undergoing AICD often produce large amounts of IFNg. Moreover, 
studies have also reported the necessity of IFNg for the induction of apoptosis 
(536, 537). This suggests that IFNg producing Th1 cells at non-inflamed tissues 
may be undergoing apoptosis. 
T cell expression of CD69, an early lymphocyte activation marker was also 
analysed prior to transfer and after recovery from tissues. CD69 has previously 
been described as a lectin that promotes memory T cell persistence and 
retention in peripheral tissues (523). Almost all Th1 cells were found to be CD69 
positive prior to transfer. Following recovery from tissue however, no 
differences were observed in the proportion of T cells expressing CD69. This 
result suggests that the activation state of the T cell may dictate the mechanism 
of its persistence. I.e. effector T cells use a different signal for tissue 
persistence than naïve or memory T cells. 
3.3.4 Activation state of T cell and inflammatory stimuli affects T 
cell persistence 
T cells differ significantly in their function and receptor expression based on 
their state of activation (538, 539). Naïve T cells express high levels of CCR7 to 
enable them to home to SLOs (345). Effector T cells in contrast express tissue 
specific CKRs such as CCR5 (Th1) or CCR4 (Th2) (393, 401, 504). This enables 
them to traffic to inflamed or infected tissues. To understand whether 
persistence of T cells at LPS inflamed tissue was subtype specific, naïve T cells 
or T cells stimulated with peptide alone (Th0) were transferred into inflamed or 
resting ear pinnae. Greater numbers of naïve and Th0 T cells were recovered 
from inflamed tissues compared to resting tissues, phenocopying the Th1 
experiments. In contrast to the Th1 experiments, reduced number of transferred 
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naïve T cells were recovered from inflamed dLNs compared to resting ones. No 
differences were observed in the recovery of Th0 cells between resting and 
inflamed dLNs. This result indicated that naïve T cell persistence at inflamed 
tissues was due to decreased egress to draining lymph nodes, unlike Th1 and Th0 
cell persistence. Studies by Debes et al. and Bromley et al. have previously 
indicated a role for CCR7 in controlling T cell retention at peripheral tissues 
(451, 452). Naïve and effector T cells have different CCR7 expression profiles. 
Thus, changes in CCR7 ligand CCL19/21 at inflamed tissues could differentially 
regulate naïve and effector T cell retention. 
Inflamed tissues also differ significantly in terms of their morphology and 
cellular content. Whereas acute inflammation is driven primarily by innate 
immune cells and their cytokines, chronic inflammation is often driven by 
adaptive immune cells (61). Hence, I tested whether Th1 cells persist in a 
longer-term inflammation mediated by adaptive immune cells. No differences 
were found in the tissue persistence of Th1 cells at inflamed or resting tissues.  
Intriguingly, however, a greater proportion and number of OT-II cells were 
recovered from draining lymph nodes of chronically inflamed ears. This could be 
due to one of two reasons: Inflammation was induced using ova attached to 
polybeads, hence it was an antigen mediated system. Antigen could have 
drained to the local draining lymph node where ova specific transferred OT-II 
Th1 cells accumulated in response to antigen. Antigen specific T cell 
accumulation is well documented (9).  
Alternatively, T cell egress at chronically inflamed tissues could be controlled 
differently to that of acutely inflamed tissues. This idea was explored by Brown 
et al. who demonstrated that T cell exit from acute and chronically inflamed 
tissues are differentially regulated (453). The study demonstrated that CCR7 
plays an important role in T cell egress from acute but not chronically inflamed 
tissues. Thus, the authors suggested that other mechanisms may play a role in 
regulating T cell egress at chronic tissues. Investigating whether Th1 cells persist 
at chronically inflamed sites with a non-antigen specific inflammation, i.e. BSA-
specific T cells or inflammation induced by non-ova antigen, may reveal which 
mechanism might be at play here.  
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I also investigated the myeloid cell population in the Ova-beads inflamed tissue 
to check whether differences in myeloid cells could explain the lack of T cell 
persistence in this model. Despite a significantly prolonged inflammatory time 
point and a different type of insult, the myeloid compartment looked similar 
between LPS injected and Ova-beads injected tissues. The only difference 
observed was the increased number of CD64+ macrophages in the ova-beads 
tissues. Further investigations with a macrophage depleted ova-beads inflamed 
tissue could reveal whether they have a role in reducing T cell numbers at 
inflamed tissues.        
In conclusion, a model inflamed tissue site was developed in this chapter where 
CD4 Th1 cells persist. In the next chapter, both the tissue site and the cells are 
manipulated to dissect the signals which cause Th1 cell persistence at LPS 
inflamed tissue sites. 
 
 
4 Investigating the signals which cause CD4 T cell 
persistence at inflamed tissues 
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4.1 Introduction 
T cell entry into tissue sites is predominantly controlled by the varied expression 
of chemokines and cell adhesion molecules (CAMs) such as selectins and integrins 
(540). Once at a tissue site however, the signals which result in T cell 
persistence is not only regulated by the varied expression of chemokines and 
CAMs, but also antigen bearing APCs (541-545). Together, these molecules 
regulate the entry, movement and exit of leukocytes to, within and from 
inflamed tissues (149). 
Inflamed tissues further differ in their expression of survival and apoptotic 
signals. These include varied expression of death signals as well as cytokines and 
chemokines which promote and/or suppress cell survival and proliferation (525, 
546). Naturally, survival, proliferation and death signals also have an impact on 
tissue behaviour and exit of persistent leukocytes. 
In this introduction, these distinctive yet complementary processes are briefly 
explored as potential mechanisms of T cell persistence. Evidence in the 
literature is explored in context of the observed phenotype of T cell persistence 
at inflamed tissues as described in the previous chapter. 
4.1.1 Antigen mediated T cell persistence 
Naïve T cells circulate through secondary lymphoid organs. Here, they encounter 
antigen bearing APCs. The interaction between an antigen bearing APC and its 
cognate T cell results in arrest and persistence of the T cell in the SLO (545, 
547). It is believed this reduction in T cell velocity enables appropriate scanning 
and subsequent activation of T cells (548). 
At inflamed peripheral tissues, effector T cells likewise interact with antigen 
bearing APCs (549). A study by Reinhardt et al. demonstrated that this 
interaction also results in the increase of T cell persistence at the inflamed 
tissue site. However, unlike in the SLO, where antigen encounter results in T cell 
proliferation, no such proliferation was observed following antigen encounter at 
tissue site (392).  
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The exact mechanism of antigen mediated peripheral T cell persistence is not 
well understood. One possibility is that MHC-TCR interactions are sufficient to 
retain T cells, however, due to the low affinity of this interaction, it is unlikely 
to be true (550). The more attractive idea is that antigen encounter induces 
increased adhesion molecule expression on T cells, resulting in their increased 
persistence. Two studies by Andreasen et al. and Ray et al. report high 
expression of integrins on T cells at peripherally inflamed tissues, suggesting 
that this could be true (551-553).      
4.1.2 Control of T cell apoptosis   
Naïve T cells encounter antigen followed by their activation and clonal 
proliferation at SLOs (390). Effector T cells subsequently migrate to inflamed 
tissues to carry out their effector function (441). The final stage of an immune 
response is the contraction and memory phase. Here, the majority of activated 
and effector T cells undergo apoptotic cell death at tissue sites or develop into 
long lasting memory cells (403).  
Apoptotic cell death occurs via one of two pathways. Cell extrinsic pathways 
such as AICD or cell intrinsic pathways including, ACAD (284). Cellular apoptosis 
in both cases is primarily executed by proteolytic enzymes known as caspases 
(469). Caspases are initially produced as inactive zymogens. Later, these 
caspases undergo proteolytic processing leading to their activation and 
ultimately, to cell death (469). 
Caspase activation is a complex and multi-step process. Essentially, receptor 
triggering leads to a signalling cascade followed by the formation of a caspase 
initiation complex (554). In this complex, precursor initiator caspases are 
activated. These initiator caspases then activate effector caspases including, 
caspase-3, caspase-6 and caspase-7 (554).  
Effector caspases interfere with actin and nuclear lamins which maintain cell 
and nuclear morphology respectively. This leads to nuclear shrinkage, blebbing, 
cell fragmentation and the formation of apoptotic bodies (470, 471). Apoptotic 
cells further express extracellular phosphatidyl serine which triggers their 
phagocytosis by professional phagocytes (555). 
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4.1.3 Extrinsic and intrinsic executioners of death at inflamed 
tissues 
AICD on activated T cells is triggered by ligation of cell surface death receptors. 
Ligands include TNF, FASL and TRAIL. Activated T cells express TNFR1, FAS, 
TRAILR1/TRAILR2 and death receptors (DR) 3 and 6 to interact with these ligands 
(284). Some, or all of these ligands have been found across multiple inflamed 
tissues (546).  
Controversially, some of these death signals also generate pro-survival effects on 
T cells. TNF-a was found to interfere with FAS signalling and increase T cell 
survival (508). Moreover, DR3 signalling directly increased T cell accumulation 
and resistance to apoptosis (556, 557)  
ACAD, in contrast is initiated by TCR stimulation, DNA damage, ER stress and 
cytokine deprivation (467). Previous studies have demonstrated that TCR 
stimulation of activated T cells, without co-stimulatory signals, leads to 
increased apoptosis (524). Moreover, lack of cytokines such as IL-2, IL-4 and IL-7 
substantially increased T cell apoptosis (525).  
Interestingly, increased levels of IL-7 has been reported in multiple inflamed 
tissues including RA joints (558, 559). This suggests that T cell accumulation at 
inflamed sites might in part be regulated by decreased T cell apoptosis. 
4.1.4 Chemokines as regulators of T cell survival, apoptosis and 
chemotaxis 
Chemokines are chemotactic cytokines whose main function is controlling 
cellular migration (151). Chemokines also regulate cell proliferation, apoptosis 
and survival (560, 561). Chemokines signal through a multitude of G-protein 
coupled receptors known as chemokine receptors (154, 155). The differential 
effects of chemokines on cells is a consequence of distinct temporal and spatial 
expression of chemokine receptors (155). Moreover, chemokines display 
promiscuity for their receptors. This further enhances their functional repertoire 
(157). 
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Effector T cells home to inflamed tissues, guided by chemokines (36). 
Additionally, differentially polarised T cells display distinct chemokine receptor 
expression (393, 502). Migration of Th1 cells to inflamed tissues is mediated by a 
myriad of inflammatory chemokines. CCR4, CCR5, CCR9, CXCR3, CXCR4 and 
CX3CR1 are but a few of the Th1 chemokine receptors responsible for migration 
to inflamed tissues (393, 502).  
Additionally, signalling through some of these chemokine receptors has aided 
cell survival or apoptosis. CCL5-CCR5 interactions were found to increase 
apoptosis of human T cell lines via the ACAD pathway (562). CCL5 was found to 
aid survival of human macrophages (563, 564). In contrast, CXCL12-CXCR4 signals 
were initially described as anti-apoptotic in neurons but were later found to be 
pro-apoptotic in effector CD4 T cells (565, 566).  
CCL19/21 binding to CCR7 can also trigger effector T cell apoptosis in SLOs 
(567). In contrast, in vitro studies, revealed that CCR7 signals can aid survival of 
CD4 T cells (568). Exact mechanisms of antagonistic effects of chemokine ligands 
and receptors have not been elucidated. Receptor promiscuity and specific 
inflammatory settings may explain some of the observed discrepancies.   
4.1.5 Aims of this chapter 
This introduction highlights that T cell accumulation at tissue sites is regulated 
by multiple overlapping factors. Cytokines, chemokines, survival and apoptotic 
factors are intricately intertwined in this process.  
Greater numbers of transferred CD4 Th1 cells were recovered from the inflamed 
skin model established in the previous chapter. The aim for this chapter was to 
identify the signals which enable Th1 cells to persist at inflamed tissues 
compared to non-inflamed tissues.  
As part of this, cytokine, chemokine and pro-apoptotic factor production at 
tissue sites were compared. Furthermore, chemokine receptor and pro-apoptotic 
molecule expression on Th1 cells were investigated. Together, the data in this 
chapter aims to identify novel signals which cause CD4 T cell persistence at 
inflamed tissue sites. 
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4.2 Results 
4.2.1 Cognate antigen does not alter the persistence of CD4 Th1 
cells at inflamed tissues 
Migrational arrest and prolonged persistence of antigen specific T cells in 
response to cognate antigen on APCs is well documented. Studies have 
demonstrated that both naïve and effector T cells undergo antigen mediated 
arrest at SLOs and peripheral tissues (541-545).  
Hence, investigations were undertaken to determine whether cognate antigen 
mediated interactions altered the persistence of Th1 cells at LPS inflamed 
peripheral tissues. Mouse ears were inflamed by the administration of LPS in the 
presence or absence of heat-aggregated ovalbumin (HAO). HAO rather than 
soluble ovalbumin was used to ensure prolonged localised persistence of 
ovalbumin at the tissue site. 
In vitro polarised OT-II Th1 cells specific for ovalbumin were then transferred ID 
into the inflamed or resting ear pinnae, 24 hours after induction of 
inflammation. The animals were then allowed to rest for a further 24 hours prior 
to their euthanasia. Treated ear pinnae and their downstream draining lymph 
nodes were harvested and processed for flow cytometric analysis.  
Significantly greater numbers, but not proportion of transferred cells were 
recovered from LPS inflamed ear pinnae compared to resting ear pinnae as seen 
in previous experiments. HAO administration at inflamed ears did not further 
increase Th1 cell persistence. However, number of cells recovered from 
inflamed, HAO treated ear pinnae were not significantly higher than those 
recovered from resting ear pinnae. HAO administration at non-inflamed ear 
pinnae resulted in no significant changes in transferred T cell recovery (Figure 
4.2.1A). 
Likewise, HAO administration did not alter the recovery of T cells from draining 
lymph nodes draining either inflamed or resting ear pinnae. No significant 
differences were observed in either the proportions or numbers of recovered OT-
II T cells from draining lymph nodes between any groups (Figure 4.2.1B). In 
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summary, these data suggest that at acute LPS inflamed peripheral tissues, 
presence of cognate antigen does not alter T cell persistence. 
 
Figure 4.2.1 Cognate antigen does not alter the persistence of CD4 Th1 cells at LPS 
inflamed peripheral tissues 
Age matched C57BL/6 mice were challenged with LPS (10µg/10µl) or PBS (10µl) in their right ear 
pinnae with or without HAO (20µg/10µl). 24 hours later 5.0e6 polarised CD4 Th1 cells were 
transferred into the same ear pinna. 24 hours after that animals were euthanised and their right ear 
pinna (A) and draining lymph nodes (B) were harvested, processed and stained for FACS. Cells 
were stained with a viability dye followed by fluorescently labelled antibodies against CD45, CD4  
and CD45.1. Lymphocytes were initially gated on live CD45 cells and subsequently analysed for 
their expression of CD4 and CD45.1. FACS plots are representative of 2 independent experiments 
with ³ 3 animals in each group. Percentage and number graphs are combined data from 2 
independent experiments with 8 animals per group. Error bars represent standard error of mean. 
Statistical differences were determined by carrying out a One-way ANOVA and Tukey’s multiple 
comparison’s test in Graphpad prism. * <0.05.  
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4.2.2 CD4 Th1 cells exhibit altered behaviour at inflamed tissues 
Intravital multiphoton microscopy allows for imaging and analysis of cellular 
behaviour deep within tissues of living animals (569). Analysing parameters such 
as velocity, displacement and interaction of cells within tissue can illuminate 
novel behavioural mechanisms of T cell persistence at inflamed sites.  
To study such behaviours, fluorescent reporter animals were necessary. Th1 cells 
were polarised from OT-II mice that expressed an endogenous DsRed fluorescent 
protein within their T cells. These T cells were then transferred into LPS or 
saline treated ears of CD11cYFP mice. CD11cYFP mice endogenously express the 
fluorescent protein YFP within CD11c+ cells, which is classically expressed on 
dendritic cells (497).  
The second harmonic signal (blue) demarcates tissue structural complexes, such 
as collagen. It is often useful for the identification of landmarks within tissues 
such as lymphatic or blood vessels which are hollow and do not generate second 
harmonic signals.     
To understand the initial behaviours that may result in T cell persistence 24-
hours post transfer, animals were imaged for 4-5 hours after T cell transfer. 
Animals were anaesthetised and restrained on a temperature-controlled stage 
and time-series movies of cells in the ear were acquired.  
OT-II T cells displayed limited motility in resting ear pinnae with low velocity 
and displacement. In contrast, OT-II T cells in inflamed ears demonstrated 
higher motility as well as increased displacement rate (Figure 4.2.2A-D). Movies 
and still images further confirm that T cells were localised in similar locations 
either within or near collagen fibres in tissues (Figure 4.2.2E,F)(Video 1,2). The 
increased motility and displacement of T cells at inflamed ears are similar to 
that of T cells in LNs (570). This suggests that T cells at inflamed tissues are not 
restricted by tissue matrix. Highly motile behaviour also indicates the lack of 
cellular interactions. Consequently, no direct and prolonged interactions were 
observed with DCs. In contrast, the immobile Th1 cells at the saline treated ear 
pinnae looked similar to cells undergoing apoptosis (571). This suggested that 
the T cells were undergoing apoptotic death at non-inflamed sites.  
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Figure 4.2.2 CD4 Th1 cells travel greater distances at a greater velocity in inflamed tissues 
compared to resting sites 
CD11cYFP mice were challenged with either PBS or LPS. 24 hours later, ~2.0e3 polarised Th1 
cells expressing DsRed were transferred into the injection site at a shallow depth, in a small 
volume. The animals were allowed to rest for 4-5 hours before the ears were imaged using a Zeiss 
LSM 7MP microscope. Images were acquired using a 20x/1.0NA water immersion objective lens. 
Images were then analysed using volocity software and DsRed positive cells were individually 
tracked manually, generating their velocity and displacement rates. (A,B) X-Y plots show the 
distance of T cell tracks and are representative plots from 1 of 3 individual mice per treatment 
group. (C,D) Velocity and displacement graphs show combined values from 3 individual mice per 
group. (E,F) Representative stills from 1 of 3 individual mice per treatment group, illustrating 
distance travelled by T cells from time zero, indicated by arrows. Each data point represents a 
DsRed T cell and bars represent mean. In the movies, green cells = CD11c+ cells, blue = second 
harmonic signal and red cells = CD4 Th1 cells. Arrows demarcate the position of the same T cell at 
different time points, indicating their movement or lack thereof. Statistical differences between 
groups were assessed by carrying out a Mann-Whtiney test using Graphpad Prism *** denotes p 
value of < 0.001 and **** < 0.0001.  
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4.2.3 CD4 Th1 cells survive better at inflamed tissues 
My observation of greater Th1 cell recovery from inflamed ear tissue, without a 
concomitant decrease in the dLN, suggested that T cell proliferation or survival 
might be taking place at inflamed tissues. At non-inflamed tissues however, T 
cells were immobile and produced increased IFNg. Decreased motility as well as 
increased IFNg production have both been previously associated with apoptotic T 
cells (536, 571). Therefore, the survival and proliferation of Th1 cells in ear 
tissue was evaluated. 
To assess cellular proliferation, T cells were labelled with cell tracker blue. Cell 
tracker blue is a fluorescent dye that is equally divided into daughter cells upon 
cell division. Subsequent enumeration of cells within each fluorescent peak 
determined the proportion of proliferating cells.  
To evaluate apoptosis, T cells recovered ex vivo from ear tissue were cultured in 
the presence of a fluorescent inhibitor of caspases (FLICA) molecule. The FLICA 
molecule undergoes an enzymatic reaction when it is covalently bound to any 
active caspase 3 or 7. Apoptotic cells express caspases 3 and 7, accordingly 
FLICA labels apoptotic cells with a green colour (fluorescein) (572, 573). 
Assessment of the proportion of FLICA bound cells enabled the enumeration of 
cells at early stages of apoptosis. 
Polarised OT-II Th1 cells labelled with cell tracker blue were thus transferred 
into LPS inflamed or saline treated mouse ears. 24 hours later, the animals were 
euthanised and their ears were harvested and processed. Single cell suspensions 
of cells were stained with flow cytometry antibodies and then cultured with the 
FLICA reagent for 1 hour. Subsequently, cell survival and proliferation were 
assessed.  
A significantly greater proportion of Th1 cells recovered from non-inflamed 
tissues were found to express FLICA compared to cells recovered from inflamed 
tissues (Figure 4.2.3A,B). In contrast, Th1 cells did not undergo any proliferation 
at either the inflamed or non-inflamed tissue site (Figure 4.2.3C). Together, 
these data suggest that increased survival signals at inflamed tissues regulate 
the persistence of Th1 cells.  
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Figure 4.2.3 Fewer CD4 Th1 cells undergo apoptotic death at inflamed tissues but no 
differences are observed in T cell proliferation at tissue sites 
Age matched C57BL/6 mice at 6 weeks of age were challenged with LPS (1µg/10µl) or PBS in their 
right ear pinnae. 24 hours later 2.0e6 OT-II TH1 cells were labelled with cell tracker blue and 
transferred into the animals’ same ear pinnae. 24 hours after the transfer, mice were euthanised 
and their ears were harvested, processed and stained for FACS. Cells were stained with a viability 
dye followed by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. 
Lymphocytes were initially gated on live CD45+, CD4+, CD45.1+, Va2+ cells and the expression of 
active caspase 3 and 7 was analysed by measuring their expression of FLICA by incubating cells 
using a FLICA kit (life technologies). FLICA FACS plots are representative of 3 independent 
experiments, Cell tracker blue is representative of 2 experiments. FLICA graph shows combined 
data from 3 independent experiments with 10 animals in PBS and 11 animals in LPS groups. Error 
bars represent SEM. Statistical differences between groups were assessed by carrying out an 
unpaired Student’s T test using Graphpad Prism ** denotes p value of <0.001. 
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4.2.4 Increased survival of Th1 cells is not mediated by 
differences in IL-7, TNFa or FAS-Ligand expression at tissue 
site 
Greater recovery of T cells at tissue sites might be regulated by increased 
survival signals or decreased apoptotic signals. TNFa and IL-7 are pro-
inflammatory cytokines abundantly present at inflamed tissues (558, 574). 
Studies have suggested a role for TNFa in rescuing T cells from apoptotic death 
at inflamed tissues (508). Likewise, studies have reported IL-7 as a survival 
signal for T cells at inflamed sites (525).  
In contrast, FASL is a transmembrane protein of the TNF family that induces 
caspase mediated apoptosis. FASL is found in both transmembrane and soluble 
forms. Interaction of FASL with its receptor FAS on T cells leads to cell death 
(575). Previous reports have suggested increased FASL expression at TLR 4-
agonist mediated inflamed tissues (576).  
To assess whether TNFa, IL-7 or FASL expression is differentially regulated at 
inflamed tissues, LPS or saline treated mouse ears were harvested 24 hours post 
challenge. The ear tissue was homogenised, proteins extracted and 
concentration measured. Enzyme-linked immunosorbent assays (ELISA) were 
carried out by loading equal amount of protein for each animal and determining 
expression levels of the cytokines and FASL.  
No significant differences were observed in the production of IL-7 or TNFa 
between inflamed or resting tissues (Figure 4.2.4A,B). Likewise, no difference 
was observed in FASL expression between tissues (Figure 4.2.4C). In summary, 
these data suggest that survival of Th1 cells at inflamed tissues is not directly 
mediated by differences in TNFa, IL-7 or FASL expression. However, this does 
not rule out the possibility that signals at inflamed tissues makes cells more 
sensitive to signals from these proteins. 
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Figure 4.2.4 Survival of Th1 cells is not mediated by differences in IL-7, FASL or TNFa 
Age matched C57BL/6 mice were treated with LPS or PBS in their right ear pinnae. 24 hours later, 
animals were euthanised and their ears were harvested. The tissue was then homogenised in 
tissue protein extraction buffer (T-PER) using a tissue homogeniser. The protein concentration was 
measured using a standard BCA assay. Equal amounts of protein were then loaded into wells in 
duplicate. Concentration of cytokines and FASL was measured against a standard curve by 
following manufacturers’ guidelines as described in materials and methods. IL-7 and FASL ELISAs 
were quantikine ELISA kits from R&D systems and TNF ELISA was a Mouse TNF ELISA set from 
BD Biosciences. Graphs show data from one experiment with 4 (TNF) or 5 (IL-7 &FAS-L) animals 
per group. Error bars represent SEM. Statistical differences between groups were assessed by 
carrying out an unpaired Student’s T test in Graphpad PRISM. n.s. denotes not significant. 
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4.2.5 CCL5 is upregulated at inflamed tissues    
Another potential source of T cell survival signals are chemokines. As discussed 
in section 4.1.4, multiple chemokines have been reported to function in 
promoting T cell survival. Since no direct differences were found in cell 
survival/apoptotic signals, chemokine expression at tissues and chemokine 
receptor expression on Th1 cells were examined.  
To evaluate chemokine expression levels, a proteome profiler array was 
undertaken. This is a multiplex antibody based protein array that simultaneously 
detects the expression of 25 different chemokines. They included CCL21, 
CX3CL1, CXCL12, CCL4 and CCL5 among others. For chemokine receptor 
expression on T cells, polarised OT-II Th1 cells were stained with anti- CCR4, 
CCR5 and CX3CR1 antibodies. These chemokine receptors and ligands have been 
associated with Th1 cell migration and survival in various studies (14, 393, 502, 
513). 
To assess chemokine expression at tissue sites, mouse ear pinnae were injected 
with PBS or saline. 24 hours later, animals were euthanised and their ears were 
harvested, processed and tissue lysates extracted. The lysates were then mixed 
with detection antibodies and incubated with a membrane pre-coated with 
capture antibodies.  
Finally, the blot was developed using a chemiluminescent reagent to give spots 
in duplicate for each chemokine assayed. Mean pixel density of these spots were 
evaluated and relative differences between inflamed and resting ears was 
established. The graph displays fold change in mean pixel density of Inflamed 
ears compared to resting ears. Overall, 13 chemokines were upregulated and 12 
downregulated at LPS inflamed mouse ears (Figure 4.2.5A). Only CCL5 
underwent a greater than 1-fold increase and was therefore considered 
substantial (Figure 4.2.5A). 
Polarised OT-II Th1 cells were also assessed for their expression of CCR4, CCR5 
and CX3CR1. Almost all Th1 cells were found to express CCR5 (Figure 4.2.5B). A 
large majority of Th1 cells were also found to express CCR4 (Figure 4.2.5B). In 
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contrast, only a small population of polarised Th1 cells were found to express 
CX3CR1 (Figure 4.2.5B).  
Since CCL5 was substantially upregulated and its cognate receptor CCR5 was 
expressed in all polarised T cells, a further CCL5 ELISA was carried out. This was 
to confirm whether CCL5 upregulation was statistically significant. CCL5 was 
found to be significantly upregulated at inflamed tissues (Figure 4.2.5C). In 
combination, the data suggests that CCL5-CCR5 interactions may play a role in 
regulating Th1 cell persistence at inflamed tissue sites. 
 
Figure 4.2.5 CCL5 is increased at inflamed tissues 
Age matched C57BL/6 mice at 6 weeks of age were challenged with LPS or PBS in their right ear 
pinnae. 24 hours later, animals were euthanised and their ears harvested and tissue lysates 
prepared. The lysates were then blotted using a proteome profiler mouse chemokine array kit (A). 
Fold change was calculated by normalising the pixel density according to proteome profiler array kit 
instructions and then subtracting pixel density of PBS group values from LPS group values and 
dividing by the PBS value ((PBS-LPS)/PBS). For flow cytometry, polarised and negatively selected 
Th1 cells were stained with or without anti-mouse CCR5, CCR4 and CX3CR1 antibodies. Cells are 
pre-gated on CD4+ Lymphocytes. (B). CCL5 ELISA was carried out on protein extracted from LPS 
or PBS treated ear pinnae. The protein concentration was measured using a standard BCA assay. 
Equal amounts of protein were loaded into wells in duplicate and concentration of CCL5 was 
measured against a standard curve using standard manufacturers’ guidelines as described in 
materials and methods. CCL5 ELISA was a duoset ELISA kit from R&D systems (C). Proteome 
profiler data shown is from 1 experiment with 5 animals per group. CCL5 ELISA is data from 1 
experiment with 5 animals per group and the FACS plots are representative data from 2 
independent experiments. Error bars represent SEM. Statistical differences between groups were 
assessed by carrying out an unpaired Student’s T test using Graphpad Prism * denotes p value of 
<0.05 
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4.2.6 G-protein coupled receptor signalling mediates Th1 cell 
persistence at inflamed sites 
G-protein coupled receptors (GPCRs) are a family of seven transmembrane helix 
proteins that are critical in cell signalling. Chemokine receptors are GPCRs. 
Chemokines, signalling through GPCRs have been shown to upregulate both pro-
apoptotic and anti-apoptotic factors in cells (562-564). Chemokines are also 
more classically known for their role in cellular trafficking (155).  
To disrupt GPCR signalling, polarised Th1 cells were treated with pertussis toxin 
prior to transfer. Pertussis toxin (PTX) is an exotoxin produced by Bordetella 
pertussis (577). Upon binding the GPCR, PTX is internalised where it catalyses 
the ADP-rybosylation of the ai subunits of the G protein. This rybosylation 
prevents G-proteins from associating with GPCRs at the cell surface, disrupting 
intracellular signalling (578).  
PTX or vehicle treated Th1 cells were transferred into LPS or saline treated 
mouse ear pinnae. 24 hours after transfer, the animals were euthanised and 
their ears and dLNs were harvested, stained for flow cytometry and numbers of 
transferred cells enumerated (Figure 4.2.6A). 
PTX treatment did not alter the number of T cells recovered from resting tissue 
sites. In contrast, PTX treatment significantly reduced the number of cells 
recovered from inflamed tissues (Figure 4.2.6B). PTX treatment however, did 
not alter the number of transferred cells recovered from the draining lymph 
nodes of either inflamed or resting ear pinnae (Figure 4.2.6C). These data 
suggest that GPCR signalling is essential for Th1 cell persistence at inflamed 
tissues. 
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Figure 4.2.6 Fewer Th1 cells are recovered from inflamed sites after PTX treatment 
Age matched C57BL/6 mice at 6 weeks of age were challenged with LPS or PBS in their right ear 
pinnae. 24 hours later 2.0e6 pertussis toxin (100ng/ml) or vehicle treated OT-II TH1 cells were 
transferred into the same ear pinnae of animals. 24 hours after the transfer, mice were euthanised 
and their ears and dLN were harvested, processed and stained for FACS. Cells were stained with a 
viability dye followed by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. 
Lymphocytes were initially gated on live CD45+, CD4+ cells and subsequently analysed for their 
expression of CD45.1 and Va2. FACS plots are representative of 3 independent experiments. 
Graphs show combined data from 3 independent experiments with 9 ( PBS and PBS+PTx) or 7 
(LPS and LPS+FTY720) animals per group. Error bars represent SEM. Statistical differences 
between groups were assessed by carrying out a One-way ANOVA and Tukey’s multiple 
comparisons test using Graphpad Prism **** denotes p value <0.0001. 
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4.3 Discussion 
Effector T cell death is a critical step in the regulation of an immune response. 
It enables the dampening of inflammation and restoration of tissue homeostasis 
(579). At inflamed tissues several factors including cytokines, lipid mediators 
and chemokines regulate the decision for T cell survival or death (580-582). In 
chronically inflamed tissues however, these factors are dysregulated. This leads 
to prolonged persistence of T cells which drives local inflammation and tissue 
destruction (419, 583). In this chapter, the factors that maintain the persistence 
of Th1 cells at inflamed tissues were investigated. 
4.3.1 T cell persistence is not antigen mediated 
Previous studies have suggested that antigen-bearing APC and cognate T cell 
interactions play a role in central and peripheral T cell persistence (541-545). 
Hence, whether the presence of cognate antigen altered T cell persistence in 
the LPS inflamed tissue model was investigated. The results suggested that 
presence of cognate antigen at the tissue site does not alter T cell persistence. 
While this result contradicts previous studies, it is in some ways unsurprising. In 
my model system, animals were not previously primed for a specific antigen as 
done by Reinhardt et al. and Rosenbaum et al (392, 549). Moreover, while HAO 
was injected intradermally, its persistence in tissue for 24 hours was not 
determined. Therefore, whether cognate antigen was present at the tissue site 
at the time of T cell transfer and beyond cannot be confirmed.  
To overcome these technical limitations and address this question more 
comprehensively, animals could be primed with OVA in the presence of an 
adjuvant 7 days prior to induction of localised ear inflammation by LPS and HAO 
followed by intradermal T cell transfer. Presence of OVA at the tissue site should 
also be confirmed by fluorescent labelling.            
4.3.2 T cell motility is mediated by soluble factors 
Intravital microscopy of adoptively transferred Th1 cells demonstrated that they 
were more motile at inflamed tissues compared to resting tissues. This finding is 
supported by studies which demonstrate that T cells have increased motility at 
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inflamed tissues (391). This pattern of motility is known as a Lévy walk (584). A 
Lévy walk allows effector T cells to efficiently scan a peripheral tissue site to 
find their target cell/area (584, 585).  
Multiple factors are responsible for regulating T cell behaviour at tissues 
including intrinsic programming, physical and chemical guidance cues (391, 585). 
Intriguingly, soluble mediators have been shown to increase T cell motility 
rather than provide directional movement in vivo (425). This could suggest that 
the increased motility observed in our studies are due to increased soluble 
mediators at inflamed tissues. This hypothesis is further explored in the next 
chapter. 
Finally, a study by the Bousso group demonstrated that apoptotic T cells lose 
their motility prior to caspase 3 expression and death (571). This finding strongly 
suggests that the non-motile Th1 cells observed in resting tissues were 
undergoing apoptotic death. Ultimately though, it is difficult to conclude that 
Th1 cells at the non-inflamed tissues are apoptotic without in vivo reporter of 
apoptosis. 
4.3.3 Th1 cell persistence is regulated by inhibition of apoptosis 
at inflamed tissues 
Decreased motility of T cells at non-inflamed tissues was an indication that they 
were undergoing apoptotic death. To confirm this, an ex vivo caspase assay was 
carried out. The assay demonstrated that greater number of transferred T cells 
at resting tissues were indeed expressing active caspases compared to T cells at 
inflamed tissues.   
Effector T cells are pre-programmed to undergo apoptosis (586). However, at 
inflamed tissues several anti-apoptotic signals have been shown to prolong 
effector T cell survival (587). Elevated levels of the cytokine IL-7 has been 
reported in RA synovial fluid (581, 588). Moreover, TNF, a cytokine commonly 
elevated in multiple inflammatory disorders can have both pro and anti-
apoptotic effects on T cells (508, 589). FASL ligation to FAS is a common 
mechanism for induction of T cell death at peripheral tissues (590).  
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Levels of these death/survival cytokines were assayed to determine whether 
they were responsible for T cell persistence at LPS inflamed tissues. No 
differences were observed in the levels of any of these cytokines 24hours after 
LPS administration. The 24-hour time point investigated may account for the 
discrepancies between my findings and previous studies. 
Copeland et al. demonstrated that TNFa levels peaked in mouse blood plasma 4 
hours after systemic endotoxin administration (527). In another study by Calil et 
al., TNFa levels peaked in mouse paws 3 hours after local LPS administration 
(510). In contrast, induction of acute inflammation in mouse lungs was found to 
cause a peak in TNFa levels 24 hours post local carrageenan administration 
(591). These studies demonstrate that TNFa levels at inflamed tissues is 
regulated by both the inflammatory stimuli as well as the tissue location. LPS 
mediated TNFa production most likely peaks very early following stimuli (510, 
527). 
Similarly, FASL levels were found to be elevated 3 days after a virus induced 
acute inflammatory response in murine vaginal tissue (592). Analyses targeting 
the expression of IL-7 at acutely inflamed tissues have not been undertaken. 
However, IL-7 is believed to be an early mediator of inflammation in RA (593).       
4.3.4  Chemokines as potential regulators of T cell death 
Chemokines are another class of mediators that have roles in cell survival and 
migration. CXCL12-CXCR4 interactions have previously been reported to 
modulate T cell survival (84, 566). CCL5 has also been reported in promoting and 
inhibiting cellular apoptosis (562-564). Moreover, spatial and temporal changes 
in chemokine ligand expression is well documented during inflammatory 
responses (155). A chemokine array was performed to analyse relative 
differences in chemokine ligand expression. Surprisingly, only CCL5 levels were 
substantially altered 24 hours after LPS administration. 
Similar to the cytokine levels, chemokine expression found was a snapshot of the 
24-hour time point. Multiple studies reveal a substantial increase in CXCL8 levels 
after LPS challenge which was not observed in our case (594). Analysing 
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chemokine expression by other methods such as RNA-seq might provide more 
robust results.   
4.3.5 GPCR signals are necessary for Th1 cell persistence 
Chemokine receptors are GPCRs (154, 155). To analyse whether T cell 
persistence was mediated via chemokines, Th1 cells were treated with pertussis 
toxin prior to their adoptive transfer. Pertussis toxin inhibits GPCR signalling 
(577, 578, 595). Lower numbers of PTX treated cells were recovered from 
inflamed tissues than untreated cells from inflamed tissues. This result clearly 
demonstrated that T cell persistence was directly mediated by GPCR signals.  
This finding contradicts with multiple studies which have demonstrated that PTX 
treatment of T cells resulted in their accumulation at peripheral tissues rather 
than their disappearance (448, 596). This phenomenon is thought to be CCR7 
mediated as CCL19/21 guide T cell egress from peripheral tissues (451, 452). The 
inflammation state as well as T cell polarisation differs in my experiments from 
these studies and this may account for the observed discrepancy. 
The Bromley et al. study examined the egress of Th2 cells from lungs with the 
use of CCR7 overexpression transgenic model system. Using this system they 
demonstrated that Th2 cells require CCR7 to leave the lungs and accumulate in 
the mediastinal lymph nodes, 36 hours after intratracheal instillation. In 
contrast, Debes et al. adoptively transferred naïve T cells treated with or 
without pertussis toxin intradermally into mouse footpad. They demonstrated 
that PTX inhibited naïve T cell egress from the footpad and that this egress was 
CCR7 mediated. My studies investigated the migration of Th1 cells from an 
acutely inflamed mouse skin tissue. Hence, both my cell polarisation state and 
tissue site and state were different from these two studies (451, 452). 
Other studies have suggested roles for S1PRs in regulating T cell accumulation 
and egress from peripheral tissues (244). S1PRs are also GPCRs which are PTX 
sensitive. In the next chapter, the role S1P plays in T cell persistence is 
investigated.   
 
 
 
5 Sphingosine-1-Phosphate regulates Th1 cell 
persistence at inflamed tissues 
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5.1 Introduction 
Sphingosine-1-phosphate (S1P) is a bioactive lysosphingolipid. Sphingosine, the 
precursor to S1P is produced by the sequential degradation of cell membrane 
glycosphingolipids and sphingomyelin to make ceramide (176, 597). Ceramide is 
then hydrolysed to sphingosine which is phosphorylated by one of two kinases 
SPHK1 and SPHK2 to produce S1P (598). Studies have shown that SPHK-/- leads to 
embryonic lethality in mice emphasising the physiological importance of S1P 
(599). 
S1P is primarily produced in intracellular lysosomes of RBCs, platelets and 
endothelial cells (600-603). Subsequently, it is either used/degraded 
intracellularly or transported out of the cell (604-607). Five S1P receptors have 
been identified to date (S1PR1-5) (226). These are all high-affinity GPCRs (226). 
The varied cellular expression and signalling of each individual receptor yields 
the pleiotropic and antagonistic effects of S1P (226). 
5.1.1 Heterogeneous roles of S1P 
S1P plays an important role in vascular maintenance. Signalling via S1P receptors 
1-3 co-operatively regulates vascular angiogenesis during embryogenesis (608, 
609). The intra-extracellular S1P transporter spns2 is also critical in this process 
(608). Postnatally, S1P regulates vascular integrity. This was demonstrated when 
mice lacking plasma S1P exhibited vascular leakage under homeostatic 
conditions (610).  
Interestingly, systemic pertussis toxin administration in wild type mice induced 
similar vascular leakage. Treatment with S1PR1 agonists restored vascular 
integrity (610). Finally, S1P regulates vascular smooth muscle tone. Signalling via 
S1PR2 was found to be crucial in maintaining smooth muscle contractility (611, 
612).  
S1P is likewise crucial in embryonic neurogenesis. It was found that defects in 
either S1P biosynthesis or S1PR1 led to neural tube closure and thus embryonic 
lethality (599). In adult nervous systems, multiple S1PRs are expressed across 
several cell types including neurons and microglia. Roles for S1P has been 
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described in neurotransmitter release, microglial proliferation and pain 
pathophysiology (613-616).  
In contrast S1P plays a negative role in cancer. S1P metabolism is dysregulated 
in several tumours (617). Furthermore, S1P was found to promote tumour 
angiogenesis, proliferation, aid in metastasis and invasion as well as resist 
tumour cell death (617-622). Cancer therefore, is a hallmark of the pleiotropic 
and antagonistic effects of S1P on its targets. 
5.1.2 S1P in cell survival and apoptosis 
Many studies have investigated the role S1P plays in regulating cellular survival 
and apoptosis. One study in human hepatic fibroblasts found that S1P induced 
apoptosis in a receptor independent manner while increasing survival in a 
receptor dependent manner (623). Likewise, a few studies have suggested that 
ceramide, an intracellular pre-cursor to S1P induces pro-apoptotic signals. 
In contrast, S1P itself is pro-survival (624). The mechanism for S1P mediated 
survival remained elusive until recently, when Rutherford et al. demonstrated 
that S1P suppresses the pro-apoptotic molecule bim and promotes upregulation 
of pro-survival Mcl-1 in lung fibroblasts to aid in cell survival (625). 
Very recently, Mendoza et al. demonstrated for the first time, a role for S1P in 
regulating T cell survival. They found that knocking out the intra-extracellular 
S1P transporter SPNS2 led to increased death of naïve T cells. They further 
demonstrated that S1PR1 KO animals also had an increased number of apoptotic 
naïve T cells in LNs. Finally, they elegantly demonstrated that S1PR1 is essential 
for the maintenance of mitochondrial integrity in naïve T cells (626).   
Whether these varying mechanisms of S1P mediated cell survival are spatially 
and temporally conserved across cell types remains to be determined.  
5.1.3 S1P is a key regulator of cellular trafficking 
S1P levels across organ systems is strictly regulated in homeostatic conditions. 
Micromolar and nanomolar levels of S1P are found in the blood and lymphatic 
vasculature respectively. In contrast, interstitial fluid has either undetectable or 
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sub-nanomolar levels of S1P (217). The maintenance of this gradient is critical, 
as cells vary their S1PR expression to traffic between organs and vasculature 
(205, 224). T and B cells sense the S1P gradient via S1PR1 to traffic between 
SLOs and circulation (218). Likewise, S1P gradients regulate NK cell and 
haematopoietic stem cell mobilisation via S1PR5 and S1PR1 respectively, 
between the bone marrow and the circulation (627).   
T cell trafficking is an elegant example of how S1P, S1PR1 and its regulators are 
critical in inflammatory conditions. Naïve T cells in SLOs express high levels of 
S1PR1 and high levels of CCR7 (424, 431). This leads to T cell retention due to 
increased gradients of CCL19/21 interacting with CCR7 in SLOs (425, 426).  
Antigen exposure increases CD69 expression on T cells (432). CD69 is a negative 
regulator of S1PR1. Multiple studies have shown that CD69 directly interacts 
with, and downregulates S1PR1 expression on cell surface. This downregulation 
of S1PR1 allows T cells to dwell in SLOs while undergoing clonal expansion (432-
434).  
Once fully activated, effector T cells downregulate CCR7 and upregulate S1PR1 
(243). T cells expressing S1PR1 migrate towards higher S1P gradients in efferent 
lymphatic vessels, eventually leading to their egress to peripheral tissues (436, 
437). The S1PR1 expression profile of T cells in tissues is not well defined.  
KLF2 is a transcription factor that regulates S1PR1 expression on T cells (628). 
High levels of KLF2 has been associated with high S1PR1 expression (456). 
Studies have found that early effector cells at tissue sites are KLF2 high, but 
over time KLF2 expression is lost (629). 
Furthermore, several studies have suggested that inflamed tissues have elevated 
S1P levels. Ledgerwood et al. found that S1P levels were significantly increased 
at alloantigen or adenovirus inflamed mouse skin (244). Increased S1P levels 
were reported in joints of CIA mice as well as in the synovial fluid of RA patients 
(271, 630).  
Interestingly, Ledgerwood et al. demonstrated that migration of CD4 T cells 
across lymphatic, but not blood endothelium was inhibited from inflamed mouse 
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skin, regulated by S1PR1 (244). Thus, S1P-S1PR1 signalling regulates lymphocyte 
trafficking in homeostatic and inflammatory conditions. 
5.1.4 S1P in cytoskeletal rearrangement 
Cells use cytoskeletal machinery such as actin and myosin to migrate (631). It is 
therefore unsurprising that S1P elicits most of its physiological effects via 
regulation of the cytoskeleton. S1PR signalling directly activates the RHO family 
of GTPases which regulate actin and myosin assembly (632). This has been shown 
to have varying effects on distinct cell types.  
In endothelial cells, S1P was found to enhance chemotaxis and regulate vascular 
barrier integrity mediated via cytoskeletal rearrangements (633, 634). S1P 
mediated control of vascular smooth muscle tone is also facilitated via Rho-
kinase activation (611, 635). 
In neuronal cells, S1P modulates neuronal outgrowth by controlling RAC 
activation and thus neuron morphology (636). In contrast, S1P potently inhibits 
melanoma cell migration by preventing actin nucleation and pseudopod 
formation (637). In glioblastoma cells however, S1P promotes tumour cell 
migration and metastasis mediated via distinct S1PR and Rho GTPase activation 
(638).  
Finally, the molecular mechanisms of S1P mediated immune cell migration is 
poorly understood (632). In human DCs, S1P was found to enhance chemotaxis by 
increasing actin polymerisation (639). S1P robustly stimulates NK cell motility in 
a PI3-kinase dependent manner (640). In contrast, S1P was found to inhibit mast 
cell migration (641).             
5.1.5 Modulators of S1PRs 
S1P is difficult to detect in vivo (430). Moreover, a S1P blocking antibody was 
only made available recently (642). Therefore, functions of S1P have primarily 
been elucidated by studying the effects pharmacological modulators elicit on 
S1PRs. FTY720 was the first described S1PR modulator (438). It was later 
discovered that FTY720 was a functional antagonist of S1PR1,3,4 and 5 but had 
no effect on S1PR2 (222).  
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Later, receptor selective agonists and antagonists were synthesised. These 
included FTY720-P, an S1PR1,3,4 and 5 agonist, SEW2871, an S1PR1 selective 
agonist and W146, an S1PR1 selective antagonist (223, 240, 643). All of these 
S1PR modulators have played key roles in the current understanding of S1P 
biology. 
5.1.6 Aims of this chapter 
Greater recovery of CD4 Th1 cells from inflamed tissues was found to be GPCR 
sensitive (chapter 4). S1PRs are members of the GPCR family and regulators of T 
cell survival and trafficking. The aims for this chapter were to investigate 
whether S1PR signalling was responsible for the observed T cell persistence 
phenotype at inflamed tissues.  
S1P signalling also modulates cell survival and behaviour. Therefore, whether 
S1PR signalling modulated Th1 cell behaviour and survival was also investigated. 
Finally, a human inflammatory disease was investigated for the presence of 
elevated S1P levels, which may contribute to T cell persistence at inflamed 
tissues. 
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5.2      Results 
5.2.1 S1PR signalling is critical for Th1 cell persistence 
S1P is a pleiotropic signalling sphingolipid (644). It plays diverse roles in cellular 
communication. Studies have reported a role for S1P in regulating T cell 
trafficking and survival (243, 626). Interestingly, S1P receptors are also GPCRs, 
and sensitive to pertussis toxin mediated signalling disruption (219-221). Hence, 
to identify whether S1PR signalling contributes to the persistence of effector 
Th1 cells at inflamed tissues, T cells were treated with an S1PR pan functional 
antagonist, FTY720.   
FTY720 or vehicle treated Th1 cells were transferred into inflamed or resting ear 
pinnae. 24 hours later, animals were euthanised and their ears and dLNs were 
harvested, stained for flow cytometry and the transferred cells enumerated. 
Just like PTX treatment, significantly lower numbers of cells were recovered 
from inflamed tissues following pre-treatment with FTY720 (Figure 5.2.1A).  
FTY720 treatment did not alter the number of cells recovered from non-inflamed 
tissues (Figure 5.2.1A). No differences were observed between the draining 
lymph nodes of inflamed or resting ear pinnae irrespective of FTY720 treatment 
(Figure 5.2.1B). In sum, these data suggest that persistence of Th1 cells at 
inflamed tissues is mediated by PTX sensitive S1PR signalling. 
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Figure 5.2.1 Fewer Th1 cells are found at inflamed sites after FTY720 treatment 
Age matched C57BL/6 mice at 6 weeks of age were challenged with LPS or PBS in their right ear 
pinnae. 24 hours later 2.0e6 FTY720 or vehicle treated OT-II Th1 cells were transferred into the 
same ear pinnae of animals. 24 hours after the transfer, mice were euthanised and their ears (A,B) 
and dLN (C) were harvested, processed and stained for FACS. Cells were stained with a viability 
dye followed by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. 
Lymphocytes were initially gated on live CD45+, CD4+ cells and subsequently analysed for their 
expression of CD45.1 and Va2. FACS plots are representative of 3 independent experiments.  
Graphs show combined data from 2 independent experiments of 11 or 9 (LPS) animals per group. 
Error bars represent SEM. Statistical differences between groups were assessed by carrying out a 
One-way ANOVA and Tukey’s multiple comparisons test using Graphpad Prism *** denotes p 
value of < 0.001 and **** < 0.0001. n.s. denotes not significant. 
0
500
1000
1500
N
um
be
r o
f 
O
T-
II 
T 
ce
lls
 
PBS LPS
FTY720 - + - +
*** ****
Ear
0
5000
10000
15000
N
um
be
r o
f 
O
T-
II 
T 
ce
lls
 
PBS LPS
FTY720 - + - +
dLN
n.s.
C
D
45
.1
V⍺2
5.64 2.60
PBS PBS+FTY720
10.2 3.41
LPS+
FTY720LPSA
B
C
 
 
 163 
5.2.2 S1PR signalling regulates T cell behaviour at inflamed 
tissues 
S1P has roles in cytoskeletal rearrangement in various cell types including 
immune cells (632). S1P regulates RHO GTPases via S1PR signalling (632). RHO 
GTPases are critical in actin and myosin assembly which regulates cellular 
motility (631). In the previous chapter Th1 cells were found to be more motile at 
inflamed tissues.  
To investigate whether S1PR signalling was regulating this behaviour, FTY720 or 
vehicle treated Th1 cells were transferred into LPS inflamed ear pinnae of 
LysMGFP mice. Similar to the experiments in (Figure 4.2.2) Th1 cells were 
transferred in a small volume at shallow depths to keep tissue localisation of the 
T cells as consistent as possible. LysMGFP mice have a GFP tag associated with 
the lysozyme gene (496). This labels neutrophils in these mice, bright green in 
colour. Monocytes and macrophages also express a lower intensity of GFP.  
4-5 hours later, animals were anaesthetised and restrained on a temperature 
controlled stage. The ear of the animal was then imaged and time-series movies 
were captured (video 3, 4).  
The movies were analysed and CD4 T cells tracked to assess their velocity and 
displacement (Figure 5.2.2A, B). FTY720 treated Th1 cells had substantially 
reduced velocity compared to vehicle treated cells at inflamed sites (Figure 
5.2.2C). Arrows in the still images and videos demonstrate reduced movement of 
T cells when treated with FTY720 compared to vehicle treatment. The videos 
and still images also demonstrate T cells travelling within or near collagen fibre 
networks (Figure 5.2.2 E,F)(video 3,4), suggesting similar tissue localisation of T 
cells compared to T cells in (Figure 4.2.2). Hence, the behaviour of FTY720 
treated T cells was similar to T cells at resting tissues. FTY720 treated Th1 cells 
also exhibited decreased displacement (Figure 5.2.2D), however this was to a 
lesser extent than cells at resting tissues (Figure 4.2.2). This suggests that 
factors other than an S1P signal may also contribute to the overall behaviour of 
T cells leading to their persistence. 
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Figure 5.2.2 FTY720 treated Th1 cells travel reduced distances and at a lower velocity 
compared to untreated cells at inflamed tissues 
LysMGFP mice were challenged with either PBS or LPS. 24 hours later, ~2.0e3 polarised Th1 cells 
treated with or without FTY720 expressing DsRed were transferred into the injection site at a 
shallow depth, in a small volume. The animals were rested for 4-5 hours before the ears were 
imaged by a Zeiss LSM 7MP microscope. Images were acquired using a 20x/1.0NA water 
immersion objective lens. Images were then analysed using volocity software and DsRed positive 
cells were manually tracked individually, generating their velocity and displacement rates. (A,B) X-
Y plots show distance of T cell tracks and are representative plots from 1 of 3 individual mice per 
treatment group. (C,D) Velocity and displacement graphs show combined values from 3 individual 
mice. (E,F) Representative stills from 1 of 3 individual mice per treatment group, illustrating 
distance travelled by T cells from time zero, indicated by arrows. Each data point on graphs (C,D) 
represents a DsRed T cell and bars represent mean. In the movies, green cells = LysM+ cells 
(neutrophils/monocytes), blue = second harmonic signal and red cells = CD4 Th1 cells. Arrows 
demarcate the position of the same T cell at different time points, indicating their movement or lack 
thereof. Statistical differences between groups were assessed by carrying out a Mann-Whtiney test 
using Graphpad Prism * denotes p value of <0.05 and **** < 0.0001. 
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5.2.3 S1P mediated Th1 cell survival at inflamed tissues remains 
inconclusive 
The effect of S1P on naïve T cell survival at SLOs has only very recently been 
determined by Mendoza et al. as discussed in section 5.1.2. However, a role for 
S1P in supporting effector T cell survival at inflamed tissues has not been 
studied.  
Hence, to assess whether S1P was increasing Th1 cell survival at inflamed 
tissues, S1PR signalling was disrupted via FTY720 and Th1 cell survival assayed. 
FTY720 or vehicle treated Th1 cells were transferred into inflamed or resting ear 
pinnae. 24 hours later, animals were euthanised and their ears and dLNs were 
harvested, stained with flow cytometry antibodies and incubated with the FLICA 
reagent for an hour. The cells were then analysed and the proportion of OT-II 
cells that expressed active caspases 3 and 7 was determined via positive FLICA 
staining (Figure 5.2.3A). 
A trend to fewer apoptotic cells were found in T cells recovered from inflamed 
compared with non-inflamed tissues (Figure 5.2.3B), contradicting the results in 
Figure 4.2.3. Furthermore, FTY720 treatment somewhat reversed Th1 cell 
survival at inflamed tissues without reaching statistical significance (Figure 
5.2.3B). Taken together, this data remains inconclusive, due to it directly 
contradicting the results of section 4.2.3 which will be discussed further in the 
discussion of this chapter below.      
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Figure 5.2.3 Increased number of T cells at inflamed tissues is not due to increased survival 
mediated via S1P receptors 
Age matched C57BL/6 mice at 6 weeks of age were challenged with LPS or PBS in their right ear 
pinnae. 24 hours later 2.0e6 OT-II Th1 cells treated with or without FTY720 were transferred into 
the same ear pinnae of animals. 24 hours later, mice were euthanised and their ears were 
harvested, processed and stained for FACS. Cells were stained with a viability dye followed by 
fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were initially 
gated on live CD45+, CD4+, CD45.1+, Va2+ cells and the expression of active caspase 3 and 7 
was analysed by measuring their expression of FLICA by incubating cells using a FLICA kit (life 
technologies). FACS plots are representative of 3 independent experiments. Graphs show 
combined data from 2 independent experiments of 7 or 6 (LPS+FTY720) animals per group. Error 
bars represent SEM. Statistical differences between groups were assessed by carrying out a One-
way ANOVA and Tukey’s multiple comparisons test using Graphpad Prism. n.s. denotes not 
significant. 
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5.2.4 S1P signal is necessary and sufficient for CD4 Th1 cell 
persistence at inflamed tissues 
To date, five S1P receptors have been identified (S1PR1-5) (226). The specific 
role of S1P is determined by the cellular and temporal expression of these S1PRs 
(205, 224). S1PR signalling has resulted in effects as distinct as cellular 
proliferation, death, migration, retention and egress (644). These effects have 
been observed in diverse cell types including immune cells, neurons, tumour 
cells and endothelial cells (644). Likewise, the S1P analogue FTY720, used in 
previous studies has distinct effects on multiple S1PRs (438).  
To determine whether S1PR1 specific agonism was responsible for Th1 cell 
persistence at inflamed tissues, S1PR1 selective agonist or antagonist were used. 
Prior to transfer, Th1 polarised OT-II T cells were treated with either W146, 
SEW2871 or vehicle. W146 is a S1PR1 selective antagonist (240). SEW2871 is a 
S1PR1 selective agonist (223). Treated cells were transferred into inflamed or 
resting ear pinnae. 24 hours later, the animals were euthanised and their ears 
and dLNs were harvested, stained for flow cytometry and the transferred cells 
enumerated (Figure 5.2.4A). 
Significantly lower numbers of Th1 cells were recovered from inflamed tissues 
when pre-treated with W146 just as with FTY720 (Figure 5.2.4B). W146 
treatment however, did not affect Th1 cell recovery from non-inflamed tissues 
(Figure 5.2.4B). In contrast, agonism of S1PR1 via SEW2871 treatment resulted in 
a significant increase of Th1 cell recovery from non-inflamed tissues compared 
to vehicle treated cells (Figure 5.2.4B).  
Surprisingly however, no significant increase was observed at inflamed tissues 
when T cells were pre-treated with SEW2871 compared with vehicle treated 
cells at resting sites (Figure 5.2.4B). As in previous experiments, no significant 
differences were observed between the lymph nodes draining either inflamed or 
resting ears, irrespective of T cell pre-treatment (Figure 5.2.4C). In sum, these 
data demonstrate that S1PR1 specific signals were responsible for T cell 
persistence at inflamed tissues. Moreover, they suggest that FTY720 was acting 
as an antagonist of S1PR1 in previous experiments.  
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Figure 5.2.4 S1PR1 selective agonism results in increased CD4 Th1 cell recovery from 
tissue sites 
Age matched C57BL/6 mice at 6 weeks of age were challenged with LPS or PBS in their right ear 
pinnae. 24 hours later 2.0e6 SEW2871, W146 or vehicle treated OT-II Th1 cells were transferred 
into the same ear pinnae of animals. 24 hours later, mice were euthanised and their ears and dLN 
were harvested, processed and stained for FACS. Cells were stained with a viability dye followed 
by fluorescently labelled antibodies against CD45, CD4, CD45.1 and Va2. Lymphocytes were 
initially gated on live CD45+, CD4+ cells and subsequently analysed for their expression of CD45.1 
and Va2.  FACS plots are representative of 3 independent experiments. Graphs show combined 
data from 2 independent experiments of 6 (LPS, LPS+ SEW2871, PBS+ SEW2871, PBS+W146) 
or 7 (PBS, LPS+ W146) animals per group. Statistical differences between groups were assessed 
by carrying out a One-way ANOVA and Tukey’s multiple comparisons test using Graphpad Prism 
*** denotes p value of <0.001, ** and **** < 0.0001. n.s. denotes not significant. 
5.2.5 Th1 cells express S1PR1 prior to transfer but downregulate 
it at inflamed tissues 
S1PR1 expression on T cells is dynamic and temporally regulated. Naïve T cells in 
circulation express little surface S1PR1, but are S1PR1hi once in SLOs (389).  
Early effector T cells are S1PR1hi but down modulate its expression once at 
tissue sites for a few days (629). Measuring surface S1PR1 expression is 
challenging. Sub nano molar levels of S1P causes receptor internalisation and 
degradation of S1PR1 (212, 222, 223).  
Indeed, local S1P gradient dynamics have been elucidated by measuring cell 
surface expression of S1PR1 (431, 440, 602). Previous data suggested that signals 
through S1PR1 were responsible for Th1 cell persistence at inflamed tissues. 
Thus, it was important to examine the relative expression of S1PR1 on Th1 cells 
both in vitro and ex vivo. 
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To determine whether Th1 cells expressed S1PR1 in vitro, polarised OT-II T cells 
were stained with anti-S1PR1 antibody and analysed on a flow cytometer. 
Roughly a quarter of Th1 cells were found to express surface S1PR1 (Figure 
5.2.5A). Intracellular staining with the same S1PR1 antibody revealed that a 
large majority of cells expressed S1PR1 intracellularly (Figure 5.2.5B).  
Next, ex vivo surface and intracellular expression of S1PR1 by Th1 cells 
recovered from ear tissue was assessed. Polarised OT-II Th1 cells were 
transferred into inflamed or resting mouse ear pinnae. 24 hours later, ear tissue 
was harvested, stained for flow cytometry and cell surface and intracellular 
S1PR1 expression determined. No surface S1PR1 expression was detected from 
tissue recovered Th1 cells, possibly due to digestion (Figure 5.2.5C). Intriguingly 
however, Th1 cells were found to have reduced intracellular S1PR1 expression at 
inflamed ear tissues compared to T cells at resting tissues (Figure 5.2.5D,E). In 
sum these data suggest that Th1 cells express S1PR1 at transfer and are 
therefore responsive to S1P signals. Moreover, a reduced intracellular expression 
at inflamed ears may be attributed to increased S1P and thus increased S1PR1 
degradation at the site. 
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Figure 5.2.5 Th1 cells express S1PR1 before transfer but downregulate it at inflamed tissues 
CD4 T cells were isolated from the lymph nodes and spleens of CD45.1 OT-II mice using a 
STEMCELL technologies CD4 T cell isolation kit. The cells were then cultured with IL-12, anti-IL-4 
and ovalbumin peptide323-339 in the presence of mitomycin C treated splenocytes for 72 hours at 
37°C with 5% CO2. Thereafter, cells were stained with anti-CD4 with or without anti-S1PR1 
antibodies (A). Cells were then fixed and permeabilised with a BD cytofix/perm kit and stained with 
or without anti-S1PR1 antibody (B). Animals were treated with LPS or saline in their ear pinnae 
before 2.0e6 CD4 Th1 cells were transferred into the ear pinnae. 24 hours later animals were 
euthanised and their ears harvested and stained for flow cytometry with a cocktail of antibodies 
including anti-CD4 and anti-S1PR1 extracellularly (C). In another experiment, cells were fixed and 
permeabilised using a BD cytofix/perm kit and stained with anti-S1PR1 antibody intracellularly 
(D,E). In vitro experiments were pre-gated on live, single lymphocytes and are representative of 2 
independent experiments. Ex vivo plots are pre-gated on live, single CD45+ lymphocytes and are 
representative of two (C) or one experiment (D,E) respectively with 5 animals in each group. 
Statistical differences were determined by carrying out an unpaired Student’s T test. Error bars 
represent SEM. * denotes P value of <0.05. 
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5.2.6 Inflamed tissues express increased levels of SPHK1, the 
enzyme that generates S1P 
Sphingolipids are difficult to measure reliably. Due to a critical role for S1P in 
membrane sphingolipid metabolism, intracellular S1P is abundantly produced by 
various cell types. This makes even mass spectrometry results difficult to 
interpret (430). Instead, kinases that either help produce or degrade S1P are 
often used to measure tissue S1P levels (645). Sphingosine kinase 1 (SPHK1) and 
sphingosine kinase 2 (SPHK2) are the final two kinases responsible for 
metabolising sphingosine into sphingosine-1-phosphate (210).  
To measure S1P levels at inflamed tissues, animals were treated with LPS or 
saline in their ear pinnae to induce inflammation. 24 hours later, animals were 
euthanised and their ears harvested and fixed in neutral buffered formalin. The 
tissue was subsequently sectioned into 10µm thick sections and stained with 
human and mouse cross reactive anti-SPHK1 or isotype control antibodies. 
Secondary and tertiary antibodies were used to add fluorescent tags to the 
tissues to allow visualisation on a fluorescent microscope.  
The images were then analysed and the number of total cells and cells 
expressing SPHK1 manually counted in three randomly selected areas per section 
using ImageJ software. The percentages of cells expressing SPHK1 were then 
calculated. A significantly greater proportion of cells at inflamed tissues were 
found to express SPHK1 (Figure 5.2.6A, B). These data suggest that increased 
S1P may be produced at inflamed ear pinnae. Taken together with the T cell 
persistence data, there is strong evidence suggesting that dysregulated S1P 
production at inflamed tissues contributes to increased CD4 Th1 cell persistence 
at such sites.   
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Figure 5.2.6 Inflamed mouse ears contain a significantly greater number of cells expressing 
SPHK1 
Age matched C57BL/6 animals were injected with LPS or saline in their ear pinnae. 24 hours later, 
animals were euthanised, ears harvested and fixed in neutral buffered formalin. Ear tissue was 
mounted in paraffin and cut into 10um thick sections. The cut sections were mounted on a slide 
and stained with rabbit anti human/mouse-SPHK1 or rabbit IgG (Isotype control). Sections were 
then stained with anti-rabbit biotin, followed by streptavidin-PE. Sections were mounted in prolong 
gold with DAPI and imaged on a spinning disk confocal microscope. Images were acquired using 
uniform settings at similar locations. Images were acquired at 20x magnification. Error bar shows 
20um. Three uniform areas were randomly selected in each tile section for quantification. Number 
of SPHK1 positive dots were manually counted using imagej software. Images are representative 
from one experiment with 5 animals per group. 2 randomly selected sections were quantified from 
serially sectioned mouse ears. Error bars represent SEM. Statistical differences were analysed by 
carrying out an unpaired Student’s T test. **** denotes P value of <0.0001.                 
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Molecular pathways are difficult to study in human disease settings. Therefore, 
aspects from animal models of inflammation need to be tested in humans to 
elucidate whether similar mechanisms may be present in human disease 
settings. Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory 
condition where human joint synovia are inflamed (76). One of the hallmarks of 
RA is the accumulation of large numbers of CD4 T cells in synovial tissues (84). 
The role of S1P in regulating accumulation of T cells at human RA joints remains 
unexplored.  
To assess whether S1P is increased at RA joints, a collaborative project was 
undertaken with Dr. Aziza Elmesmari and Prof. Iain McInnes, rheumatologists at 
Gartnavel hospital, Glasgow. SPHK1 levels were measured in biopsies from RA 
patients or OA patients. OA is a form of less-inflammatory arthritis, often 
associated with age related degeneration of joint cartilage. Furthermore, 
minimal accumulation of CD4 T cells have been observed in primary OA (646).  
Biopsy sections were fixed in formalin and cut into 5µm thick sections before 
staining with the same anti-SPHK1 antibody. Using appropriate secondary, 
tertiary antibodies and Diaminobenzidine (DAB), colour was developed in 
positively stained areas for visualisation on a light microscope fitted with a 
camera module.  
The images were then semi-quantified by Dr. Aziza Elmesmari. Three 
representative fields per slide were selected and graded on a scale of 0-4 by two 
blinded observers on two independent occasions. The scores were later 
combined and statistical analysis performed to determine differences between 
groups. Blinded observers consistently scored RA tissues higher for their 
expression of SPHK1 compared to OA tissues (Figure 5.2.7A,B). These data 
indicate that inflamed RA synovial tissues may produce increased S1P. Keeping 
previous conclusions in mind, increased S1P levels in synovial tissues may 
contribute to CD4 T cell accumulation in RA. 
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Figure 5.2.7 Human RA joints express increased SPHK1 
Human RA or OA biopsy samples were fixed and embedded in paraffin. 5µm thick sections were 
cut and mounted on slides. The slides were then stained with anti-human/mouse SPHK1 or rabbit 
IgG (Isotype control). Appropriate biotinylated secondary antibody and an ABC kit were used for 
colour development before DAB was used to form positive brown deposits. Sections were imaged 
on a light microscope with a camera attachment. Images were scored on a scale of 0-4 by two 
blinded observers on two independent occasions. 0 = no staining, 1 = 0-25%, 2 = 25-50%, 3 = 50-
75%, 4= 75%-100% staining. Image is representative of 4 independent biopsy samples. Synovial 
lining layer (SLL), sub lining layer (SUL) and vascular endothelial layers (VEL) of tissue were 
scored individually and a kruskal wallis test was used to calculate statistical differences between 
OA and RA in each layer. The data was then combined in graph above. Error bars represent SEM. 
* denotes P value <0.05. 
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5.3 Discussion 
Sphingosine-1-phosphate is a pleiotropic sphingolipid responsible for numerous 
cellular processes including survival, proliferation and migration (176). S1PRs are 
GPCRs and sensitive to PTX mediated inhibition of signalling (647). In this 
chapter, the role of S1PR signals in the persistence of CD4 Th1 cells was 
investigated.   
5.3.1 S1PR1 signals are necessary and sufficient for Th1 cell 
persistence at inflamed tissues  
Following on from the last chapter where T cell persistence was found to be 
pertussis toxin sensitive, the role of S1PRs, another PTX sensitive GPCR was 
examined. Th1 cells were treated with either FTY720, W146 or SEW2871 prior to 
their adoptive transfer into inflamed or resting tissue sites. These are S1PR pan 
antagonist, S1PR1 specific antagonist and agonist respectively.  
Lower numbers of Th1 cells were recovered from inflamed tissues when treated 
with S1PR antagonists, phenocopying the pertussis toxin treatment experiments. 
These results suggested that the pertussis toxin sensitive persistence of T cells is 
mediated via S1PR1 signals. These results contradict a study by Ledgerwood et 
al. where naïve T cells treated with FTY720 were found to undergo reduced 
egress to draining lymph nodes from peripheral tissue sites (244). The authors 
suggested that the lower number of T cell recovery from draining lymph nodes 
suggested tissue retention mediated via FTY720. Ledgerwood et al. also 
demonstrate that S1P treated T cells failed to migrate to lymph nodes but rather 
are retained at tissue sites.   
The difference in the polarisation state of my T cells (activated Th1 in my 
experiments versus naïve T cells in Ledgerwood et al. experiments) as well as 
their trafficking from inflamed rather than resting tissues could explain the 
differences observed. It is also important to note that Ledgerwood et al. did not 
enumerate the number of T cells at the tissue site but rather inferred their 
presence by enumerating the draining lymph nodes. In contrast, I have 
enumerated both the tissue site and the draining lymph nodes. I believe that this 
demonstrates a more robust experimental approach. Finally, FTY720 is a 
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functional antagonist of S1PRs. The Ledgerwood study in contrast, suggests it 
may be functioning as an agonist. This makes their results difficult to interpret, 
since FTY720s function as an S1PR pan functional antagonist is well documented 
(222, 438, 439, 643). 
Another study by Brown et al. demonstrated that Th1 cell egress from 
chronically inflamed tissues is mediated via S1P signals (453). Systemic FTY720 
treatment of animals prior to adoptive transfer of T cells at tissue sites reduced 
the subsequent recovery from tissue draining lymph nodes 12 hours after 
adoptive transfer. This study once again differs from my experiments in several 
key methods. Systemic FTY720 treatment of animals can have effects on 
multiple cell types and therefore the effect on T cell egress could be indirect. 
Moreover, chronically inflamed tissues may differ significantly from acutely 
inflamed tissues, both in their cellular and molecular contents (61). Thus, S1P 
levels may be different depending on the type of inflammatory stimulus used. 
Indeed, as shown in chapter 1, my investigations using a DTH inflammatory 
model failed to demonstrate Th1 cell persistence. This may suggest that S1P 
mediated T cell persistence is inflammation specific. Thus, it would be 
informative to identify the mechanism(s) of S1P gradient dysregulation at 
inflamed tissues.          
5.3.2 S1PR1 signals may regulate T cell survival 
Since LPS inflammation mediated T cell persistence was found to increase cell 
survival at the tissue, similar investigations were undertaken to determine 
whether S1PR1 signals were regulating T cell survival directly. Intravital 
microscopy revealed a marked decrease in T cell motility at inflamed tissue 
following FTY720 treatment, indicating that they may be undergoing apoptosis. 
S1P mediated cellular motility has been explored in some studies. As mentioned 
previously, S1P was found to increase NK cell motility as well as DC chemotaxis 
(639, 640). In contrast S1P signals were found to inhibit mast cell migration 
(641). In contrast, S1PR1 deficiency was found to reduce CD8 T cell velocity in 
lymph nodes (648). S1PR agonism via FTY720-P was also found to reduce CD4 T 
cell motility in explanted lymph nodes (645). Due to the conflicting nature of 
these studies, it remains uncertain whether S1P’s effects on cellular motility is 
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differential based on the tissue type and/or the cell polarisation state. These 
results are confounded by the fact that S1P acts both as a survival and migration 
signal (239, 626). Dissecting these two pathways may indeed reveal the role 
differential cellular motility plays in regulating survival or migration. 
Active caspase expression was also measured on FTY720 treated T cells. 
However, the results proved inconclusive due to no survival phenotype observed 
in vehicle treated T cells at inflamed tissues as found previously. One reason for 
this could be the prolonged tissue processing necessary for the FTY720 treated 
set of experiments due to the increased number of experimental groups.  
A role for S1P in regulating cell survival has been widely studied in various cell 
types (623-626). Studies into the molecular mechanisms revealed that inhibition 
of caspase activation played a key role (625, 626). Hence it was rational to 
undertake a caspase assay.  
Despite my inconclusive results, a very recent study by Mendoza et al. elegantly 
demonstrated for the first time that naïve T cells require S1PR1 signals to 
maintain mitochondrial integrity and thus survival (626). They measured levels 
of several mitochondrial proteins in S1PR1 deficient T cells and found them to be 
lower than their S1PR1 sufficient controls. Moreover, Mendoza et al. performed 
RNA-seq analysis on the T cells to demonstrate differential expression of survival 
and apoptotic genes in S1PR1 deficient T cells. The differences observed in this 
study were small and thus suggest that a different assay for Th1 cell survival at 
tissues such as RNA-seq may have revealed significant differences in my case. 
5.3.3 S1P levels are dysregulated at inflamed tissues 
S1P levels are low in peripheral tissue fluids and high in blood and lymphatic 
vessels (217). Therefore, increased levels of S1P in my inflamed tissue model 
may further indicate its role in supporting early Th1 cell survival in tissues. S1P 
however is difficult to measure. S1P mRNA is constitutively expressed due to its 
role in membrane sphingolipid synthesis pathway. Intracellular S1P is also made 
by almost all cells making mass spec results difficult to interpret (430). 
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The final step of the S1P synthesis pathway involves the phosphorylation of 
sphingosine to S1P by either SPHK1 or SPHK2 (210). Multiple studies have 
demonstrated that SPHK1 regulates inflammatory S1P production whereas SPHK2 
seems to control homeostatic S1P production (649). Hence, SPHK1 expression 
was analysed by immunofluorescent microscopy in LPS inflamed mouse ears. The 
results demonstrated that a significantly greater proportion of cells expressed 
SPHK1 in inflamed mouse tissues compared to resting ones. 
Interestingly, a lot of the SPHK1 expressing cells were not nucleated. Paired 
with histology results, where large regions of blood vessel haemorrhage and 
blood components were found in tissue, this result strongly suggests that 
increased SPHK1 expression was due to blood borne cellular infiltration. Red 
blood cells and platelets are the most potent producers of S1P (217). Likewise, 
increased vascular leakage at inflamed tissues is well documented (61). Thus, I 
propose that LPS inflammation causes increased vascular leakage resulting in 
increased local S1P levels. This increased local S1P regulates the survival and/or 
migration of T cells at inflamed tissues. Future studies, either inhibiting vascular 
leakage or transferring activated platelets to produce S1P at local tissue could 
be used in lieu of LPS to confirm this hypothesis. 
Another way to enumerate relative differences in S1P levels is measuring the 
expression levels of S1PR1 on T cells (431, 440, 602). This method relies on the 
exquisite sub-nanomolar sensitivity of S1P to S1PR1. T cells exposed to very low 
concentrations of S1P potently downmodulate their receptor expression (440). 
One caveat to this method however, is that the differentiation state of the cell 
may also alter the S1PR1 expression (430). Nonetheless, relative differences 
between S1PR1 expression levels were investigated in transferred Th1 cells at 
inflamed versus resting tissues. Ex vivo staining of extracellular S1PR1 expression 
proved inconclusive possibly due to tissue digestion processes. However, 
intracellular staining demonstrated Th1 cells at inflamed tissues expressed lower 
S1PR1 levels, suggesting a relative increase in local tissue S1P level.     
Finally, studies by various groups have demonstrated that acutely inflamed 
mouse skin and gut have increased local S1P levels (244, 645). S1P levels were 
also elevated in human inflammatory diseases. Examination of bronchoalveolar 
lavages from asthma patients revealed increased S1P concentrations compared 
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to healthy controls (650). Synovial fluids of RA joints also contain elevated levels 
of S1P compared to OA joints (267). These studies correlate well with my data 
which demonstrates that human RA joints express elevated levels of SPHK1 
compared to OA joints. Interestingly, most of these human inflamed tissues also 
promote prolonged persistence of T cells. Inhibiting local T cell persistence by 
local administration of S1PR1 antagonists may provide an interesting new 
therapeutic approach in tissue inflammatory disease.
 
 
6 General Discussion and Future Directions  
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6.1 General Discussion 
Timely and efficient trafficking of T cells to and from inflamed tissues is a key 
step in controlling an inflammatory response. It enables the movement of the 
appropriate subsets of effector cells to inflamed tissues. Here, effector CD4 T 
cells participate in pathogen clearance, tissue repair and memory formation 
(276, 403). However, in chronic diseases multiple steps of the trafficking 
pathway may be dysregulated. This causes pathogenic accumulation of CD4 T 
cells at inflamed peripheral tissues (7, 84, 421, 513, 514).  
In this thesis, the signals that affect the persistence of CD4 T cells at inflamed 
tissues were investigated. A reductionist inflamed tissue model was designed to 
study signals which cause tissue persistence rather than recruitment of CD4 T 
cells. Increased understanding of these signals may allow novel therapeutic 
intervention to diminish T cell accumulation in inflammatory peripheral tissue 
diseases such as RA and psoriasis. In contrast, enhancing T cell persistence may 
aid in the development of novel vaccine candidates by enhancing memory cell 
formation for infectious diseases at the site of infection, such as in HIV (651). 
My studies have identified that LPS inflammation in mouse ear tissue increases 
local persistence of CD4 Th1 cells. Accumulation of T cells at inflamed tissues is 
a well-documented phenomenon (7, 84, 421, 498, 513, 514, 553). A myriad of 
studies have identified specific chemokines, CAMs, survival factors and lipid 
mediators as regulators of T cell accumulation at peripheral tissues (84, 244, 
421, 481, 525). 
Some of the early studies identified a role for chemokines in the attraction and 
accumulation of effector T cells at peripheral inflamed tissues. Campbell et al. 
first described the role of CCR4 in the chemoattraction of T cells to cutaneous 
sites of inflammation (14, 445). Likewise, Zabel et al. discovered the crucial role 
of CCR9 in T cell trafficking to the intestine (652). 
Chemokines however, not only act as migration cues but often have other 
functions. For example, the chemokine receptor CXCR4 has been reported to 
cause T cell accumulation in the rheumatoid synovium by both increased survival 
and chemotaxis mechanisms (6, 84, 421). Th1 cells were found to chemotax 
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towards RA synovial fluid. In addition, Vlahakis et al. found, in a separate study, 
that CXCR4 signalling confers CD4 T cells resistant to apoptosis (561). Similarly, 
CX3CL1-CX3CR1 interactions have been reported to induce both T cell survival 
and retention in models of atopic dermatitis (480).  Thus, accumulation of T 
cells at inflamed tissues could be a combination of multiple factors such as 
increased migration and increased survival, perhaps delivered by the same 
molecule.  
I further demonstrated that Th1 cells that persisted in the tissue neither 
proliferated in situ nor migrated to the dLN at greater numbers than from 
resting tissues. Interestingly, intravital microscopy revealed that T cells at 
inflamed tissues remained highly motile while those at the resting tissue were 
immotile. These findings led me to hypothesise that persistent T cells received 
signals at inflamed tissues that rendered them resistant to apoptosis. 
Caspase assays demonstrated that a lower proportion of T cells expressed active 
caspases at inflamed tissues compared to T cells at resting tissues, supporting 
my hypothesis. Akkoc et al. reported that IFNg high T cells from atopic 
dermatitis patients expressed increased caspases and underwent apoptotic cell 
death (536). They further found that these cells expressed increased FAS and 
TNF receptors and that T cell death was mediated via FAS (536). In light of this 
study as well as my caspase and microscopy results, the increased production of 
IFNg by T cells at resting tissues found in (Figure 3.2.8) may suggest that T cells 
were undergoing activation induced cell death.  
Hence, levels of FAS ligand, TNF and IL-7 were measured at inflamed and resting 
tissues. These molecules have all been identified to play a role in promoting T 
cell death or survival (525, 527, 575, 589). However, no differences were 
observed in their levels. This does not, however, rule out a role for these 
compounds in T cell survival. It is plausible that T cells at inflamed tissues alter 
their expression of FAS, TNF or IL-7 receptors, rendering them more or less 
sensitive to the same level of signal. It would, therefore be important to 
measure levels of receptor expression on T cells to definitively rule out a role 
for these compounds in T cell survival at inflamed tissues. 
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As discussed previously, chemokines could also mediate T cell survival at 
inflamed tissues. Moreover, a recent study by Mendoza et al. demonstrated a 
novel role for the lipid mediator S1P in supporting naïve T cell survival (626). 
Since both chemokines and S1PRs signal through GPCRs, I inhibited GPCR 
signalling by treating T cells with either pertussis toxin or FTY720 which are a 
pan GPCR and a pan S1PR inhibitor respectively. 
Treatment with either compound led to the disappearance of T cells from 
inflamed tissues without affecting their numbers at resting tissues or dLNs. This 
provided the first piece of evidence that S1P signalling was critical for Th1 cell 
persistence at inflamed tissues. This result however, could be interpreted in 
multiple ways.  
Studies have demonstrated a role for CCR7 and S1PR1 in controlling the egress of 
T cells from both SLOs and peripheral tissues (282). In SLOs, CCR7 and S1PR1 
were found to have linked but antagonistic roles in controlling T cell egress. 
Pham et al. demonstrated that CCR7 signals favour retention of naïve T cells 
while S1PR1 signals favoured their egress via efferent lymphatics, in SLOs (243). 
In peripheral tissues, both S1PR1 and CCR7 signals promote the egress of naïve T 
cells via afferent lymphatics (453).  
This suggests that disruption of pan GPCR signalling should lead to T cell 
retention at peripheral tissues, whereas disruption of S1PR specific signalling 
should be compensated by the presence of CCR7 signalling to enable T cell 
egress. Indeed Brown et al. demonstrate these results when they found that 
pertussis toxin treated splenocytes were retained at peripheral tissues following 
adoptive transfer (453). 
However, the balance of signals alters significantly during inflammation due to 
changes in both receptor and ligand availability. Activated T cells downregulate 
CCR7 and upregulate S1PR1 to allow their egress from SLOs (243). At inflamed 
tissues, little is known about changes in receptor expression, however, increased 
levels of S1P as well as CCL19/21 has been reported (244). This would suggest a 
possible levelling of the S1P and chemokine gradient between inflamed tissues 
and afferent lymphatics, enabling these signals to act as a temporary tissue 
retention signal. 
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Supporting this theory, Ledgerwood et al. demonstrated that S1P acts as a 
retention signal for naïve T cells at acutely inflamed tissues (244). Likewise, 
Brown et al. found T cell egress to be CCR7 dependent at acute but not 
chronically inflamed tissues (453). Interestingly, they also found that S1P signals 
promote T cell egress from chronically inflamed tissues, somewhat contradicting 
the Ledgerwood study. The differential responses of T cells to S1P signals from 
tissues suggests that expression of either S1PRs and/or S1P are dynamically 
regulated based on the length and type of inflammation.  
It is also plausible, that S1PR and S1P expression is spatially regulated. Studies 
by Skon et al. found that S1PR1 signals were less important in tissue retention of 
CD8 TRM cells in the intestinal epithelium compared to other non-lymphoid 
tissues (456). Other studies highlighted the importance of the integrin CD103 in 
the retention of these cells in the intestine (488). Thus, it is possible that CD103 
also contributes to effector/memory T cell retention at peripheral tissues in 
conjunction with CCR7 and S1PR1. 
Ledgerwood et al. and Brown et al. interpret their data with the assumption that 
S1P works as a chemotactic signal for T cells and that T cells migrate from an 
area of low S1P concentration (peripheral tissues and LN) to an area of high S1P 
concentration (blood and lymphatics). My studies find that signals through S1PR1 
are necessary and sufficient to promote Th1 cell persistence at LPS inflamed 
peripheral tissues. Some key experimental differences between my studies and 
those by Ledgerwood et al. and Brown et al. could explain the discrepancies 
observed. My experiments utilise Th1 cells and an LPS mediated inflamed tissue 
while they use naïve T cells in adenovirus (Ledgerwood) or CFA (Brown) 
inflammation.  
In addition, both the studies only quantified the number of transferred cells that 
migrate to the draining lymph node to elucidate what might be happening in the 
tissue. I believe, this limits the interpretation of their data. However, in light of 
these studies, it is difficult to definitively rule out a role for either chemokines 
or S1P in having a role in retention of Th1 cells in my model, despite not 
observing a difference in Th1 cell numbers in tissue draining lymph nodes.  
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In addition to its chemotactic properties, S1P is well known for its anti-apoptotic 
properties across multiple cell types but this has not been investigated for 
effector T cells (190, 213, 268, 623, 625{Mendoza, 2017 #740, 626). Hence, I 
hypothesised that increased effector T cell persistence at inflamed tissues was 
due to an anti-apoptotic role played by S1P. While intravital microscopy data 
supported my hypothesis, Th1 cells treated with FTY720 had demonstrably 
reduced motility at inflamed tissues akin to apoptotic cells (571), caspase assays 
did not reach significance, despite a strong trend towards increased apoptosis in 
FTY720 treated group (Figure 5.2.3).  
This result however, remains inconclusive, since the difference observed in 
caspase expression between T cells transferred into resting or inflamed tissues in 
previous experiments were not present in these experiments. As demonstrated 
by Mendoza et al. measuring apoptosis of T cells can be tricky. They used 
markers of mitochondrial integrity to identify a role for S1P in T cell survival 
(626). Perhaps using an assay similar to this would generate more replicable 
results. 
Interestingly, while Mendoza et al. speculate the effect of S1P on naïve T cell 
survival is direct, they do not rule out an indirect mechanism of S1P mediated T 
cell survival. S1PR signalling has been shown to activate STAT3 which has roles in 
the expression of Bcl-2 and Bcl-xl, both anti-apoptotic molecules (619, 653). 
Moreover, IL-7/IL-7R signalling, the quintessential T cell survival signal, also 
activates the Akt signalling pathway used by S1P signalling (654). This suggests a 
potential synergy between IL-7 and S1P signals in facilitating T cell survival. This 
may also be applicable to effector T cells which are somewhat sensitive to IL-7 
signalling and in some cases use oxidative phosphorylation and the mitochondrial 
pathway for their energy generation (482). 
Another important factor to consider is the recent body of evidence that 
suggests a role for FTY720 in inducing cellular apoptosis in a caspase 
independent manner in multiple cell types (655). Although this has not yet been 
investigated specifically in T cells, it is possible that FTY720 treatment is 
working in a similar manner to induce apoptosis of T cells in my experiments. 
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Finally, for S1P to elicit its effects on T cells at peripheral tissues, be that to 
induce survival or chemotaxis or both, it has to be present at the tissue. 
Measurement of S1P remains a challenge due to its constitutive intracellular 
expression and role in cell membrane formation (430). Therefore, I measured 
the expression of one of the enzymes that phosphorylates sphingosine to S1P, 
SPHK1. Substantially increased SPHK1 expression at LPS inflamed mouse tissues 
as well as human rheumatoid synovial tissues suggested that S1P levels may be 
elevated at such sites. This is supported by mounting evidence that indicate S1P 
levels are elevated at inflamed tissues.  
Raised levels of S1P was found in the synovial fluid of RA patients (267). 
Likewise, BAL fluid from asthma patients, intestinal IBD samples, and animal 
models of intestinal inflammation all demonstrated increased S1P (255, 645). 
Despite the growing evidence for a critical role for S1P in regulating inflamed 
tissue immunopathology, little is known about how S1P levels are elevated at 
peripheral tissues.  
Studies have identified lymphatic and blood vessel endothelial cells as producers 
of S1P. Moreover, RBCs and platelets also produce large quantities of S1P (236). 
H&E staining of inflamed and resting mouse ears demonstrated significant 
infiltration of blood derived products into inflamed tissues (Figure 3.2.1). 
Moreover, SPHK1 staining was primarily found in anucleated cells at tissue sites, 
with very little staining at resting tissues. This leads me to hypothesise that 
increased S1P levels at acutely inflamed tissues could be a side effect of 
vascular endothelial leakage. Interestingly, inflammation and in particular LPS is 
a known inducer of vascular endothelial leakage and could suggest that the 
effects observed in my model are applicable in other forms of tissue 
inflammation. 
To summarise, I believe my data suggest a novel role for S1P in regulating the 
persistence of CD4 Th1 cells at peripheral inflamed tissues. The increase in 
tissue S1P is derived from blood products which leak into LPS inflamed tissue 
sites. Furthermore, S1P may regulate Th1 cell persistence by having a dual 
effect of decreased egress as well as increased local survival. Finally, the effect 
of S1P on Th1 cell survival may not be direct but mediated via secondary survival 
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signals such as IL-7 or chemokines. This working hypothesis is summarised in 
Figure 6.1.1 below. 
 
Figure 6.1.1 Working hypothesis on how S1P regulates Th1 cell persistence at inflamed 
peripheral tissues 
1. Inflammation induces vascular damage and leakage of blood products, including RBCs and 
platelets. 2. Inflammatory stimuli such as LPS also induces activation of SPHKs in these cells, 
generating large amounts of S1P. 3. RBCs and platelets express S1P transporters allowing 
extracellular release of S1P. 4. This allows effector T cells to sense increased tissue S1P, 
increasing their survival. 5. Elevated tissue S1P also eliminates the S1P gradient between tissue 
sites and lymphatic and blood vasculature, reducing T cell egress. Together, these two factors 
increase the persistence of effector T cells at acutely inflamed tissues. 
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6.2 Future studies 
6.2.1 Targeting chemokines and integrins in T cell persistence 
The key finding of this thesis demonstrates that S1P plays a crucial role in the 
persistence of CD4 Th1 cells at inflamed tissue sites. However, my studies in 
section 4 suggest that chemokines could also play a role in T cell persistence. As 
such, experiments modulating specific chemokine receptors on T cells or their 
ligands at tissue sites could identify novel chemokine pathways that promote T 
cell persistence at inflamed tissues.   
Indeed, previous studies have demonstrated a role for CCR7 in promoting Th1 
cell egress from tissues sites (451, 452). In contrast, APC derived CCL5 was 
implicated in the retention of memory CD4 T cells at tissue sites (500). The 
integrin CD103 was directly found to promote regulatory T cell retention in 
inflamed skin tissue (450). Finally, the integrin VLA-1 was also found to promote 
CD8 T cell retention in peripheral tissue sites (7, 552).   
These studies highlight the multitude of signals which regulate T cell trafficking 
at tissue sites. Moreover, they demonstrate that the tissue state and 
differentiation status of the T cell dictates the mechanism of trafficking utilised 
i.e. inflammatory chemokines, S1P, integrins and others. Developing a 
comprehensive understanding of how these signals temporally and spatially 
regulate T cell trafficking may allow for the development of timely and targeted 
therapies to abrogate tissue inflammation. 
6.2.2 Determining S1P mediated T cell survival 
While my studies demonstrate that S1P promotes T cell persistence at inflamed 
tissues, whether this persistence is due to retention or survival is difficult to 
pinpoint. No differences were found in the numbers of transferred cells in 
downstream draining lymph nodes or other peripheral organs. Furthermore, T 
cells were not proliferating at inflamed tissues. This led me to hypothesise that 
S1P promotes increased T cell survival at the tissue site. Flow cytometry based 
caspase assays were inconclusive. However, the experiments were compounded 
by the fact that prolonged processing of the cells ex vivo might affect cell 
viability. 
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One method to overcome this problem would be to use cells from a transgenic 
caspase reporter mouse as used by Garrod et al. or by using recently developed 
caspase probes as demonstrated by Qian et al. (571, 656). This would allow for 
imaging of T cells in vivo and quantifying the number of apoptotic cells in S1P 
receptor modulated animals (FTY720 treated) versus control animals (vehicle 
treated). However, this could be difficult to accurately quantify as dead cells 
may be cleared from the tissue site prior to imaging. Moreover, T cells may be 
dying in lymphatic vessels while draining from tissue sites, making these cells 
difficult to image. 
Similarly, whole mounted or serially sectioned tissues could be stained with 
antibodies against active caspases. This method has similar limitations to 
studying apoptosis in vivo as mentioned previously. 
Another way to test whether T cell disappearance at tissue sites was due to 
apoptosis would be to transfer Bcl-2 transgenic T cells. These cells are resistant 
to apoptosis (657). Thus, any differences in the number of T cells recovered 
from inflamed vs resting tissue would not be due to apoptosis. This experiment 
would definitively rule out a role for survival or death in regulating T cell 
persistence. 
Finally, apoptosis could also be assayed by studying the mitochondrial apoptotic 
pathways. Mendoza et al. very recently discovered that S1P signals are 
important for naïve T cell survival by studying mitochondrial proteins in S1PR1-/- 
T cells in secondary lymphoid organs (626). Investigating similar mitochondrial 
protein expression in my system could potentially illuminate whether S1P signals 
aid activated Th1 cell survival at inflamed tissues in a similar manner.  
6.2.3 Utilising S1PR1-/- T cells 
In my experiments, pharmacological agents that target S1PRs were used to 
modulate S1P signals in T cells. This was achieved by pre-treating activated T 
cells in vitro with S1PR agonists/antagonists prior to their adoptive transfer. This 
method allowed me to target T cell specific S1P signals and to further study the 
effects of S1P on T cells specifically at peripheral tissue sites.  
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The use of pharmacological agents, has some drawbacks. The effect of most of 
these drugs have been studied in vivo and thus how they function in vitro is not 
well known. The length of treatment time and dosage used in my experiments 
were kept consistent with other published in vivo studies where these 
pharmacological drugs were found to have an effect on T cells (244, 453). 
However, no studies directly demonstrate how these treatment protocols 
actually affect S1PR function. Thus, the mechanism of drug action is 
inconclusive.  
Moreover, the mode of action of FTY720 remains controversial. FTY720 has been 
reported to have both agonistic and antagonistic effects on S1PRs (658-660). 
Additionally, carryover of drugs cannot be ruled out, despite extensive washing 
of cells post-treatment. Therefore, the effects observed in my experiments may 
be due to indirect effects of pharmacological agents on tissue cells following 
transfer.  
Using S1PR1-/- T cells may provide a more robust system to address these 
questions. However, using such methods poses further challenges for my system. 
Animals with S1PR1-/- T cells have peripheral lymphopenia (661). Most T cells 
accumulate in the thymus while some are found in peripheral lymph nodes. 
While studies suggest that these T cells mature normally, a role for S1P has been 
described in T cell activation and polarisation (662). Thus, it would be difficult 
to differentiate whether effects observed in such a system would be due to 
differences in T cell activation or due to S1PR1 mediated effects at tissue sites. 
Small interfering RNA (siRNA) knockdown of S1PR1 following OT-II cell 
polarisation could be used to address these issues (663).               
6.2.4 Measuring S1P levels  
SPHK1 levels were measured in this thesis as an analogue for S1P. However, S1P 
levels are regulated not only via SPHKs but also via S1P lyases and phosphatases 
(430). Additionally, S1P transporters play an important role in regulating levels 
of extracellular tissue S1P (215, 216, 253, 607). Hence, direct measurement of 
S1P remains a critical piece of missing evidence in this study.  
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Substantially elevated levels of S1P has been reported in multiple inflamed 
peripheral tissues including RA joints (synovial fluid), allergic and asthmatic 
lungs (BAL), inflamed mouse peritoneum and skin (244, 246, 267, 650). Likewise, 
SPHK levels were found to be elevated in multiple cancers (664). These studies 
lend support to my hypothesis that increased S1P at locally inflamed tissue is 
responsible for T cell persistence.   
Measuring tissue S1P directly poses many challenges. Firstly, S1P is produced 
abundantly intracellularly in almost all cell types due to its role in maintaining 
cell membranes (430). Thus, mass spectrometry data, the gold standard in S1P 
measurement, is unlikely to prove a reliable measurement of extracellular S1P. 
A single S1P ELISA kit is available from echelon biosciences. However, the ELISA 
sensitivity does not allow for detection at low levels at tissue sites.  
Perhaps the best way to measure S1P levels at tissues with any confidence would 
be to analyse mRNA levels of all the SPHKs, S1P lyases, phosphatases and 
transporters by qRT-PCR. This analysis would develop a comprehensive picture of 
S1P regulating proteins at tissue sites. Similar studies have been performed by 
Karuppuchamy et al. with promising results in murine gut tissues (645). 
6.2.5 Who produces S1P at inflamed tissues? 
Once elevated levels of S1P can be confirmed, it would be interesting to 
investigate what cell types are responsible for S1P production at inflamed 
tissues. Platelets, RBCs and mast cells are potent producers of extracellular S1P 
(217). Tissue histology of LPS inflamed mouse ears revealed significant blood 
exudate in inflamed skin tissue (Figure 3.2.1A). This in itself could elevate levels 
of tissue S1P, due to increased S1P levels in blood (665). Moreover, RBCs and 
platelets in tissue could undergo further activation by their inflammatory 
surroundings, elevating levels of tissue S1P. 
Studies involving the transfer of activated platelets or RBCs into mouse ear 
pinnae followed by transfer of T cells to investigate their persistence, could 
confirm whether platelet or RBC mediated S1P is responsible for T cell 
persistence. Likewise, challenging platelet depleted animals with LPS and then 
transferring T cells into their ear pinnae could answer similar questions.      
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6.3 Concluding remarks 
In this study, persistence of CD4 T cells at inflamed tissues was demonstrated 
using an LPS mediated skin inflammation and tissue adoptive transfer model. 
Using this system, S1P was found to be responsible for the persistence of 
activated Th1 cells at inflamed tissues. Moreover, signals through the S1PR1 
were found to be both necessary and sufficient for persistence of CD4 T cells at 
inflamed tissues. 
Blocking S1PR signals significantly reduced T cell motility in vivo at inflamed 
tissues. Finally, elevated levels of the S1P producing enzyme SPHK1 was found at 
inflamed peripheral tissues. Together, my data suggests that increased T cell 
persistence and motility is due to increased survival of T cells mediated via S1PR 
signals.  
This novel finding that S1P aids effector T cell persistence and, potentially, 
survival at peripheral inflamed tissues could lead to the development of new 
therapeutic interventions targeting peripheral tissue inflammatory diseases such 
as RA and psoriasis.
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